Podcasts about scientific advisory committee

  • 73PODCASTS
  • 93EPISODES
  • 40mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Mar 28, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about scientific advisory committee

Latest podcast episodes about scientific advisory committee

The Economy, Land & Climate Podcast
Have monopolies broken agricultural markets?

The Economy, Land & Climate Podcast

Play Episode Listen Later Mar 28, 2025 35:23


Nearly half of the global agriculture market is controlled by four companies. This level of concentration - driven by decades of mergers and poor regulation - has allowed agribusiness “titans” to dominate the farming sector.  Alasdair talks to Dr Jennifer Clapp, author of a new book about corporate domination of the farm sector and why it matters. Alasdair and Jennifer discuss how and why mass-merging has led to market distortions and high prices, and what solutions could improve the state of the sector.  Dr. Jennifer Clapp is a Professor at the School of Environment, Resources and Sustainability at the University of Waterloo, Canada. She is a member of the International Panel of Experts on Sustainable Food Systems and the Scientific Advisory Committee of the UN Food Systems Coordination Hub.  Click here to read our investigation into the UK biomass supply chain, or watch a clip from the BBC Newsnight documentary.

The Leading Voices in Food
E268: Why Corporate Control of Agriculture is Cause for Concern

The Leading Voices in Food

Play Episode Listen Later Mar 26, 2025 24:40


How big is too big? When it comes to corporate concentration many observers raise concerns about the tech industry. However, in the new book, Titans of Industrial Agriculture: how a few giant corporations came to dominate the farm sector and why it matters, political economist Jennifer Clapp draws attention to the overwhelming shadow a small handful of transnational corporations cast over the global agricultural sector. Professor Clapp argues that these corporations hold concentrated power over the agricultural sector that keep industrial agricultural practices entrenched in patterns of production, despite the concerns of the social, ecological and health impacts to society. She explains how we got to this point and what it might take to make changes. Jennifer's work at the intersection of the global economy, food security, and food systems, and the natural environment, looks specifically at issues of global governance. She is currently a member of the International Panel of Experts on Sustainable Food Systems, and a member of the Scientific Advisory Committee of the UN Food Systems Coordination Hub.  Interview Summary Norbert - Jennifer, let's just jump right in and I'd love for you to help our listeners understand a little bit more about your book. You write about corporate concentration in the agricultural input sector. Can you explain what this involves and what products are we really talking about?    Yes. The book is about what we call the agricultural inputs industry. And that's really four different product types typically, and maybe a fifth that we can talk about. So, one of them is farm machinery, and that's really referring to things like plows and tractors, harvesters, etc. That kind of machinery on the farm. The second industry is the fertilizer industry, which is all about, you know, the nutrients that we bring to the soil through fertilizer products like nitrogen, phosphorus, and potash. And the seed industry. That's another industry that is a key input for farmers. And then also pesticides. And when we talk about pesticides, we're referring to things like insecticides, chemicals that kill insects, but also chemicals that kill weeds and fungus. And so those are the four sort of big inputs that I talk about in the book. But also, the book covers a fifth input, an emerging input, which is data. And this is, especially as we're seeing the datafication and digitalization of farming. Increasingly data has now become a commodity that is bought and sold as an input into farming. Norbert - Great. I have to ask, what drew you to the input industry? I mean, let's be honest, that's not the thing that most people get excited about. Why should we be concerned? Yeah, that's a great question. I've actually had a very long interest in the seed in chemical industry. That goes way back to the start of my career because I did studies in agriculture for my PhD dissertation. But then I got quite interested in toxic waste and then that sort of drew me to this question of the global pesticide trade. And when I learned that, you know, oftentimes, like in the US there might be a banning of a pesticide that's no longer in use. But it was still being traded globally. And this, I found this very fascinating and how that industry worked. And that kind of drew me into understanding the connections between seeds and chemicals. And then when the digitalization of farming came along and in recent decades it became really clear that it wasn't just chemical and seed industry involved in that digitalization. It was also the fertilizer and the farm machinery sector. It made me want to understand the interconnections between these industries. I know it's like, maybe a bit specific, but they have huge consequences in terms of the way our food systems look like. And so that really drew me to understand where did these inputs come from? And why are they controlled by just a few large companies? Erika - Jennifer, I want to ask you a question about why this sector, especially related to the inputs, is so important when we're talking about food systems. And especially their social and ecological dimensions. And specifically in the book, you tease out many of the social and ecological costs of inputs such as pesticides. Also the social and ecological consequences of even farm machinery. So it would be great if you could elaborate on their importance.  Thanks, Erika. That's a great question and that's part of the reason why I was really drawn to study these inputs. Because I'm in a school of environmental studies, I'm very interested in these interconnections between food systems and environmental outcomes. I was really interested in learning more about where these industries came from, and as I was teasing out where they came from. And how they became dominated by such large companies, I also learned in much more depth about the ecological consequences of these inputs. I can just say a little bit about some of them because these consequences are so big that we almost forget to talk about them. They become embedded in the product itself. And so, one example is farm machinery. Farm machinery was originally seen as quite revolutionary and that it allowed farmers to harvest their fields much more quickly than they used to be able to before. But that also meant then that to make the equipment efficient and pay for them they might as well extend the size of their farm. And as farmers extended the size of their farm, in the US anyway, they moved west and displaced its indigenous people from the land, in terms of taking that land for farm production. But also, as farms began to consolidate and get larger, as mechanization continued, it also displaced others from the land. Poor farmers, black farmers, those who were renting land and didn't have access to their own. And so, people who were marginalized and we still considered marginalized in society today, were really being displaced from the land as a direct consequence of farm machinery. It's not that farm machinery is like necessarily something that we want to do away with today, but I think we need to recognize those historical connections. And really understand that when, you know, you see a book for a small child about farming and there might be a picture of a farmer and it's usually a white guy sitting on a tractor. We can forget that image has a lot of baggage associated with it in terms of displacement and inequality. And I think we need to recognize that. But it does not just stop there. There's also plowing disturbs the soil, heavy machinery compacts the soil so it can harm fertility of the soil as well. And the machinery part of the equation has long been a source of inequality in terms of being very expensive for farmers. It's been one of the main reasons farmers have often been driven into debt. Farm machinery might have been liberating in one sense to allow increased production, but it did come with costs that we should acknowledge. We also need to recognize the ecological and social costs associated with the fertilizer industry. And this industry goes way back to the 1840s and we saw the rise of the guano trade. And we can think immediately of the working conditions of the workers who were digging the guano in the Chincha islands of Peru. And often they were coming from Asia and facing really harsh working conditions. But then when we saw the rise of synthetic nitrogen in the early 20th Century, the cost shifted in a way towards the cost of fossil fuels. The huge amount of natural gas used in the synthesis of nitrogen. And also, the climate consequences of the nitrous oxides that come from the application of synthetic nitrogen into the soil. So again, there's like enormous ecological and social impacts from that particular input. Similarly, when we talk about seeds, the hybridization of seeds in the 1920s and 1930s also raise huge concerns about plant genetic diversity. And we know that in the last century or so we've lost around 75% of plant genetic diversity for crop genetic diversity. And this is because of the way in which we started to see the uniformity of the genetic makeup of seeds. The monocultural planting of seeds really reduced that kind of diversity. And then intellectual property protection on seeds that came with the hybridization of seeds also led to a decreased ability of farmers to save their own seed and exchange their own seed with their neighbors. So again, social ecological costs. And finally, when we talk about pesticides, we have seen enormous issues with respect to pollution runoff. This kind of bioaccumulation of these toxic chemicals that have enormous health consequences. So, all of these inputs have very large impacts in terms of their social and ecological costs. And we can even extend that to the issue of data today. There's a lot of concern about data platforms for digital farming where farmers are signing away the rights to the data that are coming from their own farms. And they don't have the kind of interoperability with other data sharing systems. And there's also a lack of clarity about who owns that data. So again, there's big issues with respect to these inputs and how they are affecting both social and ecological dynamics within the food system.  Erika - Thank you for helping us understand the social and ecological impacts of these inputs into the farming industry. Norbert - This is a really rich conversation and I want to understand a little bit more. There's a big part of your text that's about the concentration in the input sector. What does it look like today and was it always this way? That's a great question because it's almost a trick question because we tend to assume that this high level of concentration that we see today is something that's new. But what I found in my research is that the high degree of concentration actually has a long history that goes back about a century or more in some cases. And when we're looking at each of these sectors, the farm machinery, for example, is controlled. Most of the market is controlled by about just four firms. And they control around 50% of the global market. But when you look specifically at national markets in the US, for example, John Deere, you know, the largest company that makes farm machinery, it controls over 50% of the tractor market. So that's just one firm alone. It's similar dynamics when we look at fertilizer, seeds and pesticides and fertilizer, for example. Just two firms control a hundred percent of North American potash production. The four key companies control a large amount of the global fertilizer trade. In seeds, it's also very similar and in pesticides. In the seeds and pesticides that's especially interesting because since the 1980s and 1990s, the seed and pesticide companies actually merged with each other. We can't even say there's a set of seed companies and a set of chemical companies. It's actually seed and chemical companies. That's one set. And they control around 60% of the global seed market and around 70% of the global pesticide market. And that's really what prompted me to want to work on this book is that after 2015, there was a set of mergers in the seed and chemical sector that concentrated those firms even further. They used to be dominated by six firms. We used to call them the Big Six, and then they had major mergers where Bayer bought Monsanto, Dow and DuPont merged and formed Corteva. Syngenta group was bought by Chem China, and then bought by Sino Chem, a big Chinese chemical company. And then BASF bought up all the bits that the other companies were forced to sell to pass regulatory hurdles. And so, we ended up with a Big Four. And these companies produce both seeds and chemicals and have a quite an enormous impact in terms of their market dominance. Norbert - Wow. This is really important and I think it's a topic that many of us who look at the food industry aren't paying attention to. And I'm really appreciative of you laying out this concentration that's taking place. Jennifer, when reading the book, I was really struck by the fact that this is not just a book about the farmers themselves and the farming industry and the companies that provide the inputs. But you also touch upon the role of universities and university science and scientists; and also the role of government in helping to fuel or seed innovation in this sector. And, you know, here I was hoping you could talk about this important role for universities and also the government given that we're in a current moment where we're seeing a retrenchment from investments by government, and also the ability of universities to continue to seed innovation. So I was hoping you could share some of your insights.  Yes, it's certainly an interesting time on the landscape of spending on innovation and with a retrenchment of state pulling back away from supporting technological innovation and other innovations. And that's certainly true in the farm sector, and that's very different from the situation if we go back to the 1800s and see, as you mentioned, the role that the state played in terms of really trying to support innovation in these sectors. And what I argue in the book is that these firms, they got big in the first place, and they were able to consolidate in the first place, through a series of what I call market technology and policy factors. And it's kind of messy. I put them in these three big categories. But in terms of these market factors, that's what most people tend to think about when they think, 'oh, a firm got big. Maybe it's just more efficient. It's able to produce products more cheaply and therefore it just grew to be big.' And that's much more complicated than that of course. And that's because, as you said this role of technological change in which universities have played a really important role. And government support and throughout history in the US, a lot of the book focuses on the US because we have good information and data there. And the US set up the land grant college system really to support development in the agricultural sector. And that gave us, you know, a lot of the innovations that led to, for example, the hybridization of seeds. And the corporations that took up that innovation that the state supported through university research, those firms also work directly with universities in many instances, to have these kinds of collaborative relationships, to develop, herbicides, to develop seeds, to develop further farm machinery, etc. So that role of technological innovation is really important, and that innovation doesn't just come from nowhere. It doesn't just pop up. It doesn't just show up one day. Right? It comes from investment. Investment in universities and research and development. And so that has been a really important strand to develop this kind of industrial agriculture. And now we know from university research, etc., that there are some problems associated with it. Yet it's proving hard to get that kind of funding to spur a new transformation towards a more sustainable agriculture because we're not giving that kind of state support, and support to universities to do that research and innovative work to lead us towards more sustainable agriculture. So, I think there's a lot there that we need to work on. And that's some of the recommendations that I make at the end of the book. Is that we need to shore up that kind of public investment in innovation, in alternative systems to address some of the problems. So just let me tag on another question from that. Just what are the consequences then for having just a small number of firms dominating this sector and no longer having these investments in innovation? Yeah, so what we're seeing increasingly as the state has pulled away from supporting agricultural research, is that most of that agricultural research now is being done by private corporations. And the big concern there is that as you have a smaller and smaller number of very large firms dominating in the sector, their incentive to innovate actually weakens. It weakens because if there's not a lot of players in the marketplace that are doing innovative work, there's just not a lot of competition. And so why would you innovate if you don't have to? If you're already a monopoly and you're able to sell your product, there's not a lot of incentive to innovate in a way that might then decrease the sales of your old products. And so, what we're seeing is a shift in innovation from the private sector, away from these kinds of transformative innovations and much more towards what we call defensive innovations. They're innovating in ways that actually enable them to sell existing products. And many would say that the rise of agricultural biotechnology was actually that kind of a defensive innovation. It was modifying seeds to make them resistant to the application of existing herbicides. And so there was innovation, but it was actually spurring further sales in an existing product. And part of the reason for that was that it became very expensive for these companies. The regulatory hurdles became quite expensive for them to develop new herbicides. And so, they were like, 'oh, it's cheaper and faster to work with seeds. Why don't we do it this way and then we'll continue to sell the herbicides.' Which by the way, got them a lot more profit than selling the seeds. So that's why they bought up a lot of the seed companies and really consolidated in that period. And there's a longstanding concern among competition regulators, the regulators that try to prevent a huge concentration in the economy, about this question of innovation. And it's very relevant in the agricultural sector. There's this sense that if you allow too much concentration to happen, it can dampen that innovation and that takes away that dynamic, innovative spirit within the sector. It's definitely a big concern. Norbert - Jennifer, I really appreciate this. Earlier in my career I was a part of some research related to biotechnology and innovation that happens there. And one of the things that I learned about is this idea of building thickets. These sort of patent thickets where you create a series of patents that actually make it difficult for others to be able to innovate in that same way. There are these real challenges of this kind of defensive innovation. And that's just one of the challenges that you bring up in the book. And I am interested in understanding, as sort a last question, what are some of the recommendations? You mentioned public sector funding of agricultural research and many of my colleagues in my discipline have said we need more research for agriculture. Are there other areas of recommendation to address some of the concerns you raised in the book? Thanks, Norbert. Yes, definitely. And I definitely do call for greater public support for agricultural research. And that's something within the agricultural sector. And I think there we really need to focus efforts on alternative agricultural production methods. For example, agroecology, which tries to reduce the amount of external inputs, not to increase them, by using nature's own processes to achieve the same functions of diversity and pest control, etc. And what's troubling is that when the firms don't have that incentive to innovate, you know, they're definitely not going to innovate in ways that would reduce their profits. They're not going to do that. The public sector has to step in if we want to see that kind of research done. But we also need measures outside of that food and agriculture system that will benefit food and agriculture. One area is stronger antitrust policies. Policies that would prevent further mergers and acquisitions that would allow those firms to continue to get bigger and bigger. Those antitrust policies are used largely, we've got merger guidelines, for example, in North America. And in Europe, when two firms want to merge, they have to get regulatory approval to do so. And those merger guidelines really walk the regulators through what would be a merger that might dampen competition, that might weaken innovation, you know, that kind of thing. It's important that we make those rules stronger. They had become progressively weaker after the 1980s. There was this move in the regulatory space that was this kind of idea that maybe it's okay if firms get really, really big because they can benefit from economies of scale. Maybe they can bring down consumer prices and maybe we shouldn't worry so much about these other areas of control. And there's been a bit of a shift in view around this in recent years where we've seen the rise of concern about these very big companies, especially with what we see with the big tech companies taking control over all these aspects of our lives. And people are saying, wait a minute, maybe we don't want to have this just a few companies controlling so much of our lives. And so, you know, we need to think about other ways to enforce antitrust policies to make them stronger so that we foster more competition and not just focus on whether something's more expensive or not. And that's, I mean, it's a bit of a hard thing to explain to some people. Obviously, people want to see lower prices. But the idea that we have to get across is that when competition dies, when it's not there, that's when the monopoly can really raise prices. And so, we need to have that competitive marketplace in order to spur innovation and also to bring prices down. That's really important and that's a kind of agenda item that's involves food and agriculture, but it's outside of the food and agriculture sector. It encompasses more. And another area where I think we can do more is to reign in the kind of undue corporate influence on the policy process. And that's arising out of a concern that as we're seeing fewer and fewer dominant companies in the food sector, and in other sectors as well, they tend to gain more political power to influence the policy and governance process. And so, what we're seeing is heightened lobby activity. Sponsoring of scientific studies and yes, coming back to the question about universities. But as corporations get bigger, they can shape science in ways that can help them win regulatory approval for their products. We need broader policies on conflict of interest to prevent large companies from taking over the policy process. And I know that's a really salient topic in the US right now, given what's going on in the broader politics. And I think it is a broader politics issue that needs to be seriously addressed if we want to support a more transformative form of food and agriculture. These kinds of policies like stronger antitrust, better conflict of interest policies, and also support for public agricultural research are all really important steps. I don't think any one of them on their own is going to do the trick in terms of spurring this desperately needed transformation in our food systems. But together, I think, they can bring us closer to that goal. Bio Jennifer Clapp is a Tier I Canada Research Chair in Global Food Security and Sustainability and Professor in the School of Environment, Resources and Sustainability at the University of Waterloo, Canada. Dr. Clapp is currently a member of the International Panel of Experts on Sustainable Food Systems (IPES-Food) and a member of the Scientific Advisory Committee of the UN Food Systems Coordination Hub. From 2019-2023, she was a member of the Steering Committee of the High Level Panel of Experts on Food Security and Nutrition (HLPE-FSN) of the UN Committee on World Food Security, and served as Vice-Chair of that body from 2021-2023. Dr. Clapp has published widely on the global governance of problems that arise at the intersection of the global economy, food security and food systems, and the natural environment. Her most recent research projects have examined the political economy of financial actors in the global food system, the politics of trade and food security, and corporate concentration in the global food system. She has also written on policy and governance responses to the global food crisis, the political economy of food assistance, and global environmental policy and governance. Her most recent books include Food, 3rd Edition (Polity, 2020), Speculative Harvests: Financialization, Food, and Agriculture (with S. Ryan Isakson, Fernwood Press, 2018), Hunger in the Balance: The New Politics of International Food Aid (Cornell University Press, 2012), Paths to a Green World: The Political Economy of the Global Environment, 2nd Edition (with Peter Dauvergne, MIT Press, 2011), and Corporate Power in Global Agrifood Governance (co-edited with Doris Fuchs, MIT Press, 2009). Her forthcoming book, published with MIT Press (2025), is titled Titans of Industrial Agriculture: How a Few Giant Corporations Came to Dominate the Farm Sector and Why It Matters.

Inside Athletic Training
Chris Whitman (St. Louis Cardinals Medical Coordinator) Talks PBATS One-Day Charity

Inside Athletic Training

Play Episode Listen Later Mar 20, 2025 20:37


Chris Whitman, Minor League Medical Coordinator for the St. Louis Cardinals, joins the Inside Athletic Training podcast to talk about the PBATS One-Day Charity, which is currently raising money for the V Foundation for Cancer Research.About the One-Day CharityThe PBATS One-Day Charity is an annual charitable fundraiser established by the Minor League Coordinators under the umbrella of PBATS during the 2012 Winter Meetings. The charity was created with the mission of being able to give back to organizations with a greater cause and making an impact outside the game of baseball. This charitable fundraiser was initially based on the idea of all Minor League Athletic Trainers giving one day's meal money during Spring Training, to help support that year's charitable organization. Over the years donations have expanded across all members of baseball, both at the minor and major league levels, allowing for continued growth and success of the One-Day Charity.  Now going into our thirteenth year of the One-Day Charity Fundraiser, it was decided through a voting process that we will be honoring the V Foundation as the recipient in 2025.About the V Foundation for Cancer ResearchThe V Foundation for Cancer Research was founded in 1993 by ESPN and the late Jim Valvano, legendary North Carolina State University basketball coach and ESPN commentator. The Foundation has funded over $353 million in cancer research grants nationwide. The V Foundation awards 100 percent of direct donations to cancer research and related programs. The V Foundation's endowment covers administrative expenses. The Foundation awards peer-reviewed grants through a competitive award process strictly supervised by a Scientific Advisory Committee. For more information on the V Foundation, please visit v.org. To DonateTo learn more and/or donate, please visit the V Foundation One-Day Charity landing page: https://vfoundation.donordrive.com/campaign/PBATS-One-Day-CharityFor more information about PBATS and athletic training, visit pbats.com.

The Trauma Therapist | Podcast with Guy Macpherson, PhD | Inspiring interviews with thought-leaders in the field of trauma.

Michael Salter is an Associate Professor in Criminology at Western Sydney University, Australia and specializes in the study of organized sexual abuse.In addition to his work on complex trauma, Michael has researched and published widely on violence against women and children.Michael sits on the Scientific Advisory Committee and the Board of Directors of theInternational Society for the Study of Trauma and Dissociationand is an associate editor of Child Abuse Review, the peer-reviewed journal of the British Association for the Study and Prevention of Child Abuse and Neglect.In This Episodewww.OrganizedAbuse.comOrganised Sexual Abuse, by Michael SalterThe Alchemy of Wolves and Sheep: A Relational Approach to Internalized Perpetration in Complex Trauma Survivors, by Harvey L. Schwartz The Politics and Experience of Ritual Abuse: Beyond Disbelief, by Sara Scott---If you'd like to support The Trauma Therapist Podcast and the work I do you can do that here with a monthly donation of $5, $7, or $10: Donate to The Trauma Therapist Podcast.Click here to join my email list and receive podcast updates and other news.Become a supporter of this podcast: https://www.spreaker.com/podcast/the-trauma-therapist--5739761/support.

Principle of Charity
Can Degrowth Save the Planet? Pt. 2 On the Couch

Principle of Charity

Play Episode Listen Later Nov 4, 2024 34:36


This week economist Gene Tunny and activist-scholar Anitra Nelson join host Lloyd Vogelman on the couch for an unfiltered conversation that digs into the personal side of the Principle of Charity. Can two diametrically opposed thinkers meet in the middle when it's planetary survival that's at stake? BIOSGene Tunny is the Founder and Director of Adept Economics and the current President of the Queensland branch of the Economic Society of Australia. He is also an Adjunct Lecturer in economics at Griffith University and an Adjunct Fellow at the Centre for Independent Studies (CIS). He hosts the Economics Explored podcast. Gene is a former Treasury official who led teams in the Treasury's budget and industry policy divisions. Associate Professor Anitra Nelson is an activist-scholar with the Informal Urbanism Research Hub (InfUr-) at University of Melbourne. Her books include Beyond Money: A Postcapitalist Strategy (2022) and Small is Necessary: Shared Living on a Shared Planet (2018). She is co-author of Exploring Degrowth (2020) and co-editor of Post-Carbon Inclusion (2024), Housing for Degrowth: Principles, Models, Challenges and Opportunities (2018) and Food for Degrowth: Perspectives and Practices (2021). Anitra is on the Scientific Advisory Committee for the joint International Society for Ecological Economics–Degrowth Conference, to be held 24-27 June 2025, in Oslo (Norway) and holds a PhD from LaTrobe University (Australia). See more – https://anitranelson.info/CREDITSYour hosts are Lloyd Vogelman and Emile Sherman This podcast is proud to partner with The Ethics CentreFind Lloyd @LloydVogelman on Linked inFind Emile @EmileSherman on Linked In and XThis podcast is produced by Jonah Primo and Sabrina OrganoFind Jonah at jonahprimo.com or @JonahPrimo on Instagram Hosted on Acast. See acast.com/privacy for more information Hosted on Acast. See acast.com/privacy for more information.

Principle of Charity
Can Degrowth Save the Planet?

Principle of Charity

Play Episode Listen Later Oct 28, 2024 55:52


In this episode we're joined by economist Gene Tunny and activist-scholar Anitra Nelson to ask whether degrowth can save the planet, or if we should stay the current economic course. As recently as 150 years ago, pretty much everyone was living in what we'd now call extreme poverty. Thanks to capitalism, that rate is now just 9%, with a reduction of 38% in the last 30 years alone. So what's the problem? Well, for one thing, we've been plundering the natural world to fuel our growth, with little regard for its limitations. And it's come back to bite us. A regular economist might say – no problem. Let's just price in the cost of climate pollution, and natural capital, recognising that we'll need governments to take the lead. But there's a growing challenge to market-centrism from a number of movements who share a belief that a bit more government regulation is not going to get to the root of the problem; our erroneous assumption that the natural world is limitless.Degrowth argues that we can't save the planet, or end the systemic ills of capitalism like inequality, using the tools that created the problem in the first place. That our addiction to growth needs to be cut at its roots. It argues for a paradigm shift which sees wellbeing decoupled from economic growth. It envisages a different way of being, of caring and relating to each other, of flourishing itself, that's in harmony with our more noble instincts, unperverted by our current system of exploitation. BIOSGene Tunny is the Founder and Director of Adept Economics and the current President of the Queensland branch of the Economic Society of Australia. He is also an Adjunct Lecturer in economics at Griffith University and an Adjunct Fellow at the Centre for Independent Studies (CIS). He hosts the Economics Explored podcast. Gene is a former Treasury official who led teams in the Treasury's budget and industry policy divisions. Associate Professor Anitra Nelson is an activist-scholar with the Informal Urbanism Research Hub (InfUr-) at University of Melbourne. Her books include Beyond Money: A Postcapitalist Strategy (2022) and Small is Necessary: Shared Living on a Shared Planet (2018). She is co-author of Exploring Degrowth (2020) and co-editor of Post-Carbon Inclusion (2024), Housing for Degrowth: Principles, Models, Challenges and Opportunities (2018) and Food for Degrowth: Perspectives and Practices (2021). Anitra is on the Scientific Advisory Committee for the joint International Society for Ecological Economics–Degrowth Conference, to be held 24-27 June 2025, in Oslo (Norway) and holds a PhD from LaTrobe University (Australia). See more – https://anitranelson.info/CREDITSYour hosts are Lloyd Vogelman and Emile Sherman This podcast is proud to partner with The Ethics CentreFind Lloyd @LloydVogelman on Linked inFind Emile @EmileSherman on Linked In and XThis podcast is produced by Jonah Primo and Sabrina OrganoFind Jonah at jonahprimo.com or @JonahPrimo on Instagram Hosted on Acast. See acast.com/privacy for more information Hosted on Acast. See acast.com/privacy for more information.

The BMJ Podcast
Nutrition for health and conflicts of interests

The BMJ Podcast

Play Episode Listen Later Sep 27, 2024 21:49


Under-nutrition harms health, but so does over-nutrition. The Bill and Melinda Gate's foundation has just released their Goalkeepers' report - highlighting the detrimental impact that poor nutrition is having on children's health.  Rasa Izadnegahdar, director of Maternal, Newborn, Child Nutrition & Health at the foundation joins us to explain how they are targeting nutritional interventions. Also this week, a new investigation in The BMJ has found that the UK government's  Scientific Advisory Committee on Nutrition - the people who help guide the UK's nutrition policy - have competing interests with the food industry. We hear from Chris van Tulleken, University College London; Rob Percival, the Soil Association; and Alison Tedstone, chair of the Association for Nutrition.   Reading list: Goalkeepers Report 2024 UK government's nutrition advisers are paid by world's largest food companies, BMJ analysis reveals    

Real Talk: Eosinophilic Diseases
New Findings from the EGID Partners Registry with Dr. Elizabeth Jensen

Real Talk: Eosinophilic Diseases

Play Episode Listen Later Aug 29, 2024 33:34


Description: Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and co-host Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Sciences Advisory Council, have a conversation about the latest findings from the EGID Partners Registry.   In this episode, Ryan and Holly discuss with Dr. Elizabeth Jensen two studies drawn from data obtained by EGID Partners Registry questionnaires. One study focuses on extraintestinal pain experienced by patients living with EoE and other eosinophilic gastrointestinal disorders (EGIDs). The second study considers vitamin and iron deficiencies reported by patients living with EoE and other EGIDs. Dr. Jensen hints at connected research she would like to pursue next. Listen for more information about extraintestinal pain, vitamin deficiencies, EoE, and EGIDs.   Disclaimer: The information provided in this podcast is designed to support, not replace the relationship that exists between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:58] Ryan Piansky introduces the episode. He and co-host Holly Knotowicz will talk about the latest findings from the EGID Partners Registry.   [1:28] Holly introduces Dr. Elizabeth Jensen, an Associate Professor at the Wake Forest School of Medicine and an Adjunct Professor in the Department of Medicine at the University of North Carolina at Chapel Hill.   [1:58] Dr. Jensen has been working on research related to eosinophilic gastrointestinal diseases since she was in graduate school.   [2:11] Dr. Jensen's background is in maternal and child health. She was interested in how early life exposures alter colonization of the gut microbiome and how that can lead to immune dysregulation.   [2:33] Dr. Jensen became interested in EoE and eosinophilic gastrointestinal diseases because her family members had been affected by these conditions and researchers knew next to nothing about the pathogenesis of these conditions.   [2:52] Dr. Jensen's early research explored early life exposures that relate to the development of eosinophilic gastrointestinal diseases.   [3:02] That research paved the way for a variety of ongoing research studies in Denmark, the U.S., and through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).   [3:30] The Eosinophilic Gastrointestinal Disorders (EGID) Partners Registry is a registry of individuals who have been diagnosed with any one of the eosinophilic gastrointestinal diseases or multiple ones.   [4:21] The registry is also for individuals who haven't been diagnosed. The EGID Partners Registry gives a voice to individuals who are living with these conditions, in terms of directing where we go with research and asking patient-centered questions.   [4:58] To participate in the registry, go to EGIDPartners.org and register. Once you have registered you will receive a link to a questionnaire. The questionnaire can seem long.   [5:23] After the first questionnaire, the registry sometimes asks for updates to your baseline information and asks new questions that have been suggested by others.   [5:45] The EGID Partners Registry has a Scientific Advisory Committee, and patient advocacy groups, including APFED, physicians, and researchers, who direct where to go with the rich data that has been collected.   [6:07] Some of the questions are specific and asked by registry members with individual interests. Some of the questions are directed by input received by patient advocacy groups.   [6:48] After collecting these data, EGID Partners analyzes them and disseminates them by presenting them at meetings to get information to providers and individuals affected by these conditions.   [7:50] EGID Partners Registry did a study titled “Extraintestinal Symptoms of Pain in Eosinophilic Gastrointestinal Diseases” and published a poster on it. They explored joint pain, leg pain, and headaches, to see if they were related to an eosinophilic condition.   [8:29] They studied pain severity and frequency as well as migraines. A high proportion of individuals reported pain. They studied those with EoE only and those with another EGID, including eosinophilic gastritis, eosinophilic enteritis, and eosinophilic colitis.   [9:06] The second group included individuals with or without EoE. In general, patients who have one of these non-EoE EGIDS, with or without EoE, tend to experience more frequent pain and more severe pain.   [9:30] They've also seen that result in looking at other comorbidities. It reinforces the idea that patients who have multi-segmental EGIDs, or one of these lower EGIDS, tend to experience, on average, more severe extraintestinal symptoms.   [10:39] The three areas of pain highlighted on the poster were legs, joints, and headaches. This was based on feedback from patients saying, “This is what we're experiencing, is it something that you could look into?”   [10:48] It doesn't preclude the possibility that there may be other types of extraintestinal manifestations that we should be looking at in the future.   [11:27] This study by the EGID Partners Registry feels very impactful to Dr. Jensen. It brings awareness to some of the challenges that individuals with these conditions are experiencing. Holly points out it's a way for patients to get access to experts.   [12:20] In this study, the EGID Partners Registry also looked at what proportion of individuals were taking either over-the-counter pain management medications or prescription medication. [12:39] About the migraine headache pain, most of it was over-the-counter use, although some reported prescription medication.   [12:54] Ryan grew up experiencing leg pain all the time. He attributed it to his other chronic disorders. It wasn't until some years ago at an APFED conference that he heard a physician mention leg pain. Ryan had never considered it as an EoE symptom. [13:38] One of the challenges the EGID Partners Registry has is that they don't have enough individuals registered to start dividing the sample up further, by age. Roughly two-thirds of the respondents were adults. [14:12] It's also hard to get kids to report accurately what they are experiencing. It often comes down to the caregiver reporting it to the EGID Partners Registry, which brings its challenges.   [14:34] Ryan calls all patients listening to sign up with the EGID Partners Registry to allow the registry to get to some of these deeper questions.   [14:47] Dr. Jensen adds that people often want to understand why these pains are connected to EGIDs. EGID Partners Registry doesn't know why.   [15:02] There are underlying biological processes that could potentially contribute to this observation of the increased prevalence of extraintestinal pain manifestations. In the EGID population, there is the enrichment of connective tissue disorders and more.   [15:36] There is also evidence that there are increased comorbidities associated with a more inflammatory milieu. That could contribute to these extraintestinal manifestations of pain.   [15:55] Dr. Jensen hopes to bring greater awareness to patients and providers, honoring what the patient is experiencing and digging a little deeper to understand what may be going on for this patient.   [16:17] EGID Partners Registry also did a study on vitamin deficiency and supplement use among patients with EGIDs. They looked at those who had been diagnosed with EoE alone and those who had another EGID, with or without EoE.   [16:47] In this study, unlike with the pain manifestation, they didn't see a statistically significant difference between EoE alone and the other EGIDs. There was some higher proportion in those with the lower EGIDs, but it didn't reach statistical significance.   [17:16] They saw a high proportion reporting physician-diagnosed vitamin deficiency, mainly Vitamin D and a few others. That suggests the need to screen patients for vitamin deficiency with a new diagnosis and when monitoring response to therapy.   [18:28] There are reasons why there could be vitamin deficiencies. You may have a restrictive diet or be avoiding certain foods because you know they are going to bother you, or for the lower EGIDs, it may be that you're experiencing malabsorption.   [19:04] Holly plans to send this study to the people she is working with. She will ask them to read it, and then work to get a baseline.   [19:56] A patient could ask for this test from any provider. Dr. Jensen says if it helps them to bring the evidence from these papers, that's great; she hopes this empowers patients when they talk with their providers about the care that makes sense for them.   [20:41] EGID Partners Registry compared those reporting a deficiency between those with EoE alone and those without EoE. Eighty-two percent of those with EoE reported a Vitamin D deficiency. About a fourth of each group reported a B12 deficiency.   [21:27] Iron was another deficiency reported by 55% in the EoE group and 69% in the Non-EoE EGID group. Vitamins D and B12, and Iron were the top deficiencies reported. Many of the respondents reported they were taking vitamins or dietary supplements.    [22:32] Dr. Jensen thinks a nice follow-up study to this would be to learn the proportion of respondents taking vitamin injections or infusions because of malabsorption issues with oral supplements.   [22:37] Dr. Jensen thinks this study likely reflects an under-ascertainment of vitamin deficiency. A lot of patients aren't getting screened. We don't have the data yet because it's not a universal recommendation to screen for vitamin deficiencies.   [23:01] Dr. Jensen thinks awareness and increased screening will be key. Then we can start thinking about how we mitigate this.   [23:24] Patients did not report symptoms of vitamin deficiencies. Dr. Jensen thinks that's another good follow-up question. She stresses that it's important to screen for deficiencies whether or not symptoms of deficiencies are present.   [24:06] Holly considers her patients with various symptoms of vitamin deficiencies and wants to get on the website and ask questions. Dr. Jensen tells her there is a link on the registry site where you can suggest a question. She asks Holly to suggest a question!   [24:30] Patients were asked if they have ever had a vitamin deficiency and were also asked if they currently take vitamins or supplements. A vitamin pill is one type of supplement.   [25:10] The study also looked at the use of a variety of complementary and alternative medicine approaches that patients turn to because they're not getting adequate relief from traditional approaches to addressing their conditions.   [25:34] They saw a higher proportion of individuals with non-EoE EGIDs reporting the use of these kinds of alternative treatment approaches. Roughly a fourth of non-EoE EGID patients reported the use of a chiropractor, vs. 10% of EoE patients.   [26:11] Roughly one-fourth of non-EoE EGID patients reported turning to different herbal approaches in trying to get some relief for their conditions.   [26:49] Dr. Jensen says as a researcher, whenever she does a study, she is led to more questions. All of the research so far has opened the door to many more questions, including questions about individuals who don't have either EoE or another EGID.   [27:20] Dr, Jensen wonders, is this extraintestinal pain unique to those who have EoE and non-EoE EGIDs? How do we best mitigate this? What does the workup look like for the patient coming in with joint pain or leg pain?   [27:37] How can we understand the factors that contribute to this pain? How do we get providers thinking about screening for vitamin deficiencies so we have a better understanding of their prevalence in this patient population?   [28:04] If patients are not absorbing vitamins orally, How do we mitigate this? How do we optimize their nutrition so they are not dealing with vitamin deficiencies which can lead to other consequences down the road?   [28:24] The surprises are always, “What doors are getting opened as a result?” We've answered some questions but there are so many questions that we still need to answer.   [28:56] Ryan asks if a correlation was found in these studies between vitamin deficiencies and extraintestinal pain. He notices that missing his vitamins correlates with more leg pain. Dr. Jensen asks Ryan to go onto the website and pose that question!   [29:10] Dr. Jensen has not looked at the data in that way but she thinks it would be an interesting way to bring these two studies together and try to explain some of what they are observing.   [29:21] Holly thanks Dr. Jensen for sharing her expertise and this fascinating research to help all EGID patients have less painful and better quality lives.   [29:52] Dr. Jensen makes this request. “Please consider checking out the EGID Partners Registry website, joining, learning more about how you can contribute to this research, and introducing questions.”   [30:04] “We're always looking for new questions and are excited to think about how we can partner with patients in addressing questions that matter to them. Help us continue to answer some of these critical questions.”   [30:32] One topic Dr Jensen is interested in researching is the implications for reproductive health for having these conditions. Some research in another data source suggests potential implications.   [30:54] EGID Partners Registry observed and reported this year that there may be some indication of a longer time to pregnancy and a lower proportion of EGID patients experiencing a pregnancy. They want to look at that and understand it better.   [31:12] They want to understand it with more detail than they can get from the administrative data source with the initial questionnaire. EGID Partners Registry is pushing out a reproductive health history questionnaire now.   [31:29] EGID Partners Registry needs individuals to join and respond to the reproductive health questionnaire to help them understand this more deeply and some of the findings they are seeing initially in some of these other data sources.   [31:49] Ryan encourages listeners to learn more about Dr. Jensen's research and EGID Partners Registry by visiting EGIDPartners.org. To learn more about eosinophilic gastrointestinal disorders, visit APFED.org/egids.   [32:13] To find a specialist in eosinophilic disorders, use APFED's Specialist Finder at APFED.org/specialist. To connect with others impacted by eosinophilic diseases, join APFED's online community on the Inspired network at APFED.org/connections.   [32:31] Ryan thanks Dr. Jensen for joining us on Real Talk. Dr. Jensen thanks Ryan and Holly for having her on the podcast to talk about this research. Holly also thanks Education Partners, GSK, Sanofi, and Regeneron for supporting this episode.   Mentioned in This Episode: Dr. Elizabeth Jensen PhDAssociate Professor at Wake Forest University School of MedicineAdjunct Professor in the Department of Medicine at the UNC at Chapel Hill Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) EGID Partners Registry Digestive Disease Week (DDW)   “Extraintestinal Symptoms of Pain in Eosinophilic Gastrointestinal Diseases” “Frequent Report Of Vitamin Deficiencies And Use Of Supplements And Complementary/Alternative Treatment Approaches In Patients With Eosinophilic Gastrointestinal Diseases” (EGIDPartners Registry) APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.org/egids apfed.org/specialist apfed.org/connections   Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, and Regeneron.   Tweetables:   “The Eosinophilic Gastrointestinal Disorders (EGID) Partners Registry is a registry of individuals who have been diagnosed with any one of the eosinophilic gastrointestinal diseases or with multiple ones.” — Dr. Elizabeth Jensen   “The EGID Partners Registry studied extraintestinal pain severity and frequency and migraines. There was a high proportion of individuals reporting experiencing pain.” — Dr. Elizabeth Jensen   “EGID Partners Registry also did a study on vitamin deficiency and supplement use among patients with EGIDs.” — Dr. Elizabeth Jensen   “Is this unique to EoE and non-EoE EGIDs? … How do we best mitigate this for the patient who is coming in with joint pain or leg pain? What does the workup look like for those patients?” — Dr. Elizabeth Jensen   “The surprises are always, ‘What doors are getting opened as a result?' We've answered some questions but there are so many questions that we still need to answer.” — Dr. Elizabeth Jensen

Admissible: Shreds of Evidence

Content advisory: this episode makes mention of the sexual assault and murder of a child. Please take care if listening. In this special update episode of Admissible, Tessa Kramer returns to the mic to explore the aftermath of our 12-part series. Our investigation exposed the Virginia state crime lab's mishandling of a whistleblower's allegations against Mary Jane Burton, the lab's long-time Chief Serologist. Since our initial reporting, the Virginia Department of Forensic Science and its Scientific Advisory Committee have taken steps to confront the fallout. This episode highlights the case of Marvin Grimm, who spent 45 years in prison. The egregious nature of Burton's flawed evidence in this case not only clears Grimm's name, but also underscores the urgent need for the lab to take more drastic action in responding to our concerns about Mary Jane Burton. Audio of Mary Jane Burton testimony is from the Jens Soering trial. For more about that trial, we recommend the 2023 documentary "Till Murder Do Us Part: Soering vs. Haysom or the podcast, Small Town Big Crime Podcast - https://www.smalltownbigcrimepodcast.com/ --- Produced and edited by: Tessa Kramer and Ellen Horne Mixed and scored by: Charles Michelet Special thanks to: Megan Pauly, Ben Paviour, Meg Lindholm, Gavin Wright, Chloe Wynne, Dana Bialek, Danielle Elliot, Kim Nederveen Pieterse, and Steve Humble. --- Listen now on (https://admissible.vpm.org) or your favorite podcast platform. Learn more about your ad choices. Visit megaphone.fm/adchoices

Biotech 2050 Podcast
Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati

Biotech 2050 Podcast

Play Episode Listen Later Jun 13, 2024 51:22


Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The conversation covers the convergence of neurology and psychiatry, advanced technologies in drug development, and addressing unmet medical needs in neuroscience. Join us for insights into the future of biotech and developments in neuroscience. Biography: Dr. Bruce Leuchter brings deep-rooted, wide-ranging experience to his role as President and CEO at Neurvati, spanning neuroscience, clinical neuropsychiatry, biotechnology equity research, healthcare investment banking and entrepreneurship. His expertise captures all aspects of building and leading a neuroscience company, and his experiences have generated deep empathy for the patient journey. Across his many roles in the clinic, industry, and beyond, Dr. Leuchter has maintained a passion for knowledge and has aimed to purposefully apply that knowledge to help patients suffering from diseases of the brain and nervous system. A physician by training and neuropsychiatrist by specialty, Dr. Leuchter completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a voluntary faculty appointment in the Department of Psychiatry. Dr. Leuchter has also held multiple financial services roles including biotechnology equity research at Goldman Sachs, healthcare investment banking at Credits Suisse, and biotechnology mergers and acquisitions at PJT Partners, all of which drive a nuanced understanding of the biotechnology industry and particularly the neuroscience ecosystem. Dr. Leuchter is Co-Founder and Founding Neuropsychiatrist of a digital therapeutics company, Click Therapeutics, which specializes in the treatment of neurological and psychiatric disorders. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, as a member of the Life Science Institute Leadership Council at the University of Michigan, as a member of the Advisory Board at Michigan Drug Discovery, and as a Business Advisory Board member at FOXG1 Research Foundation.

Happy Bones, Happy Life
How to Increase Bone Density Through the Onero™ Osteoporosis Exercise Program With Dr. Belinda Beck

Happy Bones, Happy Life

Play Episode Listen Later Apr 23, 2024 46:47


Just because you have Osteoporosis doesn't mean you can no longer lead an active lifestyle or you have to stay indoors to minimize the risk of falls and fractures.    Certain kinds of high-intensity loading can be safe and effective even for people with low bone mass if supervised under the right conditions. And that's what Dr. Belinda Beck and I are discussing today.   Dr. Belinda Beck, a powerhouse in the field of bone health, holds a BMHS(Ed), MS, PhD, and FACSM and is a professor in the School of Health Sciences & Social Work at Griffith University.    She developed Onero™, an evidence-based exercise program based on the LIFTMOR study conducted at Griffith University. With over 20 years of teaching musculoskeletal anatomy and conducting bone research, her expertise has garnered national and international recognition.    Dr. Beck serves on the Medical and Scientific Advisory Committee of Healthy Bones Australia (formerly Osteoporosis Australia) and the Healthy Bones Australia National Consumer Advisory Committee.    Discover how Onero™ can improve your quality of life in today's informative episode of the Happy Bones, Happy Life podcast! “A number on the DEXA scan doesn't even matter to me as long as the quality of life is improving. That's what I care about as a human, not as a researcher. As a postmenopausal person, I'm at risk like everybody else. So I care what my quality of life is like.” - Dr. Belinda Beck     In this episode: - [04:17] - What is Onero™? - [08:33] - Delivering Onero™ to people who need it - [14:47] - Reduction in fractures and falls with the use of Onero™ - [20:52] - Transforming couch potatoes into strong and active women - [23:28] - Who can or can't do Onero™? - [28:36] - Learn what makes the program safe and how you can become an accredited Onero™ coach - [33:14] - How to find a certified Onero™ coach in your area - [36:09] - Onero™ training program for providers   Resources mentioned - The Bone Clinic Website - https://theboneclinic.com.au/ - Become an Onero™ Academy Accredited Practitioner - https://onero.academy/ - Discounted supplements through Fullscript - https://us.fullscript.com/welcome/mbissinger - Website for Dr. Claudia Tamas' Onero™ program in NJ - https://www.nmrnj.com/   More about Margie - Website - https://margiebissinger.com/  - Facebook - https://www.facebook.com/p/Margie-Bissinger-MS-PT-CHC-100063542905332/  - Instagram - https://www.instagram.com/margiebissinger/?hl=en    DISCLAIMER – The information presented on this podcast should not be construed as medical advice. It is not intended to replace consultation with your physician or healthcare provider. The ideas shared on this podcast are the expressed opinions of the guests and do not always reflect those of Margie Bissinger and Happy Bones, Happy Life Podcast. *In compliance with the FTC guidelines, please assume the following about links on this site: Some of the links going to products are affiliate links of which I receive a small commission from sales of certain items, but the price is the same for you (sometimes, I even get to share a unique discount with you). If I post an affiliate link to a product, it is something that I personally use, support, and would recommend. I personally vet each and every product. My first priority is providing valuable information and resources to help you create positive changes in your health and bring more happiness into your life. I will only ever link to products or resources (affiliate or otherwise) that fit within this purpose.

Robin's Nest from American Humane
Haley Grimes, Director, Farm Program Operations at American Humane

Robin's Nest from American Humane

Play Episode Listen Later Apr 15, 2024 22:33


In this episode of Robin's Nest, Georgia Boyer talks with Haley Grimes, Director of American Humane's Farm Program Operations. American Humane is a leader in improving animal welfare in agriculture and has created standards in concert with a Scientific Advisory Committee comprised of leading experts in agriculture, species-specific animal behavior, and ethics. Certified farmers create an environment that fosters the mental and physical well-being of animals by providing, among other things, appropriate space, lighting, air quality, food, and water to their animals.

Food Talk with Dani Nierenberg
430. Opening a New Area of Science to Benefit Society

Food Talk with Dani Nierenberg

Play Episode Listen Later Apr 12, 2024 44:26


On “Food Talk with Dani Nierenberg'' Dani moderates a discussion about new research and tools that can help the world adapt to a changing climate, protect agrobiodiversity, and transform our approach to and understanding of food and nutrition. Speakers dive into the architecture of a food system that will help eaters make sustainable choices, the recent work that aims to better understand diets around the globe, and measuring progress from farm to plate.  Speakers include Jessica Fanzo, Professor of Climate and Director of the Food for Humanity Initiative at the Columbia Climate School; Anna Herforth, Senior Research Associate at the Harvard T.H. Chan School of Public Health and a member of the Periodic Table of Food Initiative's Scientific Advisory Committee; Gary Paul Nabhan, a writer, ethnobiologist, Research Social Scientist Emeritus at the University of Arizona, and the Co-Founder of Native Seeds/SEARCH; Andy Jarvis, Director of Future of Food at the Bezos Earth Fund; and Jonathan Lundgren, the Founder and Director of the Ecdysis Foundation. While you're listening, subscribe, rate, and review the show; it would mean the world to us to have your feedback. You can listen to “Food Talk with Dani Nierenberg” wherever you consume your podcasts.

Psound Bytes
Ep. 215 "Shared Decision-Making: Psoriatic Care Designed for You" A UCB-sponsored episode

Psound Bytes

Play Episode Listen Later Jan 9, 2024 12:16


On this episode we'll talk about shared decision-making - when a patient and their healthcare practitioner work together to discuss and create a personalized approach to care with guests Karen Camp, a patient advocate who is living with psoriasis, and Dr. Jason Hawkes, a medical dermatologist in the greater Sacramento area who serves on the Medical Board and Scientific Advisory Committee of NPF. This podcast episode is sponsored by UCB. 

Ageless by Rescu
Suzie Hoitink | Highlights Season 7

Ageless by Rescu

Play Episode Listen Later Oct 11, 2023 12:38


Join me on the latest episode of Ageless by Rescu as we dive into the world of personalised aesthetics treatment plans with Suzie Hoitink, a member of the Scientific Advisory Committee for the Australian Non Surgical Symposium (NSS). With over two decades of experience as an aesthetics entrepreneur and healthcare professional, Suzie is a highly sought-after advisor in the industry. Her mission? To revolutionise patient safety, results, and care through training, support, and education for doctors and nurses in their practices. In this conversation, we explore the future of aesthetic procedures, evolution of clinics and the exciting advancements in non-surgical treatments available to consumers. Discover how multimodality treatment plans are your best friend, and can help you achieve natural, safe, and long-lasting results on your aesthetic journey. Suzie's expertise extends beyond treatments alone. She shares invaluable insights on selecting the right practitioner who will genuinely understand your goals, budget, and safety concerns. With her guidance, you'll be empowered to collaborate with an aesthetics professional who will create a bespoke aesthetic plan tailored just for you. But that's not all- Suzie's passion for the healthcare industry's future shines through as she highlights the tremendous potential for innovation in both clinical and business practices. Get excited for a future where aesthetic practices become even more sophisticated and safer for every patient. I'm so delighted to give you exclusive access to Suzie Hoitink's wealth of knowledge so we can discover the possibilities that lie ahead in the world of personalised aesthetics.  Listen to the full podcast here: https://omny.fm/shows/ageless-by-rescu/suzie-hoitink-member-of-non-surgical-symposiumSee omnystudio.com/listener for privacy information.

The Pain Podcast
Episode 38: Prof. Steven Kamper - Science for Clinicians

The Pain Podcast

Play Episode Listen Later Sep 27, 2023 34:25


Professor Kamper shares his expertise on how researchers can bridge the gap to assist clinicians in comprehending scientific findings effectively, while also empowering clinicians to interpret and apply the science within their practice adeptly. An engaging conversation that sheds light on the symbiotic relationship between research and clinical application, ultimately improving patient care and outcomes.   Dr Steve Kamper is Professor of Allied Health at the School of Health Sciences and Nepean Blue Mountains Local health District. He has been continuously supported by NHMRC fellowships since 2008, and is currently a NHMRC Emerging Leader Fellow . He has over 190 publications in peer-reviewed journals, has presented his work in >10 countries, and received >$5 million in competitive research funding from Australia, Ireland, Canada, and Norway. Steve is senior editor of the Journal of Orthopaedic and Sports Physial Therapy, associate editor in the Cochrane Back and Neck Group, Vice-chair of the Executive Orgainsing Committee of the International Back and Neck Pain Forum, and member of the Scientific Advisory Committee of the Australia New Zealand Musculoskeletal Clinicial Trials Network. Supporting and connecting early career researchers is an important part of Steve's professional life. In 2011 he established the International Collaboration of Early Career Researchers (http://the icecream.org), he has provided input regarding ECR programming at International conferences, conducts mentoring and training, and gives lectures on academic skills such as writing and presenting.   https://pubmed.ncbi.nlm.nih.gov/29852833/ Evidence in Practice: A New Series for Clinicians   The series "Evidence in Practice" by Professor Steven Kamper is designed to bridge the gap between research and clinical application. In this series, clinicians can expect to find valuable insights into effectively incorporating scientific evidence into their daily practice. Kamper's work aims to empower clinicians with the knowledge and tools they need to make informed decisions, ultimately enhancing patient care and outcomes. Whether you're a seasoned practitioner or a budding clinician, "Evidence in Practice" offers a practical and informative resource to help you navigate the complexities of evidence-based healthcare.

Freedom Pact
#293: Professor Thomas Seyfried - A New Approach For Fighting Cancer

Freedom Pact

Play Episode Listen Later Aug 13, 2023 55:16


Professor Thomas Seyfried is an American professor of biology, genetics, and biochemistry at Boston College. He received his PhD from the University of Illinois Urbana-Champaign in 1976. His postdoctoral fellowship studies were in the Department of Neurology at the Yale University School of Medicine where he served as an assistant professor in neurology. Professor Seyfried's research focuses on mechanisms of chronic diseases such as cancer, epilepsy, neurodegenerative lipid storage diseases, and caloric restriction diets. Prof. Seyfried has been published in over 150 peer-reviewed publications. He previously served as chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro. His 2012 book is Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer. In this episode today, Prof. Seyfried, and I discuss: - What is cancer? - Current outlooks for cancer treatments - The causes of cancer - Metabolic therapy vs other forms of cancer treatment - Empirical data for metabolic therapy - Common rebuttals to metabolic therapy - Water only fasting vs the keto diet - Cancer prevention & more! Connect with us: https://freedompact.co.uk/newsletter​ (Healthy, Wealthy & Wise Newsletter) https://instagram.com/freedompact​ tiktok.com/personaldevelopment https://twitter.com/freedompactpod freedompact@gmail.com Connect with Prof. Seyfried: https://cancerevolution.film https://www.bc.edu/bc-web/schools/mca... DISCLAIMER: The content provided by the Freedom Pact Podcast is for educational and entertainment purposes only. Our content is not intended to constitute or be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have heard on the podcast or on our social media or other platforms.

Pushing The Limits
Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer With Dr Thomas Seyfried

Pushing The Limits

Play Episode Listen Later Jun 22, 2023 80:17


In this week's episode of "Pushing the Limits I had the privilege of interview world renown cancer researcher Professor Thomas Seyfried the author of over 150 peer reviewed publications and the author of the book "Cancer as a Metabolic Disease"   For 30 years Professor Seyfried has been in the trenches as a geneticist and biochemist studying cancer cells and working out the intricacies of how to stop them proliferating. He says there are two primary fuels that cancer cells use in their abhorrent metabolism, Glucose and Glutamine and that if we can cut the fuel supply of these two things to the cancer cells we have a powerful non toxic way of killing cancer cells. He and colleagues designed the Press-pulse: a novel therapeutic strategy for the metabolic management of cancer and in this interview we dive into his latest research and what you can do if you have cancer or want to lower your chances of getting cancer.   If you enjoyed this episodes make sure to check out our Ebook/Interview series "What Your Oncologist isn't telling you" Ebook  with 20 world leading experts on this approach and adjunct therapies.   People can donate to Professor Seyfried's crucial work via this link the https://foundationformetaboliccancertherapies.com/   Dr Thomas Seyfried Bio Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer(Wiley, 1st ed., 2012).   Health Optimisation and Life Coaching with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clincian with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis She can help you navigate the confusing world of health and medicine and can advocate for you. She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whether you are facing challenges from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out.: Consult with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community   Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialised range of exclusive longevity, health optimising supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her mum but couldn't get in NZ. Check out the range at her LongLifeLabs shop   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books My latest book Relentless chronicles the inspiring journey of how my mother and I defied the odds after an aneurysm left my mum, Isobel, with massive brain damage at age 74. The medical professionals told me there was absolutely no hope of any quality of life again. Still, I used every mindset tool, years of research and incredible tenacity to prove them wrong and bring my mother back to full health within three years. Get your copy here: Lisa's Books   Our NMN Bio Flagship Longevity Range A range by molecular biologist Dr Elena Seranova NMN: Nicotinamide Mononucleotide, an NAD+ precursor Researchers have found that Nicotinamide Adenine Dinucleotide or NAD+, a master regulator of metabolism and a molecule essential for the functionality of all human cells, decreases dramatically over time.   What is NMN? NMN Bio offers a cutting edge Vitamin B3 derivative named NMN (beta Nicotinamide Mononucleotide) that can boost the levels of NAD+ in muscle tissue and liver. Take charge of your energy levels, focus, metabolism and overall health so you can live a happy, fulfilling life. Founded by scientists, NMN Bio offers supplements of the highest purity and rigorously tested by an independent, third-party lab. Start your cellular rejuvenation journey today.   Support Your Healthy Aging We offer powerful third-party tested NAD+ boosting supplements so you can start your healthy ageing journey today. Shop now: NMNBIO NMN (beta Nicotinamide Mononucleotide) 250mg | 30 capsules NMN (beta Nicotinamide Mononucleotide) 500mg | 30 capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 250mg | 30 Capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 500mg | 30 Capsules Boost Your NAD+ Levels — Healthy Ageing: Redefined Cellular Health Energy & Focus Bone Density Skin Elasticity DNA Repair Cardiovascular Health Brain Health Metabolic Health Listen to the episodes with Dr Seranova on the show: https://www.lisatamati.com/podcast--dr-elena-seranova/ https://www.lisatamati.com/podcast--dr-elena-seranova-part-3/   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr MInkoff here:  Ketone Products by HVMN The world's best  exogenous Ketone IQ Listen to the episode with Dr Latt Mansor Lisa's  ‘Fierce' Sports Jewellery Collection For Lisa's gorgeous and inspiring sports jewellery collection, 'Fierce', go to Jewellery   For Vielight Device Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com Use code "tamati" at checkout to get a 10% discount on any of their devices.   Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts. To pushing the limits, Lisa and team

Ageless by Rescu
Suzie Hoitink | Member of Non Surgical Symposium Scientific Advisory Committee | The Ultimate Personalised Aesthetics Treatment Plan

Ageless by Rescu

Play Episode Listen Later Jun 19, 2023 41:20


Join me on the latest episode of Ageless by Rescu as we dive into the world of personalised aesthetics treatment plans with Suzie Hoitink, a member of the Scientific Advisory Committee for the Australian Non Surgical Symposium (NSS). With over two decades of experience as an aesthetics entrepreneur and healthcare professional, Suzie is a highly sought-after advisor in the industry. Her mission? To revolutionise patient safety, results, and care through training, support, and education for doctors and nurses in their practices. In this conversation, we explore the future of aesthetic procedures, evolution of clinics and the exciting advancements in non-surgical treatments available to consumers. Discover how multimodality treatment plans are your best friend, and can help you achieve natural, safe, and long-lasting results on your aesthetic journey. Suzie's expertise extends beyond treatments alone. She shares invaluable insights on selecting the right practitioner who will genuinely understand your goals, budget, and safety concerns. With her guidance, you'll be empowered to collaborate with an aesthetics professional who will create a bespoke aesthetic plan tailored just for you. But that's not all- Suzie's passion for the healthcare industry's future shines through as she highlights the tremendous potential for innovation in both clinical and business practices. Get excited for a future where aesthetic practices become even more sophisticated and safer for every patient. I'm so delighted to give you exclusive access to Suzie Hoitink's wealth of knowledge so we can discover the possibilities that lie ahead in the world of personalised aesthetics.  Watch the episode here: https://youtu.be/u5yHwLyrRNw Book a one on one Ageless Coaching session with BaharI'm so pleased to now offer one one one mentoring, coaching sessions, VIP membership and the opportunity to ask me specific questions via the Sunroom platform. This is the first and only place I'll be offering in depth, personal and exclusive content that I don't share here or on my social platforms. I am excited to personally support your Ageless journey in a private and supportive space. Join Sunroom to learn more about my membership which is only $15 a month and VIP Custom Experiences ranging from quick questions to in-depth coaching. Join my Sunroom Here https://sunroom.so/BE.AgelessSee omnystudio.com/listener for privacy information.

The Real Truth About Health Free 17 Day Live Online Conference Podcast
Is There A Greater Risk Of Brain Cancer From Cell Phone Use For Younger People?

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Jun 9, 2023 22:09


Is There A Greater Risk Of Brain Cancer From Cell Phone Use For Younger People? Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Learn Skin with Dr. Raja and Dr. Hadar
Episode 151: The Science and Clinical Approach to JAK Inhibitors in Atopic Dermatitis

Learn Skin with Dr. Raja and Dr. Hadar

Play Episode Listen Later Jun 1, 2023 30:44


Wondering when to consider JAK inhibitors? We've got just the expert. This week, we're joined by Dr. Jason Hawkes as he outlines just when clinicians should consider implementing JAK inhibitors. Listen in as he talks about the many factors of JAK inhibitor treatments and practical tips for counseling patients on systemic therapies. Each Thursday, join Dr. Raja and Dr. Hadar, board certified dermatologists, as they share the latest evidence based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Jason Hawkes, MD MS is a board-certified dermatologist in the greater Sacramento area. He received his medical degree and completed his dermatology residency training from the University of Utah School of Medicine, where he was also enrolled in the Program's 2+2 dermatology research track. Dr. Hawkes then worked as a medical dermatologist as a faculty member in the Departments of Dermatology at the University of Utah, Icahn School of Medicine at Mount Sinai, and University of California Davis. In addition to being a board-certified dermatologist, he completed a research fellowship in translation immunology at the National Institutes of Health (NIH) and received a master's degree in Clinical Investigation from Rockefeller University in NYC.   Dr. Hawkes is currently serving on the Medical Board and Scientific Advisory Committee of the National Psoriasis Foundation (NPF), as well as his role as Councilor in the International Psoriasis Council (IPC). He is the recipient of multiple research grants and teaching awards, including the 2021 NPF Outstanding Educator in Psoriatic Disease. He has served as the Principal Investigator and Co-Investigator of multiple pharmaceutical-sponsored and investigator-initiated clinical trial protocols. He is the author of more than 60 peer-reviewed publications and 10 book chapters. Dr. Hawkes' principal clinical and research interests are the treatment of complex inflammatory skin diseases, such as psoriasis, hidradenitis suppurativa, and eczema, using novel systemic or biologic therapies.   To learn more about the Interaction of the Immune and Digestive Systems in the Context of Skin Disease, attend Dr. Hawkes' lecture at the 2023 Integrative Dermatology Symposium.

The Real Truth About Health Free 17 Day Live Online Conference Podcast
Is It Safe For People With Cancer To Eat Fruit And Beans?

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later May 10, 2023 9:57


Is It Safe For People With Cancer To Eat Fruit And Beans? Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Animal Training Academy
Susan Friedman; Functional assessments, Negative reinforcement & non-linear contingency analysis [Episode 200]

Animal Training Academy

Play Episode Listen Later May 8, 2023 69:01


Dr. Susan G. Friedman, Ph.D. is a professor emeritus in the Department of Psychology at Utah State University. Susan has co-authored chapters on behavior change in five veterinary texts, and her popular articles have been translated into 17 languages. She teaches seminars and courses on animal learning online (How Behavior Works: Living & Learning With Animals), with students from 63 countries so far. Susan also consults with zoos and animal organizations around the world. She was appointed to the F&WS California Condor Recovery Team from 2002 – 2010, after which time the team was retired due to the success of the birds in the wild. She is the Chairperson of the Scientific Advisory Committee of American Humane Association (AHA) Film and TV Unit, and a member in good standing of ABAI, ABMA, IAATE and IAABC. For links visit here >>> https://atamember.com/2023/05/08/function-assessments/

RealTalk MS
Episode 296: Everything You Should Know About MS Relapses with Dr. Sam Hooshmand

RealTalk MS

Play Episode Listen Later May 1, 2023 35:30


This week, we're in New York, attending the Pathways To Cures Global Summit. The National MS Society is convening the world -- bringing together the best and brightest minds in MS research, the CEOs of major MS Societies, representatives from the pharmaceutical industry and people affected by MS -- to update the scientific foundation of the Pathways To Cures research roadmap and set the global MS research agenda for the next 3-5 years. Don't miss next week's episode of RealTalk MS, when you'll hear from many of the experts on hand for this historic meeting. In this week's episode, we're talking about exacerbations, flares, attacks -- these are just some of the words we use when we're describing an MS relapse. Relapses impact over 85% of the people living with MS. And today, we're reviewing the things you need to know when it comes to MS relapses with Dr. Sam Hooshmand, the Director of the Multiple Sclerosis Clinic at the Milwaukee Veterans Affairs Medical Center, and Assistant Professor of Neurology at the Medical College of Wisconsin. We're also extending an invitation for you to spend a quick couple of minutes taking the RealTalk MS listener survey...and we're adding some motivation to that invitation by giving you an opportunity to win a $100 Amazon gift card. We'll introduce you to a remarkable MS research scientist and the Chair of the National MS Society's Scientific Advisory Committee, Dr. Tika Benveniste.  We're sharing the outcome of a study that compared the benefits of yoga and physical therapy for people living with MS. And we'll tell you about a first-of-its-kind collaboration between Cariloop and Walgreens that's designed to support MS caregivers. We have a lot to talk about! Are you ready for RealTalk MS??! Greetings from the Pathways to Cures Global Summit  :22 Take the RealTalk MS listener survey...you might win a $100 Amazon gift card!  2:09 This Week: Everything you should know about MS relapses  2:49 Meet the Chair of the National MS Society's Scientific Advisory Committee, Dr. Tika Benveniste   3:35 Study compares the benefits of yoga and physical therapy for people living with MS  16:53 Cariloop and Walgreens announce collaboration to support MS caregivers  21:19 Dr. Sam Hooshmand reviews everything you should know about MS relapses  24:13 Share this episode  34:09 Please remember to take our listener survey!  34:30 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/296 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Take the RealTalk MS Listener Survey  https://realtalkms.com/survey RealTalk MS Episode 125: From the Pathways To Cures Think Tank  https://realtalkms.com/125 RealTalk MS Episode 238: The Pathways To Cures Research Roadmap  https://realtalkms.com/238 RealTalk MS Special Podcast Series: Barancik Prize Conversations Part 1 https://realtalkms.com/barancik1 RealTalk MS Special Podcast Series: Barancik Prize Conversations Part 2 https://realtalkms.com/barancik2 STUDY: Yoga vs Physical Therapy in Multiple Sclerosis: Results of a Randomized Controlled Trial and the Training Protocol https://journals.sagepub.com/doi/full/10.1177/09727531231161994 Take the RealTalk MS Listener Survey  https://realtalkms.com/survey Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 296 Guests: Dr. Tika Benveniste and Dr. Sam Hooshmand Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

The Real Truth About Health Free 17 Day Live Online Conference Podcast
GBM And Other Stage 4 Cancers Should Not Be Considered Terminal If Treated With Ketogenic Metabolic Therapy

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Apr 10, 2023 27:23


GBM And Other Stage 4 Cancers Should Not Be Considered Terminal If Treated With Ketogenic Metabolic Therapy Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Physical Activity Researcher
Physical Activity and Brain Plasticity: New Discoveries and Future Directions - Prof Charles Hillman (Pt2)

Physical Activity Researcher

Play Episode Listen Later Mar 28, 2023 23:49


In this episode, we are joined by Dr. Charles Hillman, a Professor in the Department of Psychology and the Department of Physical Therapy, Movement, and Rehabilitation Sciences at Northeastern University in Boston, Massachusetts. Dr. Hillman is also the co-director of the Center for Cognitive and Brain Health, which focuses on understanding how lifestyle choices and behaviors impact brain health and cognition. Throughout his career, Dr. Hillman has published over 300 articles and co-edited a text on Functional Neuroimaging in Exercise and Sport Sciences. He has also served on numerous committees, including the Institute of Medicine of the National Academies and the Health and Human Services Physical Activity Guidelines for American's Scientific Advisory Committee. In this conversation, we delve into Dr. Hillman's research on how lifestyle choices such as physical activity and diet impact brain health and cognitive function. We also discuss the mission of the Center for Cognitive and Brain Health and its research on how to maximize health and well-being and promote effective functioning for individuals across the lifespan. Join us as we explore the fascinating research of Dr. Charles Hillman and his team at the Center for Cognitive and Brain Health. -------- This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behaviour and Physical Activity Research with Less Hassle --- Learn more about Fibion Sleep and Circadian Rhythm Solutions: https://sleepmeasurements.fibion.com/ --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS: https://sens.fibion.com/ --- SB and PA measurements, analysis, and feedback made easy.  Learn more about Fibion Research : fibion.com/research --- Fibion Kids - Activity tracking designed for children. https://fibionkids.fibion.com/ --- Collect self-report physical activity data easily and cost-effectively https://mimove.fibion.com/ --- Follow the podcast on Twitter https://twitter.com/PA_Researcher Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen Follow Fibion on Twitter https://twitter.com/fibion https://www.youtube.com/@PA_Researcher

Physical Activity Researcher
Maximizing Brain Health: The Effects of Physical Activity Across the Lifespan - Prof Charles Hillman (Pt1)

Physical Activity Researcher

Play Episode Listen Later Mar 21, 2023 19:49


In this episode, we are joined by Dr. Charles Hillman, a Professor in the Department of Psychology and the Department of Physical Therapy, Movement, and Rehabilitation Sciences at Northeastern University in Boston, Massachusetts. Dr. Hillman is also the co-director of the Center for Cognitive and Brain Health, which focuses on understanding how lifestyle choices and behaviors impact brain health and cognition. Throughout his career, Dr. Hillman has published over 300 articles and co-edited a text on Functional Neuroimaging in Exercise and Sport Sciences. He has also served on numerous committees, including the Institute of Medicine of the National Academies and the Health and Human Services Physical Activity Guidelines for American's Scientific Advisory Committee. In this conversation, we delve into Dr. Hillman's research on how lifestyle choices such as physical activity and diet impact brain health and cognitive function. We also discuss the mission of the Center for Cognitive and Brain Health and its research on how to maximize health and well-being and promote effective functioning for individuals across the lifespan. Join us as we explore the fascinating research of Dr. Charles Hillman and his team at the Center for Cognitive and Brain Health. ----------- This podcast episode is sponsored by Fibion Inc. | Better Sleep, Sedentary Behaviour and Physical Activity Research with Less Hassle --- Learn more about Fibion Sleep and Circadian Rhythm Solutions: https://sleepmeasurements.fibion.com/ --- Collect, store and manage SB and PA data easily and remotely - Discover ground-breaking Fibion SENS: https://sens.fibion.com/ --- SB and PA measurements, analysis, and feedback made easy.  Learn more about Fibion Research : fibion.com/research --- Fibion Kids - Activity tracking designed for children. https://fibionkids.fibion.com/ --- Collect self-report physical activity data easily and cost-effectively https://mimove.fibion.com/ --- Follow the podcast on Twitter https://twitter.com/PA_Researcher Follow host Dr Olli Tikkanen on Twitter https://twitter.com/ollitikkanen Follow Fibion on Twitter https://twitter.com/fibion https://www.youtube.com/@PA_Researcher

The Rational View podcast with Dr. Al Scott
Dr. Robert Gale talks about treating Chernobyl victims

The Rational View podcast with Dr. Al Scott

Play Episode Listen Later Mar 18, 2023 55:38


In this episode I am returning to explore the truth about the Chernobyl disaster. I have the great fortune to interview one of the doctors who treated the exposed workers in Moscow following the explosion.  Let's see what he thinks of the health risks of nuclear power. Robert Peter Gale was born in New York in 1945. He received his MD from the State University of New York at Buffalo and PhD in microbiology and immunology from the University of California, Los Angeles (UCLA). After that Gale was on the faculty of the UCLA School of Medicine, and served as Chairman of the Scientific Advisory Committee of the Center for International Blood and Marrow Transplant Research, and later chaired the Scientific Advisory Board of the Center for Advanced Studies in Leukemia. He was President of the Armand Hammer Center for Advanced Studies in Nuclear Energy and Health. Gale is currently Visiting Professor of Haematology at Sun Yat-sen Cancer Centre, Guangzhou, China and Honorary Professor of Hematology at the Institute of Hematology at Peking Union Medical College. He is the Editor-in-Chief of LEUKEMIA, Associate Editor of CLINICAL TRANSPLANTATION, Executive Editor of BONE MARROW TRANSPLANTATION and a reviewer for many scientific journals in hematology, oncology, immunology, transplantation, radiation biology and internal medicine. Prof. Gale is also an expert on the medical response to nuclear and radiation accidents. From 2007-2019 he was executive director of clinical research and development at Celgene Corp and an honorary member of the Russian and Chinese Academies of Medical Science. He is the recipient of several distinguished awards and honorary degrees including the Presidential Award, and an Emmy award. Gale has published over 1,350 scientific articles and 25 books on medical topics, nuclear energy and weapons and politics of US-Russian relations and received an Emmy award. His latest book is “Radiation: What it is, What you need to Know”. Support the podcast at patron.podbean.com/TheRationalView Join the Facebook discussion @TheRationalView Twitter @AlScottRational Watch the video version on YouTube! #TheRationalView #podcast #chernobyl #nuclearenergy #radiation #health

Bridging the Carbon Gap
Rebecca Willis on solving climate change with more democracy [Season 2, Episode 2]

Bridging the Carbon Gap

Play Episode Listen Later Mar 10, 2023 51:01


Rebecca Willis is a Professor in Energy & Climate Governance at Lancaster Environment Centre, where she leads the Climate Citizens  project. In 2020 she was an Expert Lead for Climate Assembly UK, the Citizens' Assembly established by the UK Parliament. Rebecca is a Trustee of the New Economics Foundation and an adviser to the National Lottery's Climate Action Fund. She features on the Woman's Hour Our Planet Power List which highlights 30 women making an impact by helping to protect our planet.  Her book, Too Hot To Handle? The democratic challenge of climate change was published by Bristol University Press in March 2020.Previously, she was a research fellow for the IGov project at the University of Exeter, investigating energy governance. From 2015-2019 she was a member of the Scientific Advisory Committee of UKRI's Energy Programme, and from 2011-15 she was a Council Member of the Natural Environment Research Council. She was Vice-Chair of the UK Sustainable Development Commission, advising the Prime Minister and First Ministers of the devolved administrations, from 2004-2011.  In 2009 Rebecca founded Green Alliance's Climate Leadership Programme, an initiative to support Members of the UK Parliament, and earlier served as Green Alliance's Director.

The Real Truth About Health Free 17 Day Live Online Conference Podcast
A Novel Therapeutic Strategy For The Metabolic Management Of Cancer

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Mar 10, 2023 10:59


A Novel Therapeutic Strategy For The Metabolic Management Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

The Real Truth About Health Free 17 Day Live Online Conference Podcast
If We Target Glucose And Glutamine We Can Manage The Majority Of Cancers

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Feb 7, 2023 14:12


If We Target Glucose And Glutamine We Can Manage The Majority Of Cancers Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

UNBREAKABLE - The OC Podcast
Osteoporosis and Osteoarthritis: What You Need To Know with Dr. Heather McDonald-Blumer

UNBREAKABLE - The OC Podcast

Play Episode Listen Later Feb 2, 2023 24:21


The terms osteoporosis and osteoarthritis are often mistakenly used interchangeably as they are two separate diagnoses. Dr. Heather McDonald-Blumer, a rheumatologist is a member of the Division of Rheumatology at Mt. Sinai Hospital/University Health Network. Her clinical interests include osteoporosis and inflammatory joint disease. She is the associate director of the Osteoporosis Program at UHN and is a member of Osteoporosis Canada's Scientific Advisory Committee. On this episode, Dr. McDonald-Blumer discusses each condition, what makes them similar, how you can manage both conditions and more.

Nutrition with Judy
210. Metabolic Therapy for Cancer Patients - Thomas Seyfried

Nutrition with Judy

Play Episode Listen Later Jan 9, 2023 56:36 Very Popular


I'm excited to sit down with Dr. Thomas Seyfried. We talk about cancer, metabolic therapy, and much more. Make sure to listen to the full interview to learn more.Dr. Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology.Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.We discuss the following:All about Dr. Thomas SeyfriedWhat is cancer?Warburg studyBest ways to protect ourselves from cancerGlucose and glutamineMetabolic therapy for cancer patientsZero carb diet and cancerThoughts on breast and ovarian cancer genesCancer and environmentThoughts on a carnivore diet for cancerTips to cancer patientsWhere to find Dr. Thomas Seyfried_____RESOURCESPubMed studies: https://pubmed.ncbi.nlm.nih.gov/?term=Seyfried+TN&cauthor_id=23237552 Foundation for metabolic cancer therapies: https://foundationformetaboliccancertherapies.com/ ____CHECK OUT MY BOOK, Carnivore CureSIGN UP FOR MY WEEKLY NEWSLETTER_____ ADDITIONAL RESOURCESNutrition with Judy ArticlesNutrition with Judy ResourcesCutting Against the Grain Podcast_____ FIND ME

The Real Truth About Health Free 17 Day Live Online Conference Podcast
Evidence That Challenges The Somatic Mutation Theory Of Cancer

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Jan 7, 2023 16:16


Evidence That Challenges The Somatic Mutation Theory Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

The Real Truth About Health Free 17 Day Live Online Conference Podcast
Mitochondrial Respiratory Damage Is The Origin Of Cancer

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Dec 7, 2022 8:32


Mitochondrial Respiratory Damage Is The Origin Of Cancer Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited.  This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate. The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University.  Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society.  Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor.  Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

Whole Grain
Cyber Attacks: How Should the Grain Industry Respond?

Whole Grain

Play Episode Listen Later Nov 14, 2022 35:24


What are the current risks to our national and global food security? How do cyber-attacks play a role? What are the conflicts in the grain industry that prevent us from moving forward? Dr. Molly Jahn and Col. John Hoffman, two of the most sought-after food security experts in the world, provide their recommendations for real solutions to this growing problem.  About the guests: Dr. Molly Jahn is a professor at the University of Wisconsin-Madison where she holds appointments in the Department of Agronomy, the Nelson Institute, and the Global Health Institute. She is currently on an interagency personnel agreement from UW-Madison to work as a program manager at the Defense Advanced Research Projects Agency (DARPA). She is also appointed Joint Faculty at the US Department of Energy Oak Ridge National Laboratory (ORNL) where she chairs the Scientific Advisory Committee of the Energy and Environmental Sciences Directorate and sits on the Lab Director's SAC.  Col. John T. Hoffman is a senior research fellow with the Food Protection and Defense Institute (FPDI), a U.S. Department of Homeland Security Center of Excellence at the University of Minnesota. Col. Hoffman has extensive experience in developing, operating, hardening and sustaining extensive cyber systems.  Episode topics: Current global food security measuresImplications of cyber threats on food securityCyber-attack preparedness and current limitationsAction steps for the grain industryTo find more helpful resources, be sure to visit the GEAPS website and the membership page.   Grain Elevator and Processing Society champions, connects and serves the global grain industry and its members. Be sure to visit GEAPS' website to learn how you can grow your network, support your personal professional development, and advance your career. Thank you for listening to another episode of GEAPS' Whole Grain podcast.

The Animal Turn
S5E1: Biosecurity with Steve Hinchliffe

The Animal Turn

Play Episode Play 26 sec Highlight Listen Later Oct 17, 2022 82:13 Transcription Available


Claudia launches season 5 of The Animal Turn with a conversation on biosecurity with Steve Hinchliffe, a renowned geographer. They discuss how biosecurity is centered on the idea of keeping life safe and how this often operates through spatial logics of trying to keep threats out. They touch on how animals are often blamed for biosecurity threats, questions about whose lives are kept safe, and the various walling work that is done under the banner of biosecurity.  Date Recorded: 21 September 2022 Steve Hinchliffe is Professor of Human Geography at the University of Exeter, UK and a Fellow of the Academy of Social Sciences. His books include Pathological Lives (2016, Wiley Blackwell) and Humans, animals and biopolitics: The more than human condition (2016, Routledge). He currently works on a number of interdisciplinary projects on disease, biosecurity and drug resistant infections, focusing on Europe and Asia.  He is a member of the Wellcome Centre for Cultures and Environments of Health at Exeter, and sits on the UK Government's Scientific Advisory Committee on Exotic Diseases and on the UK Department for Environment, Food and Rural Affairs Science Advisory Group's Social Science Expert Group. Find out more about Steve on Exeter's website.  Claudia (Towne) Hirtenfelder is the founder and host of The Animal Turn. She is a PhD Candidate in Geography and Planning at Queen's University and is currently undertaking her own research project looking at the geographical and historical relationships between animals (specifically cows) and cities. She was awarded the AASA Award for Popular Communication for her work on the podcast. Contact Claudia via email (info@theanimalturnpodcast.com) or follow her on Twitter (@ClaudiaFTowne). Featured: For Space, by Doreen Massey; Walled States, Waning Sovereignty, by Wendy Brown; Cow, a movie directed by Lin Gallagher; Pleasurable Kingdom: Animals and the nature of feeling good by Jonathan Balcombe; Encounters in Borderlands: Borderlining Animals and Technology at Frankfurt Airport by Susanne Bauer, Nils Güttler, and Martina Schlünder; More Than a Meal: The Turkey in History, Myth, Ritual, and Reality, by Karen Davis. Animal Highlight: TurkeysThe Animal Turn is part of the  iROAR, an Animals Podcasting Network and can also be found on A.P.P.L.E, Twitter, and Instagram Thank you to Animals in Philosophy, Politics, Law and Ethics (A.P.P.L.E) for sponsoring this podcast; the BiosecuritA.P.P.L.E Animals in Philosophy, Politics, Law and Ethics (A.P.P.L.E)Biosecurities Research Collective The Biosecurities and Urban Governance Research brings together scholars interested in biosecurity.

The Real Truth About Health Free 17 Day Live Online Conference Podcast
Cancer As A Metabolic Disease: Implications For Novel Therapeutics - Thomas N. Seyfried, PhD

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Oct 16, 2022 112:46


New 2022 - Cancer As A Metabolic Disease: Implications For Novel Therapeutics - Thomas N. Seyfried, PhD Dr. Thomas Seyfried, • Contact: thomas.seyfried@bc.edu • Book – Cancer as a Metabolic Disease #ThomasSeyfried#Cancer #MetabolicDisease Dr. Thomas Seyfried, is a professor and author publishing a groundbreaking book; Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer.This book addresses controversies related to the origins of cancer and provides solutions to cancer management and prevention. It expands upon Otto Warburg's well-known theory that all cancer is a disease of energy metabolism.  However, Warburg did not link his theory to the "hallmarks of cancer" and thus his theory was discredited. This book aims to provide evidence, through case studies, that cancer is primarily a metabolic disease requiring metabolic solutions for its management and prevention.  Support for this position is derived from critical assessment of current cancer theories.  Brain cancer case studies are presented as a proof of principle for metabolic solutions to disease management, but similarities are drawn to other types of cancer, including breast and colon, due to the same cellular mutations that they demonstrate.The book also provides extensive information showing that cancer can be best defined as a mitochondrial metabolic disease rather than as a genetic disease. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet. Experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Dr. Thomas Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He has a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).”To Contact Dr Thomas N. Seyfried, Ph.D. email:  thomas.seyfried@bc.edu CLICK HERE - To Checkout Our MEMBERSHIP CLUB: http://www.realtruthtalks.com  • Social Media ChannelsFacebook: https://www.facebook.com/TRTAHConferenceInstagram : https://www.instagram.com/therealtruthabouthealth/ Twitter: https://twitter.com/RTAHealth Linkedin: https://www.linkedin.com/company/the-real-truth-about-health-conference/ Youtube: https://www.youtube.com/c/TheRealTruthAboutHealth    • Check out our Podcasts  Visit us on Apple Podcast and Itunes search:  The Real Truth About Health Free 17 Day Live Online Conference Podcast Amazon: https://music.amazon.com/podcasts/23a037be-99dd-4099-b9e0-1cad50774b5a/real-truth-about-health-live-online-conference-podcastSpotify: https://open.spotify.com/show/0RZbS2BafJIEzHYyThm83J Google:https://www.google.com/podcasts?feed=aHR0cHM6Ly9mZWVkcy5zaW1wbGVjYXN0LmNvbS8yM0ZqRWNTMg%3D%3DStitcher: https://www.stitcher.com/podcast/real-truth-about-health-live-online-conference-podcastAudacy: https://go.audacy.com/partner-podcast-listen-real-truth-about-health-live-online-conference-podcastiHeartRadio: https://www.iheart.com/podcast/269-real-truth-about-health-li-85932821/ Deezer: https://www.deezer.com/us/show/2867272 Reason: https://reason.fm/podcast/real-truth-about-health-live-online-conference-podcast • Other Video ChannelsYoutube:https://www.youtube.com/c/TheRealTruthAboutHealthVimeo:https://vimeo.com/channels/1733189Rumble:  https://rumble.com/c/c-1111513 Facebook:https://www.facebook.com/TRTAHConference/videos/?ref=page_internal DailyMotion: https://www.dailymotion.com/TheRealTruthAboutHealth BitChute:  https://www.bitchute.com/channel/JQryXTPDOMih/ Disclaimer:Medical and Health information changes constantly. Therefore, the information provided in this podcast should not be considered current, complete, or exhaustive. Reliance on any information provided in this podcast is solely at your own risk. The Real Truth About Health does not recommend or endorse any specific tests, products, procedures, or opinions referenced in the following podcasts, nor does it exercise any authority or editorial control over that material. The Real Truth About Health provides a forum for discussion of public health issues. The views and opinions of our panelists do not necessarily reflect those of The Real Truth About Health and are provided by those panelists in their individual capacities. The Real Truth About Health has not reviewed or evaluated those statements or claims. 

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast
Episode 65: Special Guest interview w/Cardiologist Dr Aseem Malhotra, and the Facts about heart health and diet

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast

Play Episode Listen Later Aug 19, 2022 68:07


Dr Aseem Malhotra is an NHS Trained Consultant Cardiologist, and visiting Professor of Evidence Based Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil. He is a world renowned expert in the prevention, diagnosis and management of heart disease. He is honorary council member to the Metabolic Psychiatry Clinic at Stanford University school of medicine California, and is Cardiology MSc examiner at the University of Hertfordshire, UK. He is a founding member of Action on Sugar and was the lead campaigner highlighting the harm caused by excess sugar consumption in the United Kingdom, particularly its role in type 2 diabetes and obesity. FIND OUT MORE ABOUT DR MALHOTRA AT: Board of Trustees https://phcuk.org/trustees/ Scientific Advisory Committee https://phcuk.org/sac/ PHC bio https://phcuk.org/members/dr-aseem-malhotra/ Website https://doctoraseem.com/ Social Media: Twitter @draseemmalhotra IG @lifestylemedicinedoctor FB Aseem Malhotra Patreon Dr Aseem   SPONSORS: X3 bar system with discount code "DRCHAFFEE" https://www.kqzyfj.com/click-100676052-13511487 THE CARNIVORE BAR: Discount Code "Anthony" for 10% off all orders! https://the-carnivore-bar.myshopify.com/?sca_ref=1743809.v3IrTuyDIi CARNIVORE CRISPS: Discount Code "DRCHAFFEEMD" for 10% off all orders! www.carnivorecrisps.com Shop Amazon https://www.amazon.com/shop/anthonychaffeemd?ref=ac_inf_hm_vp FOLLOW AND CONTACT ME: PATREON for early releases, bonus content, and weekly Zoom meetings https://www.patreon.com/AnthonyChaffeeMD Sign up for our 30-day carnivore challenge and group here! https://www.howtocarnivore.com/ INSTAGRAM: @anthonychaffeemd www.instagram.com/anthonychaffeemd/ TWITTER: @Anthony_Chaffee TIKTOK: @AnthonyChaffeeMD Apple Podcast: The Plant Free MD https://podcasts.apple.com/au/podcast/the-plant-free-md-podcast/id1614546790 Spotify: The Plant Free MD https://open.spotify.com/show/0WQtoPLuPMWWm3ZT3DYXzp?si=PPc2rXZzQXuzjIRK__SEZQ For Consults or collaborations, please email me at the below address. Please understand that I can not give advice over email, but only in a consultation setting: AnthonyChaffee@gmail.com For more of my interviews and discussions, as well as other resources, go to my Linktree at: https://linktr.ee/DrChaffeeMD OR my website at: www.TheCarnivoreLife.com And please like and subscribe to my podcast here and Apple/Google podcasts, as well as my YouTube Channel to get updates on all new content! Music track: Acoustic Breeze from Bensound.com #keto #fyp #cholesterol #carnivore #carnivorediet #weightloss #thecarnivorelife #weightsandsteaks #teamcarnivore #meatheals #yestomeat #nutrition #diet #autoimmune #rugby #rugbyunion #rugbyplayer #weightlossjourney #weightlifting #steak #bodybuilding #strength #strengthtraining #weighttraining #zerocarb  #ketovore #ribeye #liondiet #ketodiet #carnivoreketo #ketotransformation #carnivore75hard #vegan #sowell #thomassowell #dairy #milk #cheese #nsng #lchf #lcif

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast
Episode 60: The Hard Facts about Cancer and Diet with Professor Thomas Seyfried of Boston College

The Plant Free MD with Dr Anthony Chaffee: A Carnivore Podcast

Play Episode Listen Later Jul 22, 2022 99:21


Professor Thomas Seyfried has published over 150 peer reviewed studies in biology and cancer biology and has verified Nobel Prize Winner Otto Warburg's assertation that cancer is a metabolic disease of the mitochondria, not a genetic disorder. If we misunderstand the origin of the disease, the treatment is going to be wrong as well, and this is exactly what has happened. Ever think about why the cancer rates have tripled in the past 40 years? Well, this is why. Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried is also the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012).   FOLLOW PROFESSOR SEYFRIED: Instagram: https://www.instagram.com/thomasseyfriedbc/   FOLLOW AND CONTACT ME AT: MY PATREON https://www.patreon.com/AnthonyChaffeeMD Sign up for our 30-day carnivore challenge and group here! https://www.howtocarnivore.com/ ORDER THE CARNIVORE BAR! Discount Code "Anthony" for 10% off all orders! https://the-carnivore-bar.myshopify.com/?sca_ref=1743809.v3IrTuyDIi ORDER CARNIVORE CRISPS! Discount Code "DRCHAFFEEMD" for 10% off all orders! www.carnivorecrisps.com For Consults or collaborations, please email me at: AnthonyChaffee@gmail.com Shop Amazon https://www.amazon.com/shop/anthonychaffeemd?ref=ac_inf_hm_vp INSTAGRAM: @anthonychaffeemd www.instagram.com/anthonychaffeemd/ TWITTER: @Anthony_Chaffee TIKTOK: @AnthonyChaffeeMD Facebook Group: The Carnivore Fix https://www.facebook.com/groups/1078241659422805 Weekly Q&A sessions: https://www.patreon.com/thecarnivorelife For more of my interviews and discussions, as well as other resources, go to my Linktree at: https://linktr.ee/DrChaffeeMD OR my website at: www.TheCarnivoreLife.com And please like, comment, share, and subscribe to my podcast here and Apple/Google/Spotify podcasts, as well as my YouTube Channel to get updates on all new content, and please give a 5-star rating! Music track: Acoustic Breeze from Bensound.com   RESOURCES: Professor Thomas Seyfried cancer as a metabolic disease https://youtu.be/06e-PwhmSq8 Ketogenic diets and cancer treatment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375425/ Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies https://www.frontiersin.org/articles/10.3389/fnut.2021.594408/full Carnivore cancer treatment center, Hungary https://humanperformanceoutliers.libsyn.com/episode-84-dr-zsofia-clemens Keto as cancer treatment and prevention https://youtu.be/DlI6DMZxgBY Dr Thomas Seyfried Cancer, mitochondria, and ketogenic diet and fasting in cancer treatment https://youtu.be/PuG5XZSR4vs Keto and glutamine, GBM treatment Seyfried https://www.nature.com/articles/s42003-019-0455-x Cancer causing polyunsaturated fat (Mitochondria effect) https://www.sciencedirect.com/science/article/pii/S2213231714001359 Red meat doesn't increase risk of colon cancer or all cause mortality https://www.mdpi.com/2072-6643/13/1/32   #carnivore #keto #weightloss #thecarnivorelife #carnivorediet #weightsandsteaks #teamcarnivore #meatheals #yestomeat #nutrition #diet #autoimmune #rugby #rugbyunion #rugbyplayer #weightlossjourney #weightlifting #steak #bodybuilding #strength #strengthtraining #weighttraining #zerocarb #ketovore #ribeye #liondiet #ketodiet #carnivoreketo #ketotransformation #carnivore75hard #vegan #sowell #thomassowell #dairy #milk #cheese #nsng #lchf #lcif

The Nick Bryant Podcast
Organized Abuse with Dr. Michael Salter

The Nick Bryant Podcast

Play Episode Listen Later Jul 1, 2022 69:00


This episode of the Nick Bryant podcast features Dr. Michael Salter, the Scientia Associate Professor in Criminology at the University of New South Wales, Australia. He specializes in the study of organized sexual abuse and its treatment. Dr. Salter is on the Scientific Advisory Committee and the Board of Directors of the International Society for the Study of Trauma and Dissociation.   nickbryantnyc.com patreon.com/thenickbryantpodcast

Ruthless Compassion with Dr. Marcia Sirota
112 - Dr. Melanie Badali: Offering Evidence-Based Support for People With Anxiety

Ruthless Compassion with Dr. Marcia Sirota

Play Episode Listen Later Jun 16, 2022 36:58


Dr. Melanie Badali is an award-winning clinical psychologist with over 20 years of experience working as a psychotherapist, researcher, and educator. At the North Shore Stress and Anxiety Clinic, she helps people optimize their personal and professional potential using science-based strategies. A committed mental health advocate, she believes everyone should have access to mental health information and services. After serving on the Board of Directors for Anxiety Canada for 8 years, she is now on the Scientific Advisory Committee. She enjoys sharing what she knows about psychology through writing, public speaking, and media communication. You can find Dr. Badali online... Website Twitter LinkedIn

Doggy Dojo
Exploring Extinction with Susan Friedman, PhD

Doggy Dojo

Play Episode Listen Later Apr 19, 2022 42:36 Very Popular


Susan G. Friedman, Ph.D. is a professor emeritus in the Department of Psychology at Utah State University. Susan has co-authored chapters on behavior change in five veterinary texts, and her popular articles have been translated into 17 languages. She teaches seminars and courses on animal learning online (How Behavior Works: Living & Learning With Animals), with students from 60 countries so far. Susan also consults with zoos and animal organizations around the world. Susan was appointed to the F&WS California Condor Recovery Team from 2002 – 2010, after which time the team was retired due to the success of the birds in the wild. She is the Chairperson of the Scientific Advisory Committee of American Humane Association (AHA) Film and TV Unit, and a member in good standing of ABAI, ABMA, IAATE and IAABC. Website: www.behaviorworks.org Facebook: www.facebook.com/behaviorworks If you want to work with me, Susan Light, you can find me at: www.doggydojopodcast.com The music was written by Mac Light, you can find him at: www.maclightsongwriter.com If you like the show, please Subscribe, Rate, Review, and Share to help others find the show! I'll see you in two weeks with a brand new episode of the Doggy Dojo!

RealTalk MS
Episode 238: The Pathways to Cures Research Roadmap with Dr. Carol Whitacre and Prof. Alan Thompson

RealTalk MS

Play Episode Listen Later Mar 21, 2022 35:29


The Pathways to Cures initiative is focused on stopping MS progression, restoring lost function, and ending MS forever. This bold initiative has already been endorsed by more than 20 MS research and patient organizations around the world. And now, the publication of the Pathways to Cures Research Roadmap has brought us to a pivotal moment in the history of MS research. Joining me in this episode of RealTalk MS are two very special guests, Dr. Carol Whitacre and Professor Alan Thompson. We're taking a close look at what Pathways to Cures is all about, where we are on the Pathways to Cures Research Roadmap, and what this initiative means for people affected by MS. Dr. Whitacre is the former Senior Vice-President of Research at The Ohio State University, and the current Chair of the National MS Society's Scientific Advisory Committee. Professor Thompson is a clinician scientist who has been the recipient of virtually every high honor and award that's given in the field of multiple sclerosis research, including the John Dystel Prize for MS Research in 2017, the Sobek Research Prize in 2020, and the 2021 Charcot Award, which recognizes a lifetime of achievement in outstanding research into understanding and treating MS. We have a lot to talk about! Are you ready for RealTalk MS??! The Pathways to Cures Research Roadmap  :22 Dr. Carol Whitacre discusses the significance of the Pathways to Cures initiative  3:34 Prof. Alan Thompson reviews the status of MS research to stop progression, restore lost function, and end MS, then looks ahead to next steps in the Pathways to Cures research roadmap    16:14 Share this episode  33:52 Have you downloaded the RealTalk MS app?   34:12 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/238 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance RealTalk MS Episode 125: The Pathways to Cures Think Tank  https://realtalkms.com/125 Pathways to Cures https://pathwaystocures.org Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 238 Guests: Dr. Carol Whitacre and Prof. Alan Thompson Tags: MS, MSAwareness MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

RNZ: Nine To Noon
Global step in right direction to end plastic pollution

RNZ: Nine To Noon

Play Episode Listen Later Mar 14, 2022 19:48


The recent commitment by 175 UN nations to end plastic pollution waste is being hailed as an historic moment and a huge global step in the right direction. Earlier this month, Heads of State, Ministers for the environment and other representatives, including New Zealand, endorsed a resolution at the UN Environment Assembly in Kenya. The aim is to draft a legally-binding treaty by 2024 - to stop the proliferation of plastic. But what does this mean in practice, and what is achievable from this large global commitment?. To discuss the scope of the mandate and what negotiations lie ahead to actually stem and prevent plastic pollution, Kathryn talks to Dr Trisia Farrelly who is on the United Nations Environment Programme's Scientific Advisory Committee and Expert Group and Marine biologist and Senior Scientist at ESR and Dr Olga Pantos. Olga is the co-lead of the MBIE-funded national project 'Aotearoa Impacts and Mitigation of Microplastics'.

Paging Dr. Mom with Julie La Barba, MD, FAAP
#5 - Moms Are Society's Shock Absorber with Dr. Suzie Wotton

Paging Dr. Mom with Julie La Barba, MD, FAAP

Play Episode Listen Later Mar 2, 2022 49:44


(Note: Recorded 1/19/22. Information that was correct and relevant at the time may be outdated.)   Susan H. Wootton, MD | McGovern Medical School Physicians Mom's Group Ask Lisa: The Psychology of Parenting on Apple Podcasts https://podcasts.apple.com/us/podcast/a-bit-of-optimism/id1515385282 Three Steps https://anewamericanwe.com/accelerating-a-paradigm-shift-towards-interbeing/ Your Local Epidemiologist Vaccine Education Center | Children's Hospital of Philadelphia   How is Covid affecting families, especially working moms in healthcare who can't do their jobs remotely?   In this anxiety-filled time, there's so much we cannot control. What we can do is connect to ourselves and connect to each other.   Rather than more Covid data which is readily available, we want to provide a different conversation today, steeped in hope and real social strategies for both work and home in terms of navigating it all.    Dr. Wooton focuses on the hope that we will get through this together, shares her own personal challenges, and highlights steps to make it through each long day, including personal experience in navigating everything from birthday parties to family reunions.    Doctor moms with kids under 5 and how stressful Covid has been to not be able to work from home/ all the pivoting it has required Strategies to stay sane and avoid burnout in the process: exercise, sleep, nutrition, asking for help Future outlook: historical knowledge and confidence that by definition, pandemics end at some point. Navigating invitations to gather with unvaccinated friends and family   As the Co-Chair of the Women Faculty Forum, she also shares helpful advocacy resources for moms in medicine.   Dr. Susan Wootton is a professor in Pediatric Infectious Diseases and member of the Center for Clinical Research and Evidence Based Medicine at the McGovern Medical School at UTHealth.  She graduated from Washington and Lee University with a B.A. in Mathematics, the Medical College of Georgia and then completed her pediatric residency at the University of Virginia.  She served as an Epidemic Intelligence Officer with the Centers for Disease Control and Prevention after which time she completed her pediatric infectious disease fellowship at Texas Children's Hospital and post-doctoral fellowship in Vaccinology at the University of British Columbia's Vaccine Evaluation Center in Vancouver, B.C.  Since joining the McGovern Medical School in 2007,  Dr. Wootton has been involved in all levels of teaching, clinical care and has received multiple clinical research awards.  Her research focuses primarily on vaccine-preventable infections and vaccine delivery.  She serves on the Texas Pediatric Society Infectious Disease Committee, The Immunization Partnership's Scientific Advisory Committee, and the Pediatric Infectious Disease Society's Vaccine Advocacy Committee.

The Green Room Podcast
Ep 55: Flowing into the industry - Cannapreneurship continued.. An interview w/ Jim Makoso, CEO at Flowe Tech

The Green Room Podcast

Play Episode Listen Later Feb 1, 2022 19:49 Transcription Available


Jim Makoso is a veteran in the cannabis industry, and he attended mjbizcon 2021 in Las Vegas where we caught up with him for an interview.   In this episode we discuss his background in the finance industry and the transition to the cannabis industry.   Jim is the CEO of Flowe Technology and Director of Lucid Lab Group. Jim holds board seats in several organizations including Marijuana Business Daily and Biomedican while also serving as Vice Chair of the Scientific Advisory Committee with the National Cannabis Industry Association.  Jim is the go-to person for flow technology involving cannabis oil extraction and distillation.Flowe is the first to combine microcrystalline cannabinoids and ingredients within a water-based solution. Infused product manufacturing will never be the same.  Learn more about Jim & Flowe Technology:https://www.flowetech.com/https://www.instagram.com/flowetech/Be sure to subscribe to be notified of our next episode. Like & Share... Visit our website to learn about our Cannabis PR Solutions.

Microbe Magazine Podcast
WHO Critical Review of the Antibacterial Pipeline (AAC ed.)

Microbe Magazine Podcast

Play Episode Listen Later Jan 28, 2022 42:00


AAC just published a review from the WHO advisory panel on the antibacterial pipeline analyzing ‘traditional' and ‘non-traditional' antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens, mycobacteria and Clostridioides difficile. Today, we will dissect this important publication Objectives: • Understand the role of the WHO in antimicrobial resistance • Discuss the analysis of the antibacterial pipeline • Deliberate on important highlights from the review and the future of antibacterial research. Guests: - Dr. Peter Beyer, Senior Advisor for the Antimicrobial Resistance Division at the World Health Organization. - Dr. Mark Butler, MSBChem Consulting, Brisbane, Queensland, Australia - Dr. Prabhavathi Fernandes. Member, Scientific Advisory Committee, GARDP, Geneva, Switzerlandand The National Biodefense Science 17Board, Health and Human Services, Washington DC, USA This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias. AAC is available at https://aac.asm.org. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. Subscribe to the podcast at https://asm.org/eic

The Crossover with Dr. Rick Komotar
Laura Grelck - The V Foundation

The Crossover with Dr. Rick Komotar

Play Episode Listen Later Dec 16, 2021 26:57


The V Foundation for Cancer Research was founded by ESPN and legendary basketball coach Jim Valvano with one goal in mind: to achieve Victory Over Cancer®. Since its formation in 1993, the V Foundation has awarded more than $260 million in cancer research grants nationwide and has grown to become one of the premier supporters of cutting-edge cancer research. Uniquely, due to generous donors, the Foundation has an endowment that covers administrative expenses. Therefore, 100% of direct donations benefit cancer research and programs. This means that not a single penny of donations goes to operating expenses. Period.The mission of The V Foundation is to fund game-changing research and all-star scientists to accelerate victory over cancer and save lives. Researchers are continually developing better screening tools and learning more about prevention and early detection. Scientists are developing more targeted therapies that keep the whole patient healthier while zeroing in on the disease. While there aren't cures yet, each breakthrough is one step closer to finding them. Donations make research possible, and it's why every donation makes a difference.The V Foundation awards competitive grants through a process vetted by a Scientific Advisory Committee. This committee is comprised of the nation's top doctors and scientists in cancer research. The V Foundation has awarded grants to more than 154 institutions in 40 states, as well as in Canada.

Filling the Sink
Sixth wave – Covid certificate FAQs, travel rules, Omicron and Xmas forecast

Filling the Sink

Play Episode Listen Later Dec 3, 2021 20:17


Dr Magda Campins – chair of Catalonia's Covid-19 Scientific Advisory Committee and head of Preventive Medicine and Epidemiology at Vall d'Hebron Hospital in Barcelona – on the Omicron variant, booster shots and why Christmas office parties should be avoided. Lorcan Doherty, Cristina Tomàs White and Guifré Jordan discuss the profile of a sixth wave patient, the latest travel rules, and FAQs from residents and tourists on the use of Covid certificates in cafes, bars and restaurants. This week's Catalan phrase is 'cada dos per tres'. It means something that happens very frequently.

Progress, Potential, and Possibilities
Dr Corinne Leach, Ph.D. - Gerontology, Digital Health, Behavioral Science - American Cancer Society

Progress, Potential, and Possibilities

Play Episode Listen Later Nov 24, 2021 43:35


Dr. Corinne Leach, PhD, MPH, MS, is a gerontologist, digital health strategist, and behavioral scientist, who serves as the Senior Principal Scientist, Behavioral Research, at the American Cancer Society (https://www.cancer.org/). Dr. Leach, leads survivorship research on behalf of the Population Sciences group, serving as the Principal Investigator of the American Cancer Society (ACS) survivorship cohorts, and as the ACS-lead for the ACS-National Cancer Institute online self-management platform, Springboard Beyond Cancer, a novel eHealth tool that empowers cancer survivors to better manage their cancer-related symptoms, live healthier, and improve their communication skills about cancer (as well as other health conditions), during and after treatment. Dr. Leach's cancer survivorship research focuses in the areas of aging, cancer-related symptom assessment, and chronic disease self-management, and her research aims to improve the understanding of: behavioral factors that contribute to healthy aging and the best way to promote them, the unique experiences of older cancer survivors, such as physical late effects and psychosocial issues, and ways to improve survivors' self-management of cancer-related issues. Dr. Leach also studies accelerated aging after a cancer diagnosis, including the accumulation of multiple chronic conditions after a cancer diagnosis, and she evaluates the benefits of health behavior interventions, such as chronic disease self-management. Dr. Leach is also a Gerontological Society of America Fellow, member of the Cancer and Aging Research Group (CARG), Scientific Advisory Committee member for Pack Health and Dr. Susan Love Foundation for Breast Cancer Research, Adjunct Professor at Emory, Rollins School of Public Health, Susan B Anthony Aetna Award Winner for Excellence in Research on Older Women, American Public Health Association (APHA), and has authored over 70 peer-reviewed publications. Dr. Leach has an MPH from the Harvard T.H. Chan School of Public Health, a PhD in Gerontology from University of Kentucky, and an MS in Experimental Psychology from Villanova University.

MeatRx
Revero Carnivore Community Meeting with Dr Thomas Seyfried

MeatRx

Play Episode Listen Later Oct 18, 2021 59:26


Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master's degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army's First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honours have come from such diverse organisations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, the Ketogenic Diet Special Interest Group of the American Epilepsy Society, the Academy of Comprehensive and Complementary Medicine, and the American College of Nutrition. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book, Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley, 1st ed., 2012). Find him on Twitter: https://twitter.com/tnseyfried or YouTube:https://www.youtube.com/channel/UC3usB3s0qqOo4wImv3fgf5A/featured This episode is hosted by Dr. Shawn Baker MD. Find him at https://shawn-baker.com Donate to the Carnivore Diet Clinical Trial: https://gofundme.com/f/carnivore-research

Health Professional Radio - Podcast 454422
Neonmind Biosciences - Psychedelic Compounds For Weight Loss

Health Professional Radio - Podcast 454422

Play Episode Listen Later Jul 21, 2021 13:41


Dr. Clive Ward-Able is the Medical & Scientific Affairs Consultant of NeonMind Biosciences, a company exploring psilocybin as an alternative approach to weight loss and appetite suppression. He shares his insights on the potential of psychedelics in the treatment of obesity, the current trials underway, and what the future may hold. #NeonmindBiosciences #WeightLoss Dr. Clive Ward-Able is a physician and a pharmacist who has worked in the pharmaceutical industry for over 28 years with 21 of those at the executive level. He has worked in large and small pharmaceutical and biotechnology companies in Canada, the U.S., UK, Switzerland, and South Africa in the departments of R&D, medical, marketing, and sales. He is currently a member of the Board of Directors for Clinical Trials Ontario and has been a member of the Medical & Scientific Advisory Committee of Innovative Medicines Canada.

ChatChat - Claudia Cragg
Dr Neil Schachter in the NY War On Covid For More Than 16 Months

ChatChat - Claudia Cragg

Play Episode Listen Later Jun 17, 2021 30:53


After 16 months on the front lines of the COVID war in New York at Mount Sinai, Dr Schachter @MountSinaiNYC does not focus on exhaustion or trauma, but rather the possibilities that have come with dealing with such wide-scale and going medical trauma.  Dr. Schachter is currently the Maurice Hexter Professor of Pulmonary and Community Medicine and Medical Director of Pulmonary Rehabilitation at Mount Sinai Medical Center. He has established and directs the Mount Sinai Pulmonary Rehabilitation program. Author of five books and over 400 articles and abstracts on pulmonary disease, Dr. Schachter is past president of the American Lung Association of the City of New York, the Connecticut Thoracic Society and the National Association of Medical Directors of Respiratory Care. He currently serves on the board of directors and as the chairman of the Scientific Advisory Committee of the American Lung Association of the Northeast. In 2005 he was an honoree of the American Lung Association of the City of New York at their annual Life and Breath Gala. In 2016 he received the  from the Lung Association. Dr. Schachter is an advocate for environmental lung issues. He worked with the Southern Poverty Law Center for healthier factory standards and increased workers' compensation for men and women in cotton textile mills. He lobbied for tougher anti-smoking laws in New York City on behalf of the Lung Association and the Coalition for Smoking or Health. He is currently completing a study on the health effects of air pollution on children with asthma in the inner city neighborhoods of New York City. In Schachter's new book, you can learn how to learn strategies to avoid getting pummeled by a cold.

Voices for Victory
Episode 26: A Conversation with Dr. Funmi Olopade

Voices for Victory

Play Episode Listen Later Jun 17, 2021 32:27


Today, we speak with Dr. Funmi Olopade, a member of our Scientific Advisory Committee. Dr. Olopade grew up in Nigeria and earned her medical degree there before coming to the United States determined to make a difference. She is world-renowned for her research on familial forms of cancer as well as genetic and non-genetic factors contributing to tumor progression in diverse populations. She is also an expert in cancer risk assessment and individualized treatment for the most aggressive forms of breast cancer. We'll talk to Dr. Olopade about the path that led her to science, the advice that helped clear the road for her successful career and what the future holds for cancer research. To learn more about the V Foundation, Dr. Olopade or to donate to game-changing cancer research, please visit v.org.

Table Talk
145: Exploring the impact of COVID on nutrition and our enjoyment of food

Table Talk

Play Episode Listen Later Jun 8, 2021 38:52


It sounds cliche, but COVID-19 has completely changed the way many of us think about nutrition, what we need to support our immune health, and the relationship we have with food. Combined with the one in 20 who've had COVID experiencing a prolonged loss of taste and smell due to the virus, it's clear that the impact of COVID on nutrition and our enjoyment of food has been pronounced. In this episode of the podcast we look back at two key discussions we've had in a series of podcasts focused on how nutrition and our enjoyment of food has been impacted by COVID. In a fascinating look at COVID-related loss of taste and smell we join Barry Smith, Professor, Institute of Advanced Studies, University of London to hear about the latest research on the phenomena, and what can be done to help those who are suffering because of it. Then we join Philip Calder, Professor of Nutritional Immunology and Head of School of Human Development and Health at the University of Southampton to discover what we now know about how nutrition can support our immune health for the future. Join the conversation on Table Talk. About our guests Philip Calder Philip Calder is Professor of Nutritional Immunology and Head of School of Human Development and Health at the University of Southampton in the UK. He is currently President of ILSI Europe. Professor Calder is an internationally recognised researcher on the metabolism and functionality of fatty acids with an emphasis on the roles of omega-3 fatty acids in immunity, inflammation and cardiometabolic disease. He has also conducted recognised research on amino acids, antioxidants, prebiotics, probiotics and natural products. His research addresses both life course and translational considerations and includes research in cell and animal models and in healthy humans and patients. Professor Calder has published over 600 scientific articles (excluding abstracts) and according to Web of Science his work has been cited over 33,000 times. He has a Web of Science h-index of 100, a Google Scholar h-index of 130 (i10 index 489) and has been included in every listing of Highly Cited Researchers. He has received many awards and prizes for his work including ESPEN's Cuthbertson Lecture (2008), the Ralph Holman Lifetime Achievement Award from the American Oil Chemists' Society (2015), the prestigious Danone International Prize for Nutrition (2016) and the DSM Lifetime Achievement Prize in Human Nutrition (2017). Professor Calder was President of the International Society for the Study of Fatty Acids and Lipids (2009-2012), Chair of the Scientific Committee of the European Society for Clinical Nutrition and Metabolism (ESPEN) (2012-2016) and President of the Nutrition Society (2016-2019). He is currently President of the Federation of European Nutrition Societies. He was Editor-in-Chief of the British Journal of Nutrition (2006 to 2013) and is currently Associate Editor of Clinical Science and Journal of Nutrition. He previously served on many Editorial Boards of journals in the nutrition, lipidology and biochemistry fields. Professor Calder has a long association with ILSI Europe having served on its Scientific Advisory Committee, as Scientific Co-Chair of one of its Task Forces, and as a member (including Chairing) several Expert Groups. Barry Smith Barry C Smith is a professor of philosophy and director of the Institute of Philosophy at the University of London's School of Advanced Study, as well as the founding director of the Centre for the Study of the Senses, which pioneers collaborative research between philosophers, psychologists and neuroscientists. He is also the UK lead in the study of the long term impact of the loss of taste and smell in Covid-19 sufferers. He has held visiting professorships at the University of California at Berkeley and the Ecole Normale Superiéure in Paris, and in 2012 he was appointed as the AHRC Leadership Fellow for the Science in Culture Theme, as well as Pro-Dean for new academic initiatives at the School of Advanced Study.

In The Doctor's Chair
Leadership, Being True to Your Purpose, Continuous Learning and Love with Heather Fennimore

In The Doctor's Chair

Play Episode Listen Later Apr 26, 2021 48:34


Heather Fennimore has been an owner and partner at Humanscale since 1986.  Ms. Fennimore has established a successful sales organization of over 300 sales professionals and managers in the Americas.  She created the Humanscale University Program, the Recruiting Division, Humanscale Consulting, and Customer Service. Currently, Ms. Fennimore oversees Humanscale Global Healthcare and the Global IT distribution organizations, along with expanding Humanscale Consulting globally.  She's the first chairperson of the Scientific Advisory Committee for Cornell University's Atkinson Center for Sustainable Futures.  She also sits on several boards and is a member of the Hoover Council at Stanford University. Ms. Fennimore is an avid environmentalist and animal advocate.  She resides in Colorado with her husband. Today, Ms. Fennimore joins me to share her story. She shares what prompted her to found Humanscale and discusses the importance of motivation to want to make things better. She talks at length about her parents and their influence, and she shares her definition of leadership. She also offers her views on women in leadership, and she notes that good leaders know they have more to learn. She talks about the importance of caring in whatever you do, and she shares what she's learned and accomplished in a year of COVID-19. She expounds on her love for the environment and animals and notes the importance of our physical aspect as human beings.   “Caring is the difference between success and failure.” – Heather Fennimore This week on In the Doctor's Chair The story behind Humanscale Why “not bad” isn't good enough when it comes to the environment Speculations on the source of burnout in a job or career What is leadership Women in leadership Why believing you have nothing left to learn isn't conducive to leadership The importance of constant growth in leadership   In the Doctor's Chair  Thanks for listening to In the Doctor's Chair, the show where you'll hear conversations that share life lessons, health habits, and leadership practices that focus on positive psychology, lifestyle medicine, and ways for you to live with more vitality. If you enjoyed this episode, please subscribe to the show and leave a comment wherever you listen to your podcasts. For more resources to help you to live with more vitality, please visit my website. Apple Podcasts I TuneIn I Google Play I Stitcher I Spotify The post Leadership, Being True to Your Purpose, Continuous Learning and Love with Heather Fennimore appeared first on Mark Rowe.

In The Doctor's Chair
Leadership, Being True to Your Purpose, Continuous Learning and Love with Heather Fennimore

In The Doctor's Chair

Play Episode Listen Later Apr 26, 2021 48:34


Heather Fennimore has been an owner and partner at Humanscale since 1986.  Ms. Fennimore has established a successful sales organization of over 300 sales professionals and managers in the Americas.  She created the Humanscale University Program, the Recruiting Division, Humanscale Consulting, and Customer Service. Currently, Ms. Fennimore oversees Humanscale Global Healthcare and the Global IT distribution organizations, along with expanding Humanscale Consulting globally.  She's the first chairperson of the Scientific Advisory Committee for Cornell University's Atkinson Center for Sustainable Futures.  She also sits on several boards and is a member of the Hoover Council at Stanford University. Ms. Fennimore is an avid environmentalist and animal advocate.  She resides in Colorado with her husband. Today, Ms. Fennimore joins me to share her story. She shares what prompted her to found Humanscale and discusses the importance of motivation to want to make things better. She talks at length about her parents and their influence, and she shares her definition of leadership. She also offers her views on women in leadership, and she notes that good leaders know they have more to learn. She talks about the importance of caring in whatever you do, and she shares what she's learned and accomplished in a year of COVID-19. She expounds on her love for the environment and animals and notes the importance of our physical aspect as human beings.   “Caring is the difference between success and failure.” – Heather Fennimore This week on In the Doctor's Chair The story behind Humanscale Why “not bad” isn't good enough when it comes to the environment Speculations on the source of burnout in a job or career What is leadership Women in leadership Why believing you have nothing left to learn isn't conducive to leadership The importance of constant growth in leadership   In the Doctor's Chair  Thanks for listening to In the Doctor's Chair, the show where you'll hear conversations that share life lessons, health habits, and leadership practices that focus on positive psychology, lifestyle medicine, and ways for you to live with more vitality. If you enjoyed this episode, please subscribe to the show and leave a comment wherever you listen to your podcasts. For more resources to help you to live with more vitality, please visit my website. Apple Podcasts I TuneIn I Google Play I Stitcher I Spotify The post Leadership, Being True to Your Purpose, Continuous Learning and Love with Heather Fennimore appeared first on Mark Rowe.

In The Doctor's Chair
#06 Heather Fennimore - Leadership, Being True to Your Purpose, Continuous Learning and Love

In The Doctor's Chair

Play Episode Listen Later Apr 22, 2021 48:35


Heather Fennimore has been an owner and partner at Humanscale since 1986.  Ms. Fennimore has established a successful sales organization of over 300 sales professionals and managers in the Americas.  She created the Humanscale University Program, the Recruiting Division, Humanscale Consulting, and Customer Service. Currently, Ms. Fennimore oversees Humanscale Global Healthcare and the Global IT distribution organizations, along with expanding Humanscale Consulting globally.  She's the first chairperson of the Scientific Advisory Committee for Cornell University's Atkinson Center for Sustainable Futures.  She also sits on several boards and is a member of the Hoover Council at Stanford University. Ms. Fennimore is an avid environmentalist and animal advocate.  She resides in Colorado with her husband. Today, Ms. Fennimore joins me to share her story. She shares what prompted her to found Humanscale and discusses the importance of motivation to want to make things better. She talks at length about her parents and their influence, and she shares her definition of leadership. She also offers her views on women in leadership, and she notes that good leaders know they have more to learn. She talks about the importance of caring in whatever you do, and she shares what she's learned and accomplished in a year of COVID-19. She expounds on her love for the environment and animals and notes the importance of our physical aspect as human beings.   “Caring is the difference between success and failure.” - Heather Fennimore   This week on In the Doctor's Chair The story behind Humanscale Why “not bad” isn't good enough when it comes to the environment Speculations on the source of burnout in a job or career What is leadership Women in leadership Why believing you have nothing left to learn isn't conducive to leadership The importance of constant growth in leadership   In the Doctor's Chair  Thanks for listening to In the Doctor's Chair, the show where you'll hear conversations that share life lessons, health habits, and leadership practices that focus on positive psychology, lifestyle medicine, and ways for you to live with more vitality. If you enjoyed this episode, please subscribe to the show and leave a comment wherever you listen to your podcasts. For more resources to help you to live with more vitality, please visit my website. Apple Podcasts I TuneIn I Google Play I Stitcher I Spotify

Table Talk
119: Learning lessons from COVID-19 - how nutrition can support immune health

Table Talk

Play Episode Listen Later Mar 9, 2021 34:59


The shock of the COVID-19 pandemic has exposed huge inequalities in health outcomes across society. What role has nutrition played in exacerbating the pandemic? How has our nutrition affected susceptibility to COVID-19 and what lessons do we need to learn to protect society in the future?Joining host Stefan Gates to discuss this fascinating subject is Philip Calder, Professor of Nutritional Immunology, School of Human Development and Health, Faculty of Medicine, University of Southampton, who has recently led a review in the role of nutrition in immunity and host susceptibility to Covid-19. We'll take a look at how the food we eat, our gut microbiome, and the nutrients we consume can impact our health, and what recommendations have arisen from this fascinating research.About Philip CalderPhilip Calder is Professor of Nutritional Immunology and Head of School of Human Development and Health at the University of Southampton in the UK. He is currently President of ILSI Europe. Professor Calder is an internationally recognised researcher on the metabolism and functionality of fatty acids with an emphasis on the roles of omega-3 fatty acids in immunity, inflammation and cardiometabolic disease. He has also conducted recognised research on amino acids, antioxidants, prebiotics, probiotics and natural products. His research addresses both life course and translational considerations and includes research in cell and animal models and in healthy humans and patients. Professor Calder has published over 600 scientific articles (excluding abstracts) and according to Web of Science his work has been cited over 33,000 times. He has a Web of Science h-index of 100, a Google Scholar h-index of 130 (i10 index 489) and has been included in every listing of Highly Cited Researchers. He has received many awards and prizes for his work including ESPEN’s Cuthbertson Lecture (2008), the Ralph Holman Lifetime Achievement Award from the American Oil Chemists’ Society (2015), the prestigious Danone International Prize for Nutrition (2016) and the DSM Lifetime Achievement Prize in Human Nutrition (2017). Professor Calder was President of the International Society for the Study of Fatty Acids and Lipids (2009-2012), Chair of the Scientific Committee of the European Society for Clinical Nutrition and Metabolism (ESPEN) (2012-2016) and President of the Nutrition Society (2016-2019). He is currently President of the Federation of European Nutrition Societies. He was Editor-in-Chief of the British Journal of Nutrition (2006 to 2013) and is currently Associate Editor of Clinical Science and Journal of Nutrition. He previously served on many Editorial Boards of journals in the nutrition, lipidology and biochemistry fields. Professor Calder has a long association with ILSI Europe having served on its Scientific Advisory Committee, as Scientific Co-Chair of one of its Task Forces, and as a member (including Chairing) several Expert Groups.

Is Anybody Out There?
Episode 4: Seniors and Loneliness

Is Anybody Out There?

Play Episode Listen Later Mar 3, 2021 27:20


Some 12 million Americans over the age of 60 live alone. This doesn't mean they're all lonely, but loneliness is a massive issue for older adults, especially among those 80 and over. So, hosts Jeremy Warshaw and Judy D'Mello dig deep into one possible cause of this problem -- an issue that looms large in our society today: ageism. Ageism, in terms of popular culture and attitudes, is rife in the West. Truthfully, it's a cultural scandal that often leads to seniors being marginalized and isolated, which, in turn, leads to loneliness. But thanks to the efforts of this episode's first guest, Katie Wade, who works for Covia, an organization that's dedicated to improving life for older adults, there are available programs for seniors to find connections and companionship. She believes strongly, and it's backed up by research, that seniors need and benefit from being treated as active participants in close relationships. That in fact their brains are fully capable of creativity and conceptual thinking, and they are not just looking for caregiving support. Additionally, we hear from two older women, who experience loneliness in different ways, about the value and impact these programs have on their lives. Meanwhile, Dr. Louise Hawkley, this week's final guest, who is a research scientist at the University of Chicago and a founding member of the International Loneliness and Isolation Research Network, offers unparalleled insight into loneliness and ageism, as well as resources that can help.LinksOlder adults living aloneCoviaSocial CallNORCAARPConnect2AffectLittle Brothers – Friends of the ElderlyExperience CorpsGuest NotesKatie Wade, MEd, LPC, is passionate about ensuring we all have access to creative means of connecting with ourselves and others as we grow older. A constant thread in her work, since her very first internship, is our great need for meaningful social connection. After working as a mental health therapist with older adults in an inpatient setting, Katie maintained a private practice while providing social connection programming and other services to older adults and caregivers, and now nurtures and grows innovative creative aging programs. She is the director of Social Call, a social connection program for older adults.Dr. Louise Hawkley is a research scientist at the National Opinion Research Center, affiliated with the University of Chicago. She is a co-investigator on the NIA-funded panel study, the National Social Life, Health and Aging Project (NSHAP), and the Principal Investigator of the NSHAP COVID supplemental study which began in September 2020. Her research contributions are predominantly in the area of perceived social isolation (loneliness) and health during aging. She is a founding member of the International Loneliness and Isolation Research Network (ILINK), and a member of the Scientific Advisory Committee for the Coalition to End Social Isolation & Loneliness. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

IFOTES Podcast
Loneliness and the need to belong: aspects of loneliness - Anja MACHIELSE - Professor of ‘Empowerment of Vulnerable Older Adults', Utrecht University (NL)

IFOTES Podcast

Play Episode Listen Later Mar 1, 2021 62:53


Social relationships with relatives, friends and acquaintances are important resources for the personal functioning of people and offer a unique chance to meet belongingness needs. However, in modern Western societies, meaningful and supportive personal relationships have become less self-evident. Due to societal developments (like individualisation processes) people are less able to fall back on ‘given' bonds such as family or neighbourhood relationships. Especially major life-events can cause loneliness: a divorce, the death of a loved one, retiring, moving, a decreasing health condition, and ageing often have a negative effect on the size or quality of the social network. In her lecture, Anja Machielse explores different aspects of loneliness: the great diversity among lonely persons, the consequences of loneliness for their self-worth and self-respect, and their lack of social support. She also explores the personal competencies and social skills that are necessary to make meaningful contacts; skills that are needed to show vulnerability and to ask for help in times of adversity. Anja Machielse also gives insight into the strategies lonely people use to deal with their situation, and the possibilities they see of changing their situation. She shows that lonely people develop habits and rituals to meet their social needs that often intensify their loneliness. The lecture makes clear that social interventions should fit with the ambitions and strategies of the lonely people involved. Anja MACHIELSE - is Professor of ‘Empowerment of Vulnerable Older Adults'. Her research is focused on persons who are less able to deal with the complexity of daily life. Questions about social vulnerability (loneliness, social isolation), relational involvement and meaningfulness are central in her work. She wrote several books and articles on social contacts, loneliness and social isolation (among others: Social Isolation in Modern Society (New York/London:Routledge). She is a member of the Scientific Advisory Committee of the Dutch Government for the policy to combat loneliness and social isolation. Recorded in Udine 6th July - IFOTES Congress "Leaving loneliness, building relationships"

Emerging Topics
Ep. 10: Science vs. Supply: Addressing the Decision to Alter the Two-Dose Schedule of mRNA COVID-19 Vaccines

Emerging Topics

Play Episode Listen Later Feb 24, 2021 16:17


The published article, Science gave us excellent vaccines. Why bend the rules? in The Globe and Mail addresses the challenges in altering the recommended two-dose schedule for the two Canadian approved mRNA vaccines, Pfizer-BioNTech and Moderna. In this episode of Emerging Topics, we speak to one of the authors, Dr. Alan Bernstein to tell us more about these challenges and what considerations should be taken on whether or not to delay the second-dose. Dr. Alan Bernstein is the President and CEO of the Canadian Institute for Advanced Research (CIFAR), which is a Canadian-based, global research organization. He is one of Canada's foremost scientists with several decades of work in research leadership. A graduate from the University of Toronto, he received the James Loudon Gold Medal in Physics, and completed his PhD research with James Till. After roles at the Ontario Cancer Institute and Lunenfeld Tanenbaum Research Institute, Dr. Bernstein was asked to become the founding President of the Canadian Institutes of Health Research, where he led the transformation of health research in Canada, creating Canada’s first health research institutes. He was also an early champion of women in science and young scientists. In 2010, Dr. Bernstein became Executive Director of the Global HIV Vaccine Enterprise in New York, where he led an international alliance of organizations funding HIV vaccine research. Author of over 225 scientific publications, Dr. Bernstein has made landmark contributions to the study of stem cells, blood cell formation (hematopoiesis) and cancer. He chairs or is a member of advisory and review boards in Canada, the U.S., U.K., Italy and Australia. He serves as co-chair of the Scientific Advisory Committee for Stand Up 2 Cancer Canada AND is a member of both the Sabin-Aspen Vaccine Science and Policy Group, and the Scientific Advisory Committee of the Bill and Melinda Gates Foundation. In May 2020, Dr. Bernstein was appointed to Canada’s COVID-19 Vaccine Task Force. His contributions to science and science policy have been recognized with numerous awards and honorary degrees, including Officer of the Order of Canada, Order of Ontario, the McLaughlin Medal from the Royal Society of Canada, the Award of Excellence from the Genetics Society of Canada, the Gairdner Foundation Wightman Award, induction into the Canadian Medical Hall of Fame, and the 2017 Henry Friesen International Prize in Health Research.

Policy Options Podcast
PO Podcast 116 – The global dimensions of Canada's vaccine rollout

Policy Options Podcast

Play Episode Listen Later Jan 21, 2021 35:23


It’s just over a month into Canada’s vaccine rollout, and every day seems to bring new federal-provincial bickering or logistical nightmares. It’s difficult and confusing at a time when Canadians just want to get needles into arms. The problem is, it’s not just a Canadian issue – as recent disruptions to vaccine supply have reminded us, the pandemic is global. Our response must be global, too, whether that means helping vaccinate people beyond our borders or considering the international implications of our own COVID-19 policies. Here to discuss this and more is Dr. Alan Bernstein. He’s president and CEO of the global research organization CIFAR and was the founding president of the Canadian Institutes of Health Research. He sits on the Scientific Advisory Committee of the Bill and Melinda Gates Foundation and is a member of Canada’s COVID-19 Vaccine Task Force. Help us get to know you! Fill out our podcast listener survey here: https://options-po.li/podcastsurvey Download for free. New episodes every other Wednesday. Tweet your questions and comments to @IRPP or @jbugiel.

Fempower Health
Ovarian Cancer Research Alliance (OCRA) | Ovarian Cancer: Why Awareness Is Critical and What you Need to Know

Fempower Health

Play Episode Listen Later Sep 21, 2020 51:37


In celebration of Ovarian Cancer Awareness Month, Fempower Health interviews top leadership at the Ovarian Cancer Research Alliance, the largest global charity for ovarian cancer research and advocacy. Audra Moran is the President & CEO of Ovarian Cancer Research Alliance (OCRA). She directs overall strategy, operations and fundraising to promote progress and awareness, while hastening breakthroughs in diagnostics and treatments with the ultimate goal of finding a cure for ovarian cancer.Sarah Defeo, Vice President of Scientific Affairs & Programs, oversees OCRA’s grantmaking, programmatic, and educational initiatives. Working closely with the Scientific Advisory Committee, Sarah manages OCRA’s annual grant solicitation and review process, and under her direction applications to OCRA’s three research grant programs have quadrupled.On this episode, Audra and Sarah discuss the following about ovarian cancer:Risk factorsSymptoms, diagnosis, and treatmentHow OCRA supports efforts to raise awareness about ovarian cancer"There is no method of early detection for ovarian cancer and this is one of the biggest challenges. Ovarian cancer is not just one disease. There are different types of ovarian cancer, the most common type of ovarian cancer, and the one that is usually being referred to when people talk about ovarian cancer, is really just one type - epithelial ovarian cancer."OCRA is hosting the Ovarian Cancer National Conference on September 29 to October 3, 2020. Check it out!Share this episode with the women in your life!Join a community of women who are committed to better health:Follow Fempower Health on InstagramLike Fempower Health on FacebookFollow Fempower Health on TwitterVisit our website for more reading, resource and product recommendationsNOTE: Fempower Health may receive a nominal fee for products purchased. The purpose of the podcast, however, is for education purposes only. Always go to a medical professional of your choosing.Support the show (https://www.patreon.com/fempowerhealth)

TheHealthHub
Linking The Microbiome To Autism With Dr. James Adams

TheHealthHub

Play Episode Listen Later Sep 20, 2020 55:54


I this episode we speak with Dr. James Adams about this research in the area of autism and possible links to the microbiome. James B. Adams, Ph.D., is the Director of the Autism/Asperger's Research Program at Arizona State University. His research focuses on the medical causes of autism and how to treat and prevent it including the areas of nutrition (vitamins/minerals, essential fatty acids, carnitine, digestive enzymes, special diets), oxidative stress, gut problems, gut bacteria, toxic metals, and seizures. He has published over 150 peer-reviewed scientific articles, including over 40 related to autism. He is also the President of the Autism Society of Greater Phoenix, the President of the Autism Nutrition Research Center, the co-leader of the Scientific Advisory Committee of the Autism Research Institute, and chair of the Scientific Advisory Board of the Neurological Health Foundation. He has an adult daughter with autism. Learning Points: 1. What are key prenatal nutrients that moms need to be aware of to minimize the risk of having a child with autism? 2. What is Microbiota transplant? 3. How is this improving the health of children with autism? Website Addresses www.adamsautismresearch.com www.autismNRC.org

Therapy Show
#46 Bipolar Disorder: A "Patient Centric" Approach to Treatment. Dr. Gary Sachs Interview

Therapy Show

Play Episode Listen Later Aug 20, 2020 42:10


Dr. Gary Sachs is Clinical Vice President at Signant Health and the founder of Massachusetts General Hospital's Bipolar Clinic and Research Program. He is also an Associate Clinical Professor in Psychiatry at Harvard Medical School and was the Principal Investigator of the National Institute of Mental Health’s Systematic Treatment Enhancement Program for Bipolar disorder. Dr. Sachs is a Distinguished Fellow of the American Psychiatric Association. He chairs the Scientific Advisory Committee of the Depression and Bipolar Support Alliance (DBSA) also serves on DBSA board of directors. In March of 2020, he became president elect of the International Society for CNS Clinical Trial Methodology (ISCTM)  Dr. Sachs has authored over 200 peer reviewed articles and is a contributor to the seminal book Managing Bipolar Disorder: A Cognitive Behavior Treatment Program Therapist Guide (Treatments That Work) which addresses the management of bipolar disorder. In March of 2020, he became President Elect of the International Society for CNS Clinical Trial Methodology. Dr Sachs is an award-winning teacher and is recognized as a “Top Doctor” by US News and World Report, and by Reuters as among the world’s 100 most influential Psychiatrists, Neurologists and Neuroscientists.   Bipolar disorders are mood episodes that affect a person’s ability to function, and where a person experiences an intrusive mood episode such as mania, hypomania, or depression. These changes in mood can appear as intense highs and lows and can last for days at a time or longer. They are generally well demarcated changes in mood that interrupt previous functioning, which is to be distinguished from volatile behavior that is better explained by poor characterological temperament or the psychological effects of substance abuse. TherapyShow.com/bipolar-disorders

The Dividend Cafe
Daily Covid and Markets - Thursday July 23

The Dividend Cafe

Play Episode Listen Later Jul 23, 2020 18:24


Data this week has been quite a mixed bag with some of the encouraging data being more encouraging than I expected, and some of the negative data being more negative than expected. “Sustained outright declines in new cases are not that far off” [Ian Shepherdson, Pantheon Macroeconomics], but right now we are just watching the new case curve peak, and disparate results in different states makes it all tough to analyze. The chart and information I provide at the top of our FACT section below is, I think, the most important part of today's missive. Fundamentally, these three realities have all held up incredibly true: (1) Case growth has been mostly amongst the young and healthier, and (2) Treatments have substantially improved since March/April. I was fascinated to see that Sweden had 132 new cases countrywide yesterday, while Australia had 468. It is just an interesting contrast between a vigorous lock-down and shut-out of visitors (Australia), versus the encouragement of a herd immunity build-up. Sweden's new cases and mortalities are now so low that all eyes are really on whether or not they get a sort of “second wave.” The chairman of the Scientific Advisory Committee of the National Institute of Epidemiology in India stated yesterday that Dehli, India is fast approaching herd immunity, another massive world city showing huge positivity in seroprevalence tests and therefore a large part of the population already infected. Major League Baseball season officially kicks off tonight, and while fans are not allowed for now even with masks and distancing (no comment), it is symbolically and substantively delightful that the Yankees will be teeing off on the Washington Nationals tonight. I expect big ratings. Really big. Links mentioned in this episode: DividendCafe.com TheBahnsenGroup.com

Behind the Label with American Humane
Meet the Scientific Advisory Committee

Behind the Label with American Humane

Play Episode Listen Later Jul 21, 2020 22:50


The Ammerican Humane Certified standards for farm animals are grounded in scientific research. That starts with the Scientific Advisory Committee, a panel of experts with various specialties, from veterinary science to ruminant nutrition. In this episode, Dr. Joy Mench, an animal welfare expert who is a professor emeritus at UC Davis and has written several textbooks on animal welfare—including specifically on poultry behavior—talks about her work as a member of the Scientific Advisory Committee. American Humane’s director of Farm Program Operations Haley Grimes chimes in to share how the Committee works with the farm operations team to apply the standards.In March, HRN began producing all of our 35 weekly shows from our homes all around the country. It was hard work stepping away from our little recording studio, but we know that you rely on HRN to share resources and important stories from the world of food each week. It’s been a tough year for all of us, but right now HRN is asking for your help. Every dollar that listeners give to HRN provides essential support to keep our mics on. We've got some fresh new thank you gifts available, like our limited edition bandanas.Keep Behind the Label on the air: become an HRN Member today! Go to heritageradionetwork.org/donate. Behind the Label is powered by Simplecast. 

Masters Decoded
EP12: Dr. Rohini Srivathsa: The dots connecting back

Masters Decoded

Play Episode Listen Later May 25, 2020 57:47


In today's episode, I invited Dr. Rohini Srivathsa. Rohini currently serves as a National Technology Officer for Microsoft India, Rohini is responsible for helping our customers and partners across industry and the government drives innovation and growth through ‘tech-intensity' in the age of Industry 4.0. Her 25+ years' career spans business and technology – with strategy consulting at the Boston Consulting Group and IBM Global Business Services, operations and sales at start-ups, and R&D at AT&T Bell Laboratories. Rohini is a member of the Wiley Innovation Advisory Council, is on the Advisory Council of the ECE Dept at CMU, and serves on the Scientific Advisory Committee for NM-ICPS, Dept of Science and Technology, Government of India. She was recognized among the ‘Top-10 most influential analytics leaders in India in Rohini holds an MBA from Wharton and earned her PhD in Computer Engineering from UT Austin.

Psound Bytes CME
Ep. 66 CME.25 "Coronavirus COVID-19: Opinions from Experts in Psoriatic Disease"

Psound Bytes CME

Play Episode Listen Later Apr 10, 2020 27:22


Hear Dr. Abby Van Voorhees, Chair of Dermatology at Eastern Virginia Medical School and Chair of the NPF's Medical Board discuss intriguing COVID-19 survey results (which includes use of biologics and systemics considerations) from key dermatologists and rheumatologists who comprise the NPF's Medical Board and Scientific Advisory Committee. Results helped shape the development of the Medical Board's "COVID-19 Recommendations for Patients With Psoriatic Disease" and could provide some peer advice on how to navigate patient care during the COVID-19 pandemic. To view disclosure information and claim credit go to https://www.eeds.com/em/1166 . View the data reference sheet mentioned in this podcast at https://bit.ly/34n4veU .

Psound Bytes
Ep. 66 CME.25 "Coronavirus COVID-19: Opinions from Experts in Psoriatic Disease"

Psound Bytes

Play Episode Listen Later Apr 10, 2020 27:22


Hear Dr. Abby Van Voorhees, Chair of Dermatology at Eastern Virginia Medical School and Chair of the NPF's Medical Board discuss intriguing COVID-19 survey results (which includes use of biologics and systemics considerations) from key dermatologists and rheumatologists who comprise the NPF's Medical Board and Scientific Advisory Committee. Results helped shape the development of the Medical Board's "COVID-19 Recommendations for Patients With Psoriatic Disease" and could provide some peer advice on how to navigate patient care during the COVID-19 pandemic. To view disclosure information and claim credit go to https://www.eeds.com/em/1166 . View the data reference sheet mentioned in this podcast at https://bit.ly/34n4veU .

MY CHILD'S HEALTHY LIFE RADIO SHOW
Conundrum on the Mountain. Episode # 3

MY CHILD'S HEALTHY LIFE RADIO SHOW

Play Episode Listen Later Feb 13, 2020 67:25


What does the most popular TV show in America (2000-2010), Hawaii, the longest running police drama on television and a new framework called the "M Squared Destroyer" have to do with your child's physical health status? Come inside this weeks episode and find out how all of these are connected. This weeks EXPERT is Professor Charles Hillman. Great guy to interview. We spoke about plenty of topics in our 1 hour meeting. However in this episode I share just 15 minutes of our interview - directly related to your child or the students you teach.Here is the BIO for Professor Hillman.Dr. Hillman received his doctorate from the University of Maryland in 2000, and then began his career on the faculty at the University of Illinois, where he was a Professor in the Department of Kinesiology and Community Health for 16 years. He continued his career at Northeastern University in Boston, Massachusetts, where he currently holds appointments in the Department of Psychology and the Department of Physical Therapy, Movement, and Rehabilitation Sciences. He co-directs the new Center for Cognitive and Brain Health, which has the mission of understanding the role of health behaviors on brain and cognition to maximize health and well-being, and promote the effective functioning of individuals across the lifespan. Dr. Hillman has published more than 225 refereed journal articles, 12 book chapters, and co-edited a text entitled Functional Neuroimaging in Exercise and Sport Sciences. He has served on an Institute of Medicine of the National Academies committee entitled Educating the Student Body: Taking Physical Activity and Physical Education to School, and was a member of the 2018 Health and Human Services Physical Activity Guidelines for American’s Scientific Advisory Committee. His work has been funded by the National Institutes of Health (NIH), Intelligence Advanced Research Projects Activity (IARPA), and several private sponsors. Finally, his work has been featured in the media including: CNN, National Public Radio, Good Morning America, Time, Newsweek, and the New York Times.

Beyond the Paper
Chiropractic, Episode3, Reidar Lystad

Beyond the Paper

Play Episode Listen Later Jul 2, 2019 16:10


In this episode, Maddison interviews Dr Reidar P. Lystad about sports injury hospitalisations in children. Dr Lystad is a Research Fellow at the Australian Institute of Health Innovation, Faculty of Medicine and Health Sciences, Macquarie University. He is an injury epidemiologist with a particular interest in traumatic brain injury, spinal injury, paediatric trauma, and sports injury. His research is centred around conducting large population-based studies using data linkages of administrative data collections to investigate health outcomes following injury and to guide improvements in health service delivery and health policy. Dr Lystad is a Fellow of the Royal Society of Medicine and the European College of Sport Science, and he is an appointed member of the Public Health Committee of the World Federation of Chiropractic and the Scientific Advisory Committee of Sports Medicine Australia. Paper: Lystad RP, Curtis K, Browne GJ, et al. Incidence, costs, and temporal trends of sports injury-related hospitalisations in Australian children over a 10-year period: A nationwide population-based cohort study. Journal of Science and Medicine in Sport 2019;22:175-80. https://www.sciencedirect.com/science/article/pii/S1440244018303979

Top of Mind with Julie Rose
Farmer, Death Row Religious Freedom, Australian Biodiversity

Top of Mind with Julie Rose

Play Episode Listen Later Jun 3, 2019 100:29


Jerry Jackson of Jackson Farms on floods and tariffs. Elizabeth Clark of BYU on religious rights of death row inmates. Katherine Moseby of the University of New South Wales on Australian biodiversity. Author John Maricano on the metric system. Patrick Krueger of the University of Colorado Denver on the value of education. David Shlaes of the Scientific Advisory Committee of the Global Antibiotic Research on antibiotic.

The Healthcare Education Transformation Podcast
Dr. Steve Kamper- The Researcher's Perspective

The Healthcare Education Transformation Podcast

Play Episode Listen Later May 30, 2019 32:30


  Dr. Steve Kamper comes onto the HET Podcast to share his perspective as a researcher in academia.  He discusses issues that exist in current physiotherapy literature and systemic constraints to publishing high quality research in academia. Resources Mentioned: A randomised controlled trial of a lifestyle behavioural intervention for patients with low back pain, who are overweight or obese: study protocol  Centere for Pain, Health, and Lifestyle   Biography: Dr. Steve Kamper is Associate Professor in the School of Public Health and leads the paediatric pain theme in the Institute for Musculoskeletal Health.  He has been continuously supported by NHMRC fellowships since 2008, and is currently NHMRC Career Development Fellow.  He has over 100 publications in peer-reviewed journals, has presented his work in >10 countries, and received >$2 million in competitive research funding from Australia, Ireland, Canada, and Noway. Steve is editor of the Journal of Orthopaedic and Sports Physial Therapy, associate editor in the Cochrane Back and Neck Group, Vice-chair of the Executive Orgainsing Committee of the International Back and Neck Pain Forum, and member of the Scientific Advisory Committee of the Australia New Zealand Musculoskeletal Clinicial Trials Network. Supporting and connecting early career researchers is an important part of Steve's professional life.  In 2011 he established the International Collaboration of Early Career Researchers (http://the icecream.org), he has provided input regarding ECR programming at International conferences, conducts mentoring and training, and gives lectures on academic skills such as writing and presenting. Research Interests: Dr Kamper's main interest is in musculoskeletal pain (especially back and neck pain) in adolescents and adults. In particular he is interested in how pain interacts with broader aspects of health such as physical activity, obesity, substance use, mental health and chronic diseases. The aim of this work is to move the field forward by combining perspectives from clinical management and population health. Other research interests include patient expectations and placebo effects, mechanisms of treatment effect, research methods, and outcome measurement. His track record includes publication of systematic reviews and meta-analyses, RCTs, cohort studies, clinimetric research, and Delphi surveys. See more from Steve Kamper's work here.   Contact information: E-Mail: steven.kamper@sydney.edu.au Twitter: @stevekamper1     The PT Hustle Website Schedule an Appointment with Kyle Rice HET LITE Tool Anywhere Healthcare (code: HET)

Hills and Valleys
Ep 4: Dr. Jerry J. Zimmerman on How Medicine Can Solve Its Sepsis Problem

Hills and Valleys

Play Episode Listen Later Apr 1, 2019 36:00


Dr. Jerry J. Zimmerman is a Professor of Pediatrics and Anesthesiology at the University of Washington School of Medicine. Zimmerman has been chair of the Scientific Advisory Committee for Children's Hospital Clinical Research Center since its inception and is a member of the Steering Committee for the Center for Clinical and Translational Research. You can follow him on Twitter @jerjohzimm.

Conferencias Magistrales Fundación Rafael del Pino
Big data. Indicadores económicos y nuevas tecnologías; retos para el futuro. Roberto Rigobon

Conferencias Magistrales Fundación Rafael del Pino

Play Episode Listen Later Jul 3, 2018 48:21


La Fundación Rafael del Pino organizó la Conferencia Magistral del profesor del MIT, Roberto Rigobon, sobre el fenómeno “Big data” titulada “Indicadores económicos y nuevas tecnologías; retos para el futuro”. Roberto Rigobon es Catedrático Society of Sloan Fellows de Administración de Empresas y Catedrático de Economía Aplicada de la escuela de negocios del MIT. Desarrolla su actividad en las más relevantes instituciones académicas como, por ejemplo, el National Bureau of Economic Research y el Census Bureau’s Scientific Advisory Committee y ha recibido numerosos honores y galardones a lo largo de su extensa y prolífica carrera académica e investigadora. El profesor Rigobon obtuvo su doctorado en Economía en el MIT en el año 1997, es MBA por el IESA y licenciado en Ingeniería Eléctrica por la Universidad Simón Bolívar. Sus áreas principales de investigación son la economía internacional, la economía monetaria y la economía del desarrollo. Ha investigado, en especial, las causas de las crisis financieras y los desequilibrios de balanza de pagos. Más recientemente, ha centrado su atención en el fenómeno “Big data”, en concreto, en su aplicación al análisis económico. En este ámbito fundó el Billion Prices Project y PriceStats con la vista puesta en el análisis de los procesos de formación de los precios internacionales y en la determinación de medidas de la inflación alternativas a las tradicionales. Su objetivo es ofrecer estadísticas de inflación en el mundo mejores que las oficiales a través de la medición diaria del fenómeno inflacionista. Su metodología no consiste en el tratamiento de la información de los precios en los puntos de venta sino en obtener dicha información de los distribuidores directamente a través sus webs. El potencial de esta metodología, en plena revolución tecnológica y de conectividad global, es enorme. Es posible utilizar los datos obtenidos para mejorar el conocimiento del comportamiento de los agentes económicos, predecir la evolución de las variables macroeconómicas, etc.

Conferencias Magistrales Fundación Rafael del Pino
Big data. Indicadores económicos y nuevas tecnologías; retos para el futuro. Roberto Rigobon

Conferencias Magistrales Fundación Rafael del Pino

Play Episode Listen Later Jul 3, 2018 48:21


La Fundación Rafael del Pino organizó la Conferencia Magistral del profesor del MIT, Roberto Rigobon, sobre el fenómeno “Big data” titulada “Indicadores económicos y nuevas tecnologías; retos para el futuro”. Roberto Rigobon es Catedrático Society of Sloan Fellows de Administración de Empresas y Catedrático de Economía Aplicada de la escuela de negocios del MIT. Desarrolla su actividad en las más relevantes instituciones académicas como, por ejemplo, el National Bureau of Economic Research y el Census Bureau’s Scientific Advisory Committee y ha recibido numerosos honores y galardones a lo largo de su extensa y prolífica carrera académica e investigadora. El profesor Rigobon obtuvo su doctorado en Economía en el MIT en el año 1997, es MBA por el IESA y licenciado en Ingeniería Eléctrica por la Universidad Simón Bolívar. Sus áreas principales de investigación son la economía internacional, la economía monetaria y la economía del desarrollo. Ha investigado, en especial, las causas de las crisis financieras y los desequilibrios de balanza de pagos. Más recientemente, ha centrado su atención en el fenómeno “Big data”, en concreto, en su aplicación al análisis económico. En este ámbito fundó el Billion Prices Project y PriceStats con la vista puesta en el análisis de los procesos de formación de los precios internacionales y en la determinación de medidas de la inflación alternativas a las tradicionales. Su objetivo es ofrecer estadísticas de inflación en el mundo mejores que las oficiales a través de la medición diaria del fenómeno inflacionista. Su metodología no consiste en el tratamiento de la información de los precios en los puntos de venta sino en obtener dicha información de los distribuidores directamente a través sus webs. El potencial de esta metodología, en plena revolución tecnológica y de conectividad global, es enorme. Es posible utilizar los datos obtenidos para mejorar el conocimiento del comportamiento de los agentes económicos, predecir la evolución de las variables macroeconómicas, etc.

The Ripple Effect Podcast
The Ripple Effect Podcast #159 (Dr. Thomas Seyfried | Keto & Cancer: Manage & Prevent Disease)

The Ripple Effect Podcast

Play Episode Listen Later May 22, 2018 89:48


Dr. Thomas Seyfried joins us to talk about his book Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer, and also to talk about his research at Boston College which focuses on mechanisms by which metabolic therapy manages chronic diseases such as epilepsy, neurodegenerative lipid storage diseases, and cancer. The metabolic therapies include caloric restriction, fasting, and ketogenic diets. This new concept has implications for the development of new non-toxic cancer therapies including the ketogenic diet, and experts in the cancer research field have praised this comprehensive study as one of science's hottest topics. Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications.

Catalog of Interviews and Bits
CATCHING YOUR BREATH AFTER A COPD DIAGNOSIS

Catalog of Interviews and Bits

Play Episode Listen Later Mar 22, 2018


Knowledge and a proper diagnosis important part of taking a positive, active approach to managing COPD NOVEMBER MARKS COPD AWARENESS MONTH Chronic obstructive pulmonary disease, or COPD affects about 24 million people in the US, yet about half of those afflicted wait months and sometimes years before receiving a proper diagnosis. COPD is a disease of the lungs that includes chronic bronchitis, emphysema or both and is characterized by obstruction to airflow that interferes with normal breathing. COPD remains under-diagnosed, under-assessed and under-treated. It is a complex and progressive disease that can be discouraging for patients and physicians. Yet there are many things you can do to manage your condition and improve quality of life, such as regular physical activity, a positive approach, reducing flare-ups and working with your HCP to determine the treatment options right for you. No one knows this better than Sean Cummings, who was diagnosed with COPD nearly 5 years ago. Although he strives to get the most out of each day, since his diagnosis he admits to sometimes feeling discouraged about not being able to do everything he wants, but speaking with his physician about doing everything they can to help manage his condition has helped. Up to 80 percent of patients already have moderate to severe COPD when they are first diagnosed, and have already lost significant lung capacity. Thatâ??s why understanding the severity of the disease at the time of diagnosis is so important in order to receive proper treatment and effectively manage the disease. Sean Cummings and a COPD expert will be available to bring awareness and understanding of COPD to your audience, and outline ways to manage the often-challenging symptoms of COPD, both physically and mentally, and showcase that patients can take a positive, active approach to managing the disease INTERVIEW WITH: David Mannino. M.D. helped to launch the COPD Foundation after his retirement from the Centers for Disease Control and Prevention in 2004, where he worked in the Air Pollution and Respiratory Health Branch. At the COPD he served as a board member from 2004 through 2015, chairman of the Medical and Scientific Advisory Committee from 2010 through 2015, and Chief Scientific Officer from 2015 to 2017. Dr. Mannino recently joined GlaxoSmithKline as a regional medical expert. Sean Cummings, COPD patient

Getting Personal: Omics of the Heart
Ep 13 Svati Shah Kiran Musunuru Andrew Landstrom Katelyn Gerbin Brock Roberts

Getting Personal: Omics of the Heart

Play Episode Listen Later Feb 21, 2018 50:04


Transcript of the February Podcast, “Getting Personal: Omics of the Heart”, Episode 13   Hosted by Jane Ferguson   Assistant Professor at Vanderbilt University Medical Center & Associate Editor of the Circulation: Precision and Genomic Medicine journal of the American Heart Association Jane Ferguson:             Hello. This is episode 13 of Getting Personal: Omics of the Heart. It's February 2018. I'm Jane Ferguson, an assistant professor at Vanderbilt University Medical Center, an associate editor at Circulation: Precision and Genomic Medicine, and an occasional podcast host. This month, I talked to Kiran Musunuru and Svati Shah about how they spearheaded name changes for Circulation Cardiovascular Genetics and for the AHA Council on Functional Genomics and Translational Biology, and Andrew Landstrom talked to Kaytlyn Gerbin and Brock Roberts from the Allen Institute about some extremely cool work they are doing with CRISPR and IPS cells to create fluorescently tagged maps of live cells, which allowed them to image and better understand the structure and function of individual cells.                                     I'm delighted to have two guests on the podcast today, Dr. Svati Shah is the current chair of the AHA Council on Genomic and Precision Medicine formerly called the Council on Functional Genomics and Translational Biology. She is an associate professor of medicine at Duke University Medical Center. Dr. Kiran Musunuru is editor in chief of Circulation Genomic and Precision Medicine formerly named Circulation Cardiovascular Genetics, and he's an associate professor of medicine at the University of Pennsylvania Perleman School of Medicine.                                     Dr. Shah and Dr. Musunuru were kind enough to take time out of their busy schedules to join me for a joint discussion on the recent enhancement of name changes for our council and our journal. With tight schedules and last-minute flight cancellations we didn't have ideal settings for recording, so apologies in advance for a little more background than usual.                                     My instruction highlighted a number of name changes and astute listeners will have noticed that the new names for both the journal and the council are very nicely aligned, so I know this was not a coincidence, and I'd love to hear from both of you, what prompted the decision to change the respective names of the council and the journal, and how did you come together to streamline these name changes? Svati Shah:                   Well, maybe I'll take a first start, you know, we, we're really lucky in our council, we have a very, you know, certainly one of the smaller councils [inaudible 00:02:26] we have a very collegial spirit that wants to get things done. So, these conversations actually started probably three years ago, umm, when Jen Howell was chair of the FGTB council. And we realized that not only was our constituency broadening in expertise and breadth and depth, but also, umm, the desire to kind of move beyond the really wonderful work the council is doing around technology platform, genomics, genetics and you know important advances in many of our council members have made in the translational biology field and really thinking about the fact that we have this amazing expertise that can come together across a wealth of disciplines to really translate what's being done in the omic space, and apply it in this new world of precision medicine.                                     And so, umm, that is what stirred really thinking about a name change so that not only would it reflect this expanding constituency in expertise and hopefully draw even more people, across the, you know, wide expertise. But also to harmonize more with people who are in other councils, including clinical cardiology, and people that, really, in the end we are actually quite allied with scientifically, but perhaps those councils didn't recognize really what our council was about because of our previous name. So in that context, you know, it's been wonderful. Kiran has been a wonderful partner in all of this, he's been a real leader in the council and over the past two years we have had many conversations across council leadership and the entire council, and thinking about what this name change would be. And actually, it was almost a consensus amongst council leadership to choose Genomic and Precision Medicine as the name, really to reflect our core beliefs and our core science in genetics and genomics, but also to reflect the expanding expertise of all the different omics platforms, our expertise in clinical genetics with more genetic counselors joining our council, and our expanding expertise in computational biology. And this really allied nicely also with the American Heart Association building a very important institute, the Precision Medicine Cardiovascular Institute. So, I'll let Kiran go from here but again, Kiran has really been a great partner in this and he can kind of expand on that story and how that led to the journal name change. Kiran Musunuru:         Sure, so, with respect to the journal, I think these changes have been growing for a while. I think a lot of the same considerations came into play, the feeling that the journal with the name Circulation Cardiovascular Genetics was perhaps too narrowly defined given how the field, how the science was evolving. And the other consideration is that the Functional Genomics and Translational Biology Council has had a journal, a companion journal if you will, all of this time with a fairly distinct name, Circulation Cardiovascular Genetics, and so it wasn't necessarily obvious to those who are not on the inside so to speak that there was supposed to be a very tight connection between council and journal, that the journal really was the journal of the council and so in the process about deliberating about a council name change, it became natural to think that, "Wow, wouldn't it be nice if the journal could execute a similar name change", and separately, even though this predates my tenure as editor of the journal there had been conversations going on separately or independently that perhaps the journal would benefit from signaling that it was not just about cardiovascular genetics in the very narrow sense, but was really about a much larger area of science. And so there had already been contemplation for quite a while about a name change and so when I assumed the editorship I didn't really have to do much to convince anyone that this would be a useful thing.                                     The scientific publishing committee of the American Heart Association and all the various people involved publishing the journal were already sort of primed for a name change and then it just ended up being a nice convergence of opportunities, Svati with her work in the council and really showing the leadership to lead the transition from Functional Genomics and Transitional Biology to Genomic and Precision Medicine.                                     That really laid the groundwork, and because it was such a deliberative process, such an inclusive process, involving dozens of people on the leadership committee of the council as well as general membership of the council, it was really a no-brainer. The hard part had already been done, the thinking had already been done and I was straightforward to say that we should change the name of the journal to match, Circulation Genomic and Precision Medicine. Jane Ferguson:             Have there been any logistical difficulties in getting this name change through, or has it all happened very organically? Svati Shah:                   The American Heart Association has been a real partner in the name change, sometimes things require many layers of approval and in fact, it has been a relatively seamless process. We came up with a consensus around the name change and later applied formally for that change in the council name, and that was pretty quickly approved by the Scientific Advisory Committee, within a few months really. Our name change became official and we are in the exciting time now of advertising and kind of marketing the name change and appeal to a broader constituency and really reach out to group that perhaps wouldn't have realized that this council is a great home for them again thinking of genetic counselors and computational biologists. So, it really, you know, has been a surprisingly seamless and fun process. Kiran Musunuru:         As I mentioned before it was already kind of in the air that a change was imminent and so when I posed the name change to the Circulation Genomic and Precision Medicine it ended up being a very smooth transition. It was timed so that the volume change, that is changing from the volume associated with the calendar year 2017 to the volume associated with the calendar year 2018, January first ended up being a very logical transition time and so that's when the change occurred.                                     And happily, the council name change ended up occurring almost in lockstep; whereas, you know within a few weeks of the journal announcing its name change the council was able to announce its name change as well. I think that has had a reinforcing effect across the American Heart Association and its membership. It really signals that the council and the journal are tightly tied together, are partners in moving in lockstep. Jane Ferguson:             Svati, this question's probably more for you, so what does the name change mean specifically for existing FGTB council members, and what if anything will change, and then what might it mean for potential new members who are trying to decide what council to join? Svati Shah:                   That's a great question, Jane, you know I am a pragmatic person and I think our council also reflects that pragmatism. We get a lot of things done and we, I think, spiritually all agree that we shouldn't just change the name just for the sake of changing the name. And so we really, actually the name change followed [inaudible 00:10:18] were involved in, these discussions are a year and a half of really thinking about what direction we wanted the council to go and then what the sort of short and long term goals of our council are and then how does the name change effect the long term goals.                                     So, we have a lot of great initiatives in the short and long term, which again will capitalize on our broadening expertise in these different clinical genetics and precision medicine and really, translating genomic and omic findings into, into important patient care. And so, we have several things coming down the pipe that are sort of proof of principle examples of what the name change reflects.                                      So, one example is that we are now working on developing a certificate in medical genomics with the idea that we really need more genetics education. Our council has been very much embedded in genetics and genomics education, Kiran being a key example of that. And now we are expanding that into thinking about how genomics is applied to clinical medicine but making it at the level that is digestible and understandable and is easily applied by a general cardiologist and even primary care doctors will be able to use that resource. And the idea is this will be your self-sustaining certificate that's given through the American Heart Association, so we have a group that's been working on that certificate and hopefully that will be coming out soon.                                     Another key component of what we're doing is trying to reach out more and partnering with other associations including the American College of Medical Genetics and the National Society of Genetic Counselors, again really thinking about how we transition our important scientific discovery work into translation implementation science around patient care.                                     To give you some examples of what that means in terms of what the name change is reflecting, I think with the right use, for the second part of your question, which I think is a really important part of your question is, we want to attract more people in the computational biology field, in the precision medicine space, in the clinical genetic space and again reaching out to genetic counselors through some of these societies, because we, just the wave of precision medicine is here, is going to expand even more and the expertise within our council that was already there but that now we can expand. I think it will be leveraged to really make important contributions to making sure that those efforts in precision medicine are done well, or done responsibly and are done with the patient in mind because in the end the American Heart Association is at the forefront of patient advocacy group.                                     This is a really exciting time, I think that, you know, however you want to define precision medicine the bottom line is precision medicine is here and we can't have, it's not going to be a single faction of individuals or a single expertise that is really, is going to be able to leverage fundamental scientific discoveries whether its genetics, genomics, metabolomics, proteomics, and really translate them responsibly into patient care, so it's going to involve an interdisciplinary and multi-disciplinary effort.                                     I feel really proud that I'm part of the AHA and that we sort of have this perfect storm between Kiran's leadership in the journal, our council changing, you know, its goals and its name aligning with the Institute for Precision Cardiovascular Medicine within the AHA. And I think that, you know, it's not all rainbows and sunshine. We have a lot of work that is cut out for us in the next few years to figure out ways that we can tangibly and concretely, and again responsibly, work together across each of these three components of this perfect storm to make sure that it’s not just a glitzy name change and that there is actually substance and behind all of it, so, you know, it will be, there will be challenges, there will be obstacles, but I think that the amazing people within each of those three components, I feel very confident that we are going to be able to do it well. Jane Ferguson:             Yeah, I agree, as a member of the council, if anybody can do it I think this group of people can do it, so it's very exciting to see, so thank you both for joining, and congratulations again on the new names. It's really exciting to see these, you know, new directions for the council and the journal working together. And I really look forward to seeing all the great initiative that will be coming out in the next few years. Svati Shah:                   Thank you, Jane. Kiran Musunuru:         Thank you, Jane. Andrew Landstrom:     My name is Andrew Landstrom, and I'm an assistant professor in the department of pediatrics section of cardiology at Baylor College of Medicine. I'm a member of the early career committee of the American Heart Association Council on Genomic and Precision Medicine, previously the Council on Functional Genomics and Translational Biology, and I'm joined today by Brock Roberts and Kaytlyn Gerbin, who are scientists on the stem cell and gene editing team at the Allen Institute.  Here to discuss a little bit more about CRISPR editing and what they have done for live cell imaging using fluorescent proteins.                                     So, Brock and Kaytlyn, I'm hoping you can discuss a little bit about what the Allen Institute is and your overall research mission and goals.  Kaytlyn Gerbin:           Yeah, great, so this is Kaytlyn and thanks Andrew for having us on, and we're really excited to share a little bit of the information about what the institute is doing, because we're building a bunch of tools that we think would be really useful for the research community. So, we're excited to get the word out there. And so, the Allen Institute is a non-profit research institute, and we're based in Seattle, Washington, and, essentially what we're trying to do is better understand the cell.                                     We want to understand the various states the cell can take based on structural organization of how different organelles work together. And so, we're doing this, essentially by live cell imaging and also combining that with predictive modeling so that we can build tools to be able to understand structure-function relationships and how cells behave in a healthy state or in a diseased state. So, you can kind of think of this as, we like to say sometimes like a Google Earth for the cell, so if you kind of think about it in that context, a lot of times, you know you could look at the cell at a really high level just like you could look at the Earth at a very high level. Then you could zoom in further and you could look at an individual pathway maybe that you're interested, or perhaps, as an analogy, like a different highway within a part of a city.                                     But you don't really understand how all that works together and how the city functions together until you start to put in things with spatial organization, or maybe temporal dynamics, or how different parts of the structures, or different structures and organelles work together to form the unit that is the cell.                                     And so, essentially, we're trying to generate a bunch of data so that we can build predictive models to help us understand that better. And, we're doing this with human induced pluripotent stem cells, and the first cell state or cell type that we're studying is cardiomyocytes after differentiation.                                     And so, yeah, as we're kind of generating this data we are a non-profit institute, and all of our lines and our plasmids, protocols, data, pretty much everything that we make is becoming publicly available as it passes QC. And so, yeah, we're excited about that, I don't know if, Brock, you have anything else to add. Brock Roberts:             Yeah, just I think an important concept that we're often working with is scale. And, biology exists at certain scales, and that's certainly true for cells and the Google Earth analogy holds.                                     You know, at some level if we want to understand the cell at the scale of its entirety, but we have to kind of cut that down and understand cells at the level of its parts.  And, they're working together as we know, and can infer, but we try to find a way to look at the part one by one and then put it all together in a model that's predictive. And the predictive part is going to be really important. Much like Google Earth can allow us to, you know, look at a traffic pattern in the city or something like that once the data is filled in. We hope to fill in enough data by looking at the cells constitutive parts to make the predictive model. Andrew Landstrom:     And not only looking at, sort of, constitutive parts, you're doing this in a physiologic live cell, so really it's Google Earth, but it's Google Earth in real time as cars are driving down the freeway and people are walking down the street. Brock Roberts:             Right- Kaytlyn Gerbin:           Yeah, exactly. Brock Roberts:             Yeah, that, that's where the dynamics of the cell can really come to life if you've prioritized looking at live cells, which are obviously incredibly dynamic. Andrew Landstrom:     And so, you know to be able to accomplish this, you all have come up with some pretty novel methods. Would you talk a little bit more about your CISPR editing approach, and how you've applied this to different lines and to get, sort of, different markers into cells? Brock Roberts:             Right, sure, the, we should say that we owe a lot to the development of CRISPR-Cas9 editing, which preceded us by a few years, but we've tried to kind of scale it up in some important ways.  And, really the important thing to appreciate about this process is it's a way to make a very precise, precisely guided DNA break in the genome of a cell. And we do this in human induced pluripotent stem cells, and so we can quite precisely choose a position or location in the human genome and trigger DNA damage, trigger breaks in the DNA molecules that make up the chromosomes.                                      And we can do this with, kind of a highly specifically guided RNA molecule that we complex with this Cas9 nucleus molecule, and these are, very famous molecules now, over the last few years they've become very well known.                                     And the upshot of this is we can, sort of trick the cell into repairing that DNA break using the processes that are always at play in living cells to resolve breaks in DNA, but we can sort of trick that process to add something additional at a specific site. And the additional sequence that we use is a tag sequence that corresponds to a fluorescent protein after the DNA is expressed and translated. And so, what we can effectively do is tag proteins that are produced in a highly endogenous, natural fashion within cells.                                     And the proteins that we can tag in this way, using this method, correspond to some of the most canonically recognized structures and organelles within the cell. And so, at this level we try to choose proteins, tag them in this manner, and take advantage of the fact that they will localize predictably to some of the dozens or hundreds of structures that make up cells. Kaytlyn Gerbin:           Yeah, and a key thing I think to add that Brock kind of mentioned was that this isn't any over expression, we're doing all this endogenously. So it’s really like, pretty, I think that's a big advancement over what has typically been done in the past with a lot of fluorescent tagging of proteins within the cell. Brock Roberts:             Right, but what's important to appreciate is that we're using the cells endogenous copies of each protein, expressed from the genome. We've done it in about 30 different genes so far. And we have a high success rate in accomplishing this process, all the way through to completion, which is to say that we know that we can introduce a tag onto at least one copy of each gene that is, that encodes a protein that can be tagged this way, and then we can monitor the cells over several months and ensure that this doesn't have a negative consequence on their growth or on their ability to differentiate or something like that. Our quality control process. We have a high success rate so far. Andrew Landstrom:     And that's really, in my eyes, one of the key, key sort of, innovative factors of your work, in that these are endogenous proteins that are able to be expressed and then to be imaged in real time without really disrupting the underlying cellular physiology. Kaytlyn Gerbin:           Yeah, and we do care a lot about what you just said, that it doesn't have any negative effect on cell behavior because we are using these as a surrogate for understanding cell behavior in, hopefully, a normal context. And we do an extensive amount of quality control work and all of that QC data is available on our website, and then you can actually access all of our cells through Coriell and all of the QC data for all those cell lines is made available, and we've also done a pretty extensive job outlining the QC that goes into this process so that, hopefully, people will take a look at that when they look at our cells and understand what we've done, but we also hope that this will kind of help set a standard for things that other people should be looking at when they're doing editing on their own. Brock Roberts:             And we really hope that people take these cells and do experiments that we don't have the bandwidth to do, and test them in ever expanding ways and let us know and report on it. Let us know how the cells perform and their unique assets. Andrew Landstrom:     Yeah, and I think all that sort of transparency with the quality control really makes it user accessible and just sort of invites that degree of collaboration, that's great. Kaytlyn Gerbin:           Yeah. Brock Roberts:             Yeah, we hope so. Yeah, we think so, too. Andrew Landstrom:     So how many cell lines do you have available? Kaytlyn Gerbin:           Yeah, so, currently, and again you can access all these lines on the website, but we have 16 lines that are released that have gone through the full QC process. Those are available now, and we have another six that are listed as in progress, which means that they will be released very soon.                                     Just to give you a few examples, so again, we're tagging proteins to label organelles in the cells. So, a lot of times, you know there's a lot of different kinds of proteins you could use to tag an organelle, so we've chosen a subset of those. So, we've tagged, for example, Tom20 to label mitochondria, Lamin-B1 for the nuclear envelope, alpha tubulin to look at micro tubules, and we also have started doing a lot more endosomal trafficking pathways, so like the endosome, lysosome, peroxisome, for example, and then a few other epithelial markers such as tight junctions, desmosomes, and actin.                                      And so, there's a kind of a bunch of structures. Those are just some examples of what we've been starting with tagging, but one of the reasons why we chose to use induced pluripotent stem cells for this whole model is because they do have the ability to differentiate into many cell types. And, I mentioned earlier that we chose to start with cardiomyocytes as a key cell type to look at, and so all of our cell line, as part of the QC process go through a cardiomyocyte differentiation protocol. And that kind of helps us ensure that the cells are pluripotent and that they can become a defined cell type and that the structure that we've labeled still is present in that differentiated cell. But it also means that we can start looking at some really interesting things in terms of how these structures change during differentiation and change from the stem cell state to the cardiomyocyte state. And so, one thing that we really started doing towards the end of last year, and we have lines coming out, hopefully soon on some cardiac specific tags. And so, to give you a few examples of things that we're working on, we have cardiac troponin I 1, and this I think will be available, I think it's passed QC and will be available pretty soon. And then we also have, we're working on sarcomeric alpha-actinin, titin, some gap junctions so that connexin 43, and then also starting to do a few signaling pathways and one that is of particular interest for the cardiomyocyte field would be beta-catenin for Wnt signaling.                                     So, we are kind of expanding on that list as well. So, we're really excited to start looking at these cardiac structures in the cells. Brock Roberts:             One way to summarize kind of, our strategy and one thing unites all of the different gene and protein targets that we have produced and focused on so far is to really think about the product gene or the protein as a reporter for an organelle or a structure in the cell. So, there are of course an extraordinary number of genes and proteins using this method, and there are many different justifications that would fly for why you would target a particular molecule, a particular gene, a protein of interest, but, what we really try to focus on are proteins that serve as a reporter for a structure.  Andrew Landstrom:     So, have you tagged any ion channels? Brock Roberts:             We have several targeting experiments that are, that take advantage of tagging the transporter molecule. One that is available is a transporter in the mitochondria, a transporter to the outer membrane, Tom20. And we're also making connexin 43 available for gap junctions. These proteins that function as trans-membrane transporter molecules accommodate the approach quite well.                                     Another that is a bit further behind, but we hope to make available before too long would be marker of the sarcoplasmic reticulum and cardiomyocytes. This is a serca protein. Andrew Landstrom:     So, with all these cell lines at your disposal, you've spoken to, sort of, the dynamic changes that occur both in differentiation of cardiac myocytes and cellular development and cell physiology, what are some other thoughts that you have that these lines might be able to show us? What are some fields that might be immediately informed by these models? Kaytlyn Gerbin:           I mean, I guess just kind of on a big pictures I think that having the ability to study live cells and look at different structures in the cell will help us better understand structure-function relationships. So I think that in cardiomyocytes that, you know, makes a lot of sense, but I think even just in the stem cell field, being able to understand how localization of a particular organelle corresponds to a different state that the cell might take.                                     And so we kind of are thinking about a lot of these different stages and states that the cell can pass through and how do we characterize that based on just kind of at a healthy or just kind of quiescent state, and then comparing that to different protivations, so looking at disease or maybe change in time, change in mutations, drug response, response to stress and how are the structures changing and how does that kind of dynamic integration effect how the cell behaves as a whole?                                     And I think that that's one thing that we're really trying to do at the institute that is out of the scope that a lot of federally funded academic labs can do. A lot of times people are focusing on specific pathways or a specific molecule or a specific protein and don't necessarily have the bandwidth to look at the cell on a systems level. And so, kind of as Brock mentioned, with doing these different proteins as tagging the organelles we're hoping that being able to integrate that and generate enough data where that starts to become predictive I think can be really, really powerful. So... Brock Roberts:             Yeah, and there's another thing to add that's is kind of a larger thought that we are very preoccupied with and interested in, which is to take kind of a post genomic view of biology and cell biology in particular. Genomics has been so explosively successful in allowing us to document and document the state of cells at the level of which genes, which of the many, many, hundreds and thousands of genes are active in a particular cellular state, in a particular cell type or particular state that that cell's in.                                     We can easily get lists of genes that we know are functioning and turned on. What we want to do is take that to the next level and start defining a cellular state as a combination, a particular combination of dynamic behavior of those molecules which we can actually see. So we want to be able to see the parts work together. Not just have a list of the parts, and define states in that way. Kaytlyn Gerbin:           Yeah, and I think you kind of asked about what kinds of communities might find these tools useful and I think lot of the disease, we're thinking about how this might apply to disease modeling or drug screens or even developmental biology and kind of studying things like that, so I think a lot of our, we have some collaborations, and we've also been really trying to expand what kinds of groups and communities are using the cell lines.                                     There's been a lot of, kind of positive feedback on people taking, you know, a highly defined cell type that has a lot of QC done, and then having the right tools to be able to start to look at things like that. So, I think we kind of mentioned some of the tools we have, but I just to kind of restate that, all of the cell lines that we listed, along with many more, are available at Coriell.                                      And then, in addition to that you can get the plasmids that we've used, which have gone through also an extensive QC, so if people are working on patient derived, on their own patient derived IPS lines, you know, you could get the plasmids for whatever reporter and then put those in to your own cells. And we do have protocols available that describe our whole process in a lot of detail for how to do that and kind of different QC steps along the way. Brock Roberts:             Yeah, we describe each targeting experiment in enough detail for it to be, we hope, recapitulated in any human cell line or cell type without too much strain on behalf of the person that's doing that work. So we hope to kind of inspire people to try this, even if they might not be familiar with it. Kaytlyn Gerbin:           Yeah, and another thing is that our data is also available, so all of our imaging data that we're doing, and then, you can actually find that we have a website called the Allen Cell Explorer. And from there you can go through and look at all of the imaging, no, pretty much all of the images that have gone through our pipeline are now on the website. So you can go through and actually look at individual cells that were imaged during what, you know, as live cells, and then look at different structural tags that are in there.                                     Another thing that you can see on that is the predictive modeling, and so what we're able to start doing is predict the structure of, let's say, mitochondria based on the nuclear shape and another organelle that's in there. So, we're able to start doing a lot of that. So that, I think, will be really useful to people.                                     We going to add about the label free...? Brock Roberts:             Yeah, and some of the more interesting results that have emerged recently are, are the ability to infer through machine learning approaches and neural network approaches the status and state and sub-cellular localization of certain organelles in the cell and structures in the cell that are actually unlabeled. Those can be inferred from the sort of sophisticated analysis of bright field, you know, images that are not displaying any particularly obvious properties, any tags or anything like that.                                     But because the work has been done in the background to train these models and deep learning approaches with individual cell lines that do have these very specific reporters of distinct structures and organelles, because that data set exists, our modeling team and imaging team is able to appear actually quite deeply into the state of cells that are actually not labeled. Andrew Landstrom:     Wow. Brock Roberts:             So, it's pretty, pretty interesting. Kaytlyn Gerbin:           Yeah. Yeah, we don't have that up on our website yet, but that's in the works to get that actual predictive model. So essentially what that would mean then is that you could take a bright field image in your own lab and then put it into this model, and then get information about maybe where the nucleus is or where the mitochondria are or where the actin is predicted to be.                                     And all that is actually trained off of thousands and thousands of images that have come through the imaging and then the modeling pipeline. So, I think that that tool itself, once that is out and fully QCed I think could be, have a big impact right away. At least we're hoping that it will. Brock Roberts:             Hoping. And those computational algorithms are among the publicly available tools that we have that can be found through our website, and our publications that are coming out. Andrew Landstrom:     That's absolutely fascinating. Are you able to provide a specific example of how you've used, sort of, artificial intelligent, deep learning predictive modeling to infer a physiologic sale or response that was not directly observed? Brock Roberts:             Well, I think the response is, we're really hoping to go in that direction. To use this to, I guess, if you will, take shortcuts toward a response in the form of a state change after we alter the environment in some way, or perhaps alter the genome to mimic a disease, mutation, or something like that. Right now, we are building the relationships. So, we can, we know, and I guess one example we can give is progress through the cell cycle. Kaytlyn Gerbin:           Yep. Brock Roberts:             That would be one kind of clear example that we, we haven't done a lot yet to manipulate the cellular environment or trigger cells to go through different states, but obviously cells that are in culture and proliferating alter their state by progressing through cell cycle. So that's one example that we can detect. We can clearly look at how the morphology of cells and different cell cycle states that emerge that are their chromosomes are compacted or dispersed as they undergo synthesis or undergo division, progress through metaphase and so forth.                                     We can look at those cues and connect the state of the cell with respect to the cell cycle, to the state of some of the organelles, with the state of the mitochondria, for example. And we're hoping that same approach will hold up when we trigger, in some cases, more subtle changes to the physiology of cells. Andrew Landstrom:     That's particularly fascinating. I think the, you know, the ability to leverage that in the setting of, like you were mentioning, patient derived IPSCs from heritable diseases. You know, these sort of monogenic disease models that impart a biophysical defect in the cell could then be modeled and not only directly observed, but perhaps indirect cellular physiology might be inferred in a way that we really haven't been able to do so previously. Brock Roberts:             Absolutely. Yeah, there would be, in some cases there are monogenic disease mutations and pathologies that we know ought to have an effect, and we're really excited to see if that holds up, and how that holds up and what their phenotype is when looked at in this sophisticated way. And then there are other, more mysterious mutations that would be really excited to see a phenotype in. Kaytlyn Gerbin:           Our goal at the institute is to build the tools and provide the resources to the community to be asking these kinds of really detailed, very interesting questions. I mean, I think there's definitely interest in doing some of that work here, but our main focus is to design the tools and the methods and make that all available to the public as soon as it passes our QC. So, that's the, those are the kind of thing that I think the community will have a big impact on, testing these kinds of things in their own systems given you know, new tools and ways to do it, so. Andrew Landstrom:     Right. Brock Roberts:             Our whole, our whole ethos is to cooperate and to facilitate. And rather than compete with other investigators, we want to make things possible and that are shared and open. For example, our list of genes that we went with to target, that was on open collaboration. We asked as many specialists in the academic community as we could to develop a consensus of what would be the most useful markers for different organelles. And we chose those proteins and genes. So, we're really trying to be collaborators, as best as we can. Andrew Landstrom:     Are there specific examples of collaborations that you've felt were particularly productive or yielded some new exciting insight? Kaytlyn Gerbin:           Mm-hmm (affirmative), yeah. I could give you a few examples. So, Doctor Ben Freedman, who is at the University of Washington, he is working on kidney research. And so, he has a few of our cell lines, he actually, it's convenient because we are located right across the street from each other, so we'll see them fairly often, but, yeah. So, he works on kidney research with the different cell lines and he really wanted to get the cells into a 3D context. So, he is working on a lot of different tissue engineering to study developmented disease.                                     And so, he's also starting to make his own, their own mutations in the cell line, and so that's been, at least so far, that's been one collaboration that's I think has really been very powerful. And it's cool because we don't have the bandwidth right now to be looking at kidney organoids, but I think it's showed, kind of, the power of these kinds of cells and tools that, you know, when you have that you can do the live cell imaging with different structure within the same kind of organoid and you can get a lot of information, and so ... Andrew Landstrom:     Yeah. Kaytlyn Gerbin:           That, that's been fun to see develop. Another one that I know, Chris Chen at at Boston University is using our lines and is making cardiomyocytes with them as well and looking at the effects of patterning. And patterning is something that we also planning to do here, but that collaboration has been great to kind of get things going.                                     And we've also been working closely with a group at the University of Washington, Georg Seelig's lab, who's developed a new way of doing single cell RNA sequencing. And so, that's been fun, we've been looking at that with stem cells and then cardiomyocytes to, kind of help, help us figure out what the different states that the cells are in. And then that is going to help and form, kind of, what future tags we might do or when, when to do imaging or kind of what protivations we want to put the cells through. Andrew Landstrom:     That sounds like you're spanning the gamut really of downstream experimentation on these lines. Brock Roberts:             Yeah, and we've also had a lot of people buy the cell lines. Kaytlyn Gerbin:           Yeah. Brock Roberts:             Acquire them through the Coriell, we hope that each case of their productive application toward different research questions could be defined as a mini collaboration. Maybe we'll hear from some of these people. And in some cases we have, and there may be more things that spring out of that. Kaytlyn Gerbin:           Yeah, I think like, because the lines are available through Coriell it's, it's a little early to start seeing publications from the stuff, because we're a pretty new institute, but we do keep track of where the lines are going and, I mean it's exciting to see, I mean, pretty much all throughout the world there's people ordering the lines and starting to do research in a lot of different kinds of systems. Brock Roberts:             Right. Kaytlyn Gerbin:           So, we don't always necessarily directly collaborate with the people that are using the lines, but a lot of times we do hear from them or we'll run into people at conferences or something who have been using our lines. So that's really fun to see that its, our, you know, the work that we're doing here is actually producing things that people in the community are finding informative and useful. So, that's always fun. Brock Roberts:             It's still so early in this project. I mean we're just at the beginning of a lot of collaborative potential. So, we really hope to see this take off. Andrew Landstrom:     Yeah, and if people listening want to collaborate or want to learn more, how can they learn more and how can they get ahold of you all? Brock Roberts:             Oh, hold on, I think, first of all, we really want to funnel people to our website. We think it's a really great resource and at that allencell.org you can contact us through that link. We look forward to hearing from you. Kaytlyn Gerbin:           Yeah, so you can start with the website there. And as we mentioned before you can find all of our cell lines, plasmoids, protocols, etc. on this site. And we've also started to do a few more instructional videos, and so those are coming up on the website, too. So, some things, you know, especially as more groups are starting to use the lines, we do have the detailed protocols, but I think groups that maybe haven't done stem cell culture before or haven't worked with these kinds of IPS lines before, we're trying to provide as much content for people to make it easy for them to do the research. So we're starting to do more, sort of instructional videos. Brock Roberts:             Yeah, and we seek this out. We want to hear from people. It's not a bother. We're trying to get as much, we're trying to get the, we're trying to branch out and communicate as extensively as we can. Kaytlyn Gerbin:           Actually, one thing I just thought of that I want to add in her is that we have started to work with a few stem cell cores. And so, right now, I mean- Brock Roberts:             These are core facilities at universities. Kaytlyn Gerbin:           Yeah, stem cell core facilities at, yeah, exactly. So, part of trying to distribute the lines is that if we can, you know, individual investigators could get our lines from Coriell and get the licensing and everything to do that in their own lab, but it's, I think, going to be really great if we get some connections with the stem cell cores because then once we can provide the lines to them, they can distribute them to investigators that are part of the core.                                     And so, so far, we already have agreements in the works with University of Washington, UC Berkeley, and then the Salk Institute, but this is something that we're really hoping to expand this year. So I think, in particular, you know definitely contact us if there's questions about the lines or anything, but if you are part of a stem cell core at a university and you think that people at the university would be interested in using our lines we're working really hard to make, you know get, kind of, packages, protocol packages and everything available so that we can get these lines set up in the stem cell cores. Brock Roberts:             Right. Andrew Landstrom:     Well Brock and Kaytlyn, thank you so much for joining me. What an incredible resource that you all have created, and I especially appreciate how open and transparent you are with your lines and your quality control and how you just really, you know, try and strengthen collaborations and to start new ones. Brock Roberts:             Thank you very much for the conversation. Kaytlyn Gerbin:           Yeah, this has been fun, thank you. Jane Ferguson:             I hope you enjoyed listening to this episode of Getting Personal: Omics of the Heart. Let us know how we're doing by leaving a comment or tweeting at us at @circ_gen. We love to hear from you.   

Ketogeek's Podcast
20. Cancer As a Metabolic Disease & The Failure of the Health Industry | Dr. Thomas Seyfried

Ketogeek's Podcast

Play Episode Listen Later Jan 23, 2018 79:53


Cancer is painted as a multi-faceted and complicated disease that has many forms. However, there seems to be one common theme in all cancers which plays a massive role in combating it. In this podcast, we delve into this mechanistic behavior of cancer cells. Bio: Thomas N. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He did his undergraduate work at the University of New England, where he recently received the distinguished Alumni Achievement Award. He also holds a Master’s degree in Genetics from Illinois State University. Thomas Seyfried served with distinction in the United States Army’s First Cavalry Division during the Vietnam War and received numerous medals and commendations. He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine and then served on the faculty as an Assistant Professor in Neurology. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro, where he is a Senior Editor. Dr. Seyfried has over 150 peer-reviewed publications and is the author of the book “Cancer as a Metabolic Disease: On the Origin, Management, and Prevention of Cancer (Wiley Press).” Time Stamps:  0:16 - News from Ketogeek 4:53 – Dr. Seyfried’s bio 7:25 – Dr. Seyfried’s journey to keto & low carb 8:22 – The origins of the Ketogenic Diet, the Charlie Foundation & Cancer Research 11:16 – How do you create a ketogenic diet? 12:32 – The glucose-ketone Index 14:24 – The power of ketones & cancer preventative mechanism 17:16 – Oncogenic Paradox and what causes cancer in the body? 19:33 – Tumor metastasis & dangers of carrying out a biopsy of the lump 21:46 – Moving from chemotherapy to a metabolic solution to cancer 23:52 – What challenges do you face as a cancer researcher? 27:02 – What’s your advice for future oncologists and medical students? 30:20 – Why does glucose & glutamine fuel cancer cells and resist cell death? 32:16 – Are there exceptions to the metabolic theory? 34:30 – Can cancer cells adapt to ketones? 36:55 – How do you figure out a medical procedure works? 40:24 – Is cancer a modern disease? 42:30 – Can you predict cancer & importance of CRP level? 45:38 – What does it mean to be “healthy mitochondria”? 47:06 – What kind of cancers are still giving us trouble? 48:18 – What biomarkers are affected by tumor growth? 51:37 – How do I talk to my oncologist about my tumor? 54:12 – How do I know I am doing the right thing? 56:49 – How can educational institutions embrace change? 59:09 – The health crises in cancer therapies. 1:01:49 – What precautions can cancer survivors take? 1:03:00 – Is coffee and alcohol an issue? 1:05:52 – What books would you recommend? 1:08:52 – What kind of conferences can people attend? 1:10:45 – Final Message 1:11:46 – Dr. Seyfried’s book “Cancer As a Metabolic Disease” 1:14:21 – Final Plug 1:15:23 – The common theme in all cancers and the problem with building nonprofits around different cancers 1:17:40 – Single Cause, Single Cure foundation Plugs: Dr. Thomas Seyfried: https://www.bc.edu/bc-web/schools/mcas/departments/biology/people/faculty-directory/thomas-seyfried.html Single Cause, Single Cure: https://www.foundationformetaboliccancertherapies.com/ Heads Up Health: https://www.headsuphealth.com/ Ketogeek: https://ketogeek.com/ Nutty Carnivore: https://ketogeek.com/pages/nutty-carnivore-diet Cancer As a Metabolic Disease (Book): https://www.amazon.com/Cancer-Metabolic-Disease-Management-Prevention/dp/0470584920 Tripping over the Truth (Book): https://www.amazon.com/Tripping-over-Truth-Overturning-Entrenched/dp/1603587292    

The Empowering Neurologist Podcast
Episode 43: Thomas Seyfried

The Empowering Neurologist Podcast

Play Episode Listen Later Nov 7, 2017 51:23


Despite so many highly publicized breakthroughs in medical science, cancer remains a formidable disease. Deaths from cancer are actually continuing to rise, at a rate of 3.5 to 4% each year. My interview today is with Dr. Thomas Seyfried. Dr. Seyfried believes cancer isn’t primarily caused by damage to the genes living in the nucleus of the cell, a widely held belief, but rather represents a problem of how cells produce energy from their mitochondria. Ultimately, this defective energy production leads to increased free radical production which may then go on to damage the DNA of the cell nucleus as a secondary event. What is so elegant and compelling about his theory is that it lends itself to a powerful interventional approach centered on simply shifting the energy source of the mitochondria to products derived from fat, as opposed to carbohydrates. Dr. Seyfried received his Ph.D. in Genetics and Biochemistry from the University of Illinois and also holds a Master’s degree in Genetics from Illinois State University He was a Postdoctoral Fellow in the Department of Neurology at the Yale University School of Medicine, and then served on the faculty as an Assistant Professor in Neurology. Prior to receiving full professorship, Dr. Seyfried was an Associate Professor in the Department of Biology at Boston College. Other awards and honors have come from such diverse organizations as the American Oil Chemists Society, the National Institutes of Health, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. Dr. Seyfried previously served as Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and presently serves on several editorial boards, including those for Nutrition & Metabolism, Neurochemical Research, and the Journal of Lipid Research. Dr. Seyfried’s research program focuses on gene environmental interactions related to complex diseases, such as epilepsy, autism, brain cancer, and neurodegenerative diseases. Dr. Seyfried investigates many of these diseases from the perspective of, genetics, and energy metabolism. Much of his work, gratefully, also has direct translational benefit to the clinic. This is a somewhat science-based discussion, but hang in there as there are some critically important gems of information that we get from Dr. Seyfried. Finally, in the broadcast, Dr. Seyfried mentions a book on this subject that’s  geared to a less scientifically minded community. The book is entitled, Tripping Over the Truth, by Travis Christofferson.

Southern Alberta Council on Public Affairs (SACPA)
Canada: Long a Refugee Haven – a Model for Other Countries? (Part 2 Q&A)

Southern Alberta Council on Public Affairs (SACPA)

Play Episode Listen Later Jun 8, 2017 30:46


Canada has a long and sometimes forgotten history of accepting refugees dating back to its founding. This history connects with present-day refugee approaches and challenges that are in contrast with the emerging policies and attitudes south of our border and in many other countries. It is not only Canada's reliance on a provision in the 1976 Immigration Act that allows for groups of individuals to privately sponsor refugees that makes Canada a possible model for other countries, but our distinction as an accepting and supportive home for refugees. Refugees to Canada indeed come from war-torn, discriminatory and poor countries throughout the world. Canada resettled 60,000 refugees from places like Vietnam and Cambodia between 1979 and 1980, for example, including about 34,000 who were privately sponsored. Nearly 300,000 refugees have resettled in Canada since the late 1970s.That extraordinary effort helped Canada win the 1986 UNHCR's Nansen Refugee Award in recognition of the collective work of the government and residents. But, refugees from other places have also enriched Canada for a very long time. It is those streams that will be discussed here as forming a fundamental part of our country and communities. Speaker: Dr. Susan McDaniel Dr. Susan McDaniel is Canada Research Chair (Tier 1) in Global Population and Life Course, Prentice Research Chair in Global Population and Economy, Director of the Prentice Institute and Professor of Sociology at the University of Lethbridge. Dr. McDaniel relocated to Lethbridge in the summer of 2009 from the University of Utah where for two years she was Professor and Senior Investigator in the Institute for Public & International Affairs. She had previously taught at the Universities of Alberta and Waterloo. An internationally known sociologist/social demographer, Dr. McDaniel is the author of many books and research articles. She has been the recipient of many awards and honours: She has long been a Fellow of the Royal Society of Canada, and last year was awarded the Ingrid Speaker Medal by the U of L for Outstanding Research. She is a frequent advisor on social and science policies both in Canada and around the World. Dr. McDaniel serves as Chair of the Scientific Advisory Committee of the Canadian Council of Academies (CCA). Recently, the CCA has been asked by the Minister of Health and the Minister of Justice to do assessments related to Medical Assistance in Dying. Moderator: TBA Date: Thursday, June 8, 2017 Time: Noon - 1:30 PM (30 minutes each for presentation, lunch and Q & A) Location: Country Kitchen Catering (Lower level of The Keg) 1715 Mayor Magrath Dr. S Cost: $12.00 (includes lunch) or $2.00 (includes coffee/tea) RSVP is not necessary

Southern Alberta Council on Public Affairs (SACPA)
Canada: Long a Refugee Haven – a Model for Other Countries? (Part 1)

Southern Alberta Council on Public Affairs (SACPA)

Play Episode Listen Later Jun 8, 2017 27:36


Canada has a long and sometimes forgotten history of accepting refugees dating back to its founding. This history connects with present-day refugee approaches and challenges that are in contrast with the emerging policies and attitudes south of our border and in many other countries. It is not only Canada's reliance on a provision in the 1976 Immigration Act that allows for groups of individuals to privately sponsor refugees that makes Canada a possible model for other countries, but our distinction as an accepting and supportive home for refugees. Refugees to Canada indeed come from war-torn, discriminatory and poor countries throughout the world. Canada resettled 60,000 refugees from places like Vietnam and Cambodia between 1979 and 1980, for example, including about 34,000 who were privately sponsored. Nearly 300,000 refugees have resettled in Canada since the late 1970s.That extraordinary effort helped Canada win the 1986 UNHCR's Nansen Refugee Award in recognition of the collective work of the government and residents. But, refugees from other places have also enriched Canada for a very long time. It is those streams that will be discussed here as forming a fundamental part of our country and communities. Speaker: Dr. Susan McDaniel Dr. Susan McDaniel is Canada Research Chair (Tier 1) in Global Population and Life Course, Prentice Research Chair in Global Population and Economy, Director of the Prentice Institute and Professor of Sociology at the University of Lethbridge. Dr. McDaniel relocated to Lethbridge in the summer of 2009 from the University of Utah where for two years she was Professor and Senior Investigator in the Institute for Public & International Affairs. She had previously taught at the Universities of Alberta and Waterloo. An internationally known sociologist/social demographer, Dr. McDaniel is the author of many books and research articles. She has been the recipient of many awards and honours: She has long been a Fellow of the Royal Society of Canada, and last year was awarded the Ingrid Speaker Medal by the U of L for Outstanding Research. She is a frequent advisor on social and science policies both in Canada and around the World. Dr. McDaniel serves as Chair of the Scientific Advisory Committee of the Canadian Council of Academies (CCA). Recently, the CCA has been asked by the Minister of Health and the Minister of Justice to do assessments related to Medical Assistance in Dying. Moderator: TBA Date: Thursday, June 8, 2017 Time: Noon - 1:30 PM (30 minutes each for presentation, lunch and Q & A) Location: Country Kitchen Catering (Lower level of The Keg) 1715 Mayor Magrath Dr. S Cost: $12.00 (includes lunch) or $2.00 (includes coffee/tea) RSVP is not necessary

Southern Alberta Council on Public Affairs (SACPA)
Canada: Long a Refugee Haven – a Model for Other Countries? (Part 2 Q&A)

Southern Alberta Council on Public Affairs (SACPA)

Play Episode Listen Later Jun 8, 2017 30:46


Canada has a long and sometimes forgotten history of accepting refugees dating back to its founding. This history connects with present-day refugee approaches and challenges that are in contrast with the emerging policies and attitudes south of our border and in many other countries. It is not only Canada's reliance on a provision in the 1976 Immigration Act that allows for groups of individuals to privately sponsor refugees that makes Canada a possible model for other countries, but our distinction as an accepting and supportive home for refugees. Refugees to Canada indeed come from war-torn, discriminatory and poor countries throughout the world. Canada resettled 60,000 refugees from places like Vietnam and Cambodia between 1979 and 1980, for example, including about 34,000 who were privately sponsored. Nearly 300,000 refugees have resettled in Canada since the late 1970s.That extraordinary effort helped Canada win the 1986 UNHCR's Nansen Refugee Award in recognition of the collective work of the government and residents. But, refugees from other places have also enriched Canada for a very long time. It is those streams that will be discussed here as forming a fundamental part of our country and communities. Speaker: Dr. Susan McDaniel Dr. Susan McDaniel is Canada Research Chair (Tier 1) in Global Population and Life Course, Prentice Research Chair in Global Population and Economy, Director of the Prentice Institute and Professor of Sociology at the University of Lethbridge. Dr. McDaniel relocated to Lethbridge in the summer of 2009 from the University of Utah where for two years she was Professor and Senior Investigator in the Institute for Public & International Affairs. She had previously taught at the Universities of Alberta and Waterloo. An internationally known sociologist/social demographer, Dr. McDaniel is the author of many books and research articles. She has been the recipient of many awards and honours: She has long been a Fellow of the Royal Society of Canada, and last year was awarded the Ingrid Speaker Medal by the U of L for Outstanding Research. She is a frequent advisor on social and science policies both in Canada and around the World. Dr. McDaniel serves as Chair of the Scientific Advisory Committee of the Canadian Council of Academies (CCA). Recently, the CCA has been asked by the Minister of Health and the Minister of Justice to do assessments related to Medical Assistance in Dying. Moderator: TBA Date: Thursday, June 8, 2017 Time: Noon - 1:30 PM (30 minutes each for presentation, lunch and Q & A) Location: Country Kitchen Catering (Lower level of The Keg) 1715 Mayor Magrath Dr. S Cost: $12.00 (includes lunch) or $2.00 (includes coffee/tea) RSVP is not necessary

ADC podcast
ADC Highlights October 2016

ADC podcast

Play Episode Listen Later Sep 12, 2016 11:21


Mark Beattie introduces his highlights from the October 2016 issue of ADC. Here are the links to the articles discussed: I've got 99 problems but a phone ain't one: Electronic and mobile health in low and middle income countries - http://adc.bmj.com/content/101/10/974.full Selecting children for head CT following head injury - http://adc.bmj.com/content/101/10/929.full Clinical presentation of childhood leukaemia: a systematic review and meta-analysis - http://adc.bmj.com/content/101/10/894.full Related editorial: When should I suspect childhood leukaemia? - http://adc.bmj.com/content/101/10/874.full Update on carbohydrates and health: the relevance of the Scientific Advisory Committee on Nutrition report for children - http://adc.bmj.com/content/101/10/876.extract Family income and young adolescents’ perceived social position: associations with self-esteem and life satisfaction in the UK Millennium Cohort Study - http://adc.bmj.com/content/101/10/917.full You can access the whole issue here: http://adc.bmj.com/content/101/10.toc

Neurology® Podcast
March 17 2015 Issue

Neurology® Podcast

Play Episode Listen Later Mar 16, 2015 22:47


1) Age of first exposure to football and the effect of later-life cognitive impairment on former NFL players and 2) Topic of the month: Stroke in systemic disease. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Howard Goodkin interviews Dr. Robert Stern about his paper on the age of first exposure to football and the effect of later-life cognitive impairment on former NFL players. Dr. James Addington is reading our e-Pearl of the week about REM behavior disorder. In the next part of the podcast Dr. Michelle Johansen interviews Dr. Kevin Barrett about the topic of stroke in the setting of Endocrine disorders. The participants had nothing to disclose except Drs. Goodkin, Stern, Addington, Johansen and Barrett.Dr. Goodkin serves on the scientific advisory board for Tuberous Sclerosis Alliance and CURE Infantile Spasms; serves as an editorial board member of Neurology, Surgical Neurology International and Epilepsia; receive a royalty from UpToDate for co-authorship of an entry entitled The "choking game" and other strangulation activities in children and adolescents; will be receiving royalties for editing Epilepsy as part of the Neurology in Practice series and receives research support from the NIH.Dr. Stern serves as an Associate Editor of Journal of Neuropsychiatry and Clinical Neurosciences; serves as an editorial board member of Archives of Clinical Neuropsychology; serves as a Review Editor of Frontiers in Neurotrauma and Frontiers in Sports Neurology; serves as Series Editor of Alzheimer's Research and Therapy; serves on the Mackey-White Traumatic Brain Injury Committee of the National Football League Players Association; serves on the medical advisory board of Sports Legacy Institute, the National Graves' Disease Foundation and Amarantus Biosciences (paid advisor); serves on the Medical and Scientific Advisory Committee of the MA/NH Chapter of the Alzheimer's Association; is a consultant for Janssen Research & Development and Athena Diagnostics; receives publishing royalties from Psychological Assessment Resources, Inc. for the Visual Analog Mood Scales, the Boston Qualitative Scoring System for the Rey-Osterreith Complex Figure, and the Neuropsychological Assessment Battery; receives research support from Eisai Inc., Eli Lilly and Company, Amarantus Biosciences, Aethlon Medical, Avid Radiopharmaceuticals, the Department of Defense and the NIH; received honorariums from, Braintree Neurorehabilitation Conference, National Academy of Neuropsychology, Harvard Medical School, The German Center for Research and Innovation and Ludwig-Maximilians-Universitat Munchen, Medical University of South Carolina, Spaulding Rehabilitation Hospital and 8th Annual National Summit on Sports Concussion.Dr. Addington serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Johansen serves as a scientific advisory member of Stroke and as a contributor to Blogging Stroke.Dr. Kevin Barrett serves as an Associate Editor of Neurohospitalist; serves as an editorial board member of Neurology; and receives research support from the NIH.

Fearless Parent Radio
Ketogenic Diets for Kids with Cancer - 02.11.15

Fearless Parent Radio

Play Episode Listen Later Feb 12, 2015 57:27


Guest // Thomas Seyfried, PhDHost // Toni Bark, MDHalf of men and one-third of women will receive a cancer diagnosis sometime during their lives. Increasingly, more patients are declining conventional treatment. They are interested in a different kind of approach to cancer management and prevention.. one that is more cutting edge and incorporates the latest research.If we can understand what cancer is, what feeds it, and why metastasis happens, then we can find and apply more effective strategies to shrink (and hopefully eliminate) tumors.Meet Professor Thomas Seyfried. He is a biochemical geneticist who has been investigating the lipid biochemistry of cancer for thirty years. His pioneering research expands on Otto Warburg’s groundbreaking theory that cancer is a disease of energy metabolism. With this framework, he’s able to explain the relationship between cancer and inflammation, vascularization, cell death, drug resistance, and genomic instability. Discussion topics during today’s show include:How does this view differ from the direction in which much of current research and funding is heading? (i.e., genetics)Is the controversy largely a matter of cause and effect (i.e., mitochondrial respiration and genetic damage)?What has been the response of the scientific community?Where is the research heading? (i.e., mouse to man, clinical trials?)What is the ketogenic diet and how is it implemented? How does this differ when applied to children?What is the Press-Pulse metabolic strategy for cancer management?If you have questions, be sure to send them before the show or meet up with us on the blog afterwards to discuss.Thomas Seyfried, PhD focuses on gene environmental interactions related to complex diseases, such as epilepsy, autism, brain cancer, and neurodegenerative (the GM1 and GM2 gangliosidoses) diseases. He investigates many of these diseases from the perspective of, genetics, lipidomics, and energy metabolism. Tom received his Ph.D. in Genetics and Biochemistry from the University of Illinois, Urbana, in 1976. He  was an Assistant Professor in Neurology at Yale University School of Medicine. Tom has received awards from the NIH, The American Society for Neurochemistry, and the Ketogenic Diet Special Interest Group of the American Epilepsy Society. He was Chair, Scientific Advisory Committee for the National Tay-Sachs and Allied Diseases Association and serves on several editorial boards, for Nutrition & Metabolism, Neurochemical Research, the Journal of Lipid Research, and ASN Neuro. Read more about his work here.

Myers Detox
Is Gluten the Cause of your Health Problems? with Dr.Tom O’Bryan

Myers Detox

Play Episode Listen Later Nov 8, 2013 54:26


Is gluten the cause of your health problems? It very well could be. Gluten is the number one cause of health issues and food sensitivities. Find out why you should be eliminating it from you diet. Transcript Click here to view the full transcript for #31 Is Gluten the cause of your Health Problems? with Tom O'Bryan. It’s an interesting, and important, question to ask. Fortunately, Dr. Tom O‘Bryan has made it part of his personal mission to move this question into today’s conversations between patients and healthcare professionals. Asking this question could, potentially, improve the lives of millions now instead of years from now, which is how long it often takes for groundbreaking research to make it to mainstream practice. As a fellow health enthusiast, you may know how it too often takes 5-10 years before groundbreaking research finds its way into clinical practice; this will not be the case for gluten-related disorders. Asking this question could, potentially, improve the lives of millions now instead of years from now. About Tom O'Bryan Dr. Tom O'Bryan is an internationally recognized speaker and workshop leader specializing in the complications of Non-Coeliac Gluten Sensitivity and Coeliac Disease as they occur inside and outside of the intestines. Since 2004, he has served as a teaching clinician for international audiences of Healthcare Practitioners, and currently holds teaching Faculty positions with the Institute for Functional Medicine and the National University of Health Sciences.  He serves on the Scientific Advisory Committee of the International and American Association of Clinical Nutritionists and the Medical Advisory Board of the National Association of Nutritional Professionals. If all else fails or you find yourself at a restaurant where you never know what gluten is lurking in the food, be sure to have a bottle of Glutenza handy. I always have a bottle with me when I eat out!  If you’re enjoying the Live to 110 podcast, please leave Wendy a review in iTunes. Thanks! Are toxic metals causing your fatigue and health issues? Find out by taking Wendy’s Heavy Metals Quiz at

Take Back Your Health
The Myers Way Episode 25: Gluten Sensitivity with Dr. Thomas O'Bryan

Take Back Your Health

Play Episode Listen Later Nov 4, 2013 49:41


[Originally published on November 4, 2013] Dr. Tom O'Bryan is an internationally recognized speaker and workshop leader specializing in the complications of Non-Celiac Gluten Sensitivity and Celiac Disease as they occur inside and outside of the intestines. Since 2004, he has served as a teaching clinician for international audiences of Healthcare Practitioners, and currently holds teaching Faculty positions with the Institute for Functional Medicine and the National University of Health Sciences.  He serves on the Scientific Advisory Committee of the International and American Association of Clinical Nutritionists and the Medical Advisory Board of the National Association of Nutritional Professionals. Dr. O'Bryan is always one of the most thought-provoking, highly appreciated Speakers. Why do you think there is so much press about gluten these days? What did we do to gluten to make it so bad for us? How long does someone need to be on gf diet to see a difference? How much Gluten is too much? Tell me about the patient you had whose only exposure to gluten was a communion wafer and her symptoms? What's the relationship with Autism? How does Gluten cause a leaky gut? What is the best testing for gluten sensitivity? And problems with traditional testing. How is it that you can have gluten sensitivity and not have digestive issues? How does Gluten cause brain fog? What about other brain disorders like seizures, depression and anxiety? What is the link with Gluten and autoimmune and cancer? What are common mishaps of going on a gluten free diet? What's the deal with labeling something gluten free? Tell us about the Gluten Summit you have coming up? Connect with Dr. Myers: Website: https://www.amymyersmd.com/ Newsletter: https://www.amymyersmd.com/ec/guide-to-leaky-gut Facebook: https://www.facebook.com/AmyMyersMD Instagram: https://www.instagram.com/amymyersmd/ Connect with Dr. O'Bryan: Website: https://www.thedr.com/ Facebook: https://www.facebook.com/thedr.com.english

The Trauma Therapist | Podcast with Guy Macpherson, PhD | Inspiring interviews with thought-leaders in the field of trauma.

Today on the podcast, Michael Salter.Michael is an Associate Professor in Criminology at Western Sydney University, Australia and specializes in the study of organized sexual abuse.First off, a giant thank-you to my sponsors this week:This episode is sponsored by PESI.The latest research from neuroscience and psychotherapy has shown we can rewire the brain to facilitate trauma recovery.Now newly released workbook authored by Jennifer Sweeton, The Trauma Treatment Toolbox, teaches clinicians how to take that brain-based approach to trauma therapy, showing how to effectively heal clients’ brains with straightforward, easy-to-implement treatment techniques.You can get yours now through PESI and with this exclusive offer to save $10 plus free shipping with code JS10. Go to www.pesi.com/toolbox.This episode is also sponsored by CPTSD Foundation.CPTSD Foundation has been successfully equipping complex trauma survivors and practitioners with compassionate support, skills, and trauma-informed education since 2014.Daily Recovery Support? Yes!Free Support Groups? Yes!The Healing Book Club? Yes!A Weekly Newsletter? Definitely!Learn more about the CPTSD Foundation here. In addition to his work on complex trauma, Michael Salter has researched and published widely on violence against women and children.Michael sits on the Scientific Advisory Committee and the Board of Directors of the International Society for the Study of Trauma and Dissociation and is an associate editor of Child Abuse Review, the peer-reviewed journal of the British Association for the Study and Prevention of Child Abuse and Neglect.Support this podcast at — https://redcircle.com/the-trauma-therapist-podcast-with-guy-macpherson-phd-inspiring-interviews-with-thought-leaders-in-the-field-of-trauma/donationsWant to advertise on this podcast? Go to https://redcircle.com/brands and sign up.